KR20200106173A - Nash 및 다른 질병의 치료를 위한 개선된 펩티드 약제 - Google Patents
Nash 및 다른 질병의 치료를 위한 개선된 펩티드 약제 Download PDFInfo
- Publication number
- KR20200106173A KR20200106173A KR1020207022417A KR20207022417A KR20200106173A KR 20200106173 A KR20200106173 A KR 20200106173A KR 1020207022417 A KR1020207022417 A KR 1020207022417A KR 20207022417 A KR20207022417 A KR 20207022417A KR 20200106173 A KR20200106173 A KR 20200106173A
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- leu
- thr
- gln
- glu
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 433
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 66
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims description 57
- 229940079593 drug Drugs 0.000 title description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 12
- 201000010099 disease Diseases 0.000 title description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 88
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims abstract description 16
- -1 linker amino acid Chemical class 0.000 claims description 238
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 187
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 168
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 239000002253 acid Substances 0.000 claims description 76
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 71
- 150000001413 amino acids Chemical class 0.000 claims description 68
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 46
- 229930182470 glycoside Natural products 0.000 claims description 33
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 31
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 31
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 29
- 239000000556 agonist Substances 0.000 claims description 28
- 150000003951 lactams Chemical class 0.000 claims description 27
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 24
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 24
- 125000006850 spacer group Chemical group 0.000 claims description 23
- 235000000346 sugar Nutrition 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 19
- 150000003431 steroids Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 208000010706 fatty liver disease Diseases 0.000 claims description 16
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000004472 Lysine Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 125000000524 functional group Chemical group 0.000 claims description 12
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 9
- 238000007918 intramuscular administration Methods 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 claims description 8
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 8
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 7
- 208000020832 chronic kidney disease Diseases 0.000 claims description 7
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 229960005095 pioglitazone Drugs 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 108010016731 PPAR gamma Proteins 0.000 claims description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 claims description 4
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 108010028295 histidylhistidine Proteins 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 4
- 108010087791 pyroglutamylhistidine Proteins 0.000 claims description 4
- 229960000672 rosuvastatin Drugs 0.000 claims description 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 3
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 claims description 3
- 229960001601 obeticholic acid Drugs 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- NBTUEARNKVTGKY-RBAZEOKYSA-N (2s,3r,4s,5r,6s)-3,4,5-trihydroxy-6-[(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexoxy]oxane-2-carboxylic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O NBTUEARNKVTGKY-RBAZEOKYSA-N 0.000 claims description 2
- SHCMCJLNUOZJOR-YXISZKLHSA-N (2s,3s,4s,5r,6r)-6-dodecyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SHCMCJLNUOZJOR-YXISZKLHSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 210000002824 peroxisome Anatomy 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 abstract description 28
- 235000020824 obesity Nutrition 0.000 abstract description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 26
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 25
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 12
- 230000009471 action Effects 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 239000000047 product Substances 0.000 description 185
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 159
- 150000001408 amides Chemical class 0.000 description 112
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 94
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 87
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 82
- 229940024606 amino acid Drugs 0.000 description 82
- 235000001014 amino acid Nutrition 0.000 description 78
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 58
- 239000000203 mixture Substances 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 210000004185 liver Anatomy 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 45
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 45
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 39
- 239000011347 resin Substances 0.000 description 39
- 229920005989 resin Polymers 0.000 description 39
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 37
- 230000000694 effects Effects 0.000 description 37
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 33
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 32
- 238000009472 formulation Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 27
- 125000003118 aryl group Chemical group 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 229940112141 dry powder inhaler Drugs 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 206010019708 Hepatic steatosis Diseases 0.000 description 23
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 22
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 21
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 102100040918 Pro-glucagon Human genes 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 229920001223 polyethylene glycol Polymers 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 20
- 208000019425 cirrhosis of liver Diseases 0.000 description 20
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- 239000002202 Polyethylene glycol Substances 0.000 description 19
- 230000004761 fibrosis Effects 0.000 description 19
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 108060003199 Glucagon Proteins 0.000 description 17
- 108010063919 Glucagon Receptors Proteins 0.000 description 17
- 102100040890 Glucagon receptor Human genes 0.000 description 17
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 229960001375 lactose Drugs 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 206010016654 Fibrosis Diseases 0.000 description 16
- 102000051325 Glucagon Human genes 0.000 description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 16
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 16
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 16
- 229960004666 glucagon Drugs 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 231100000240 steatosis hepatitis Toxicity 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 108010078580 tyrosylleucine Proteins 0.000 description 15
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 229940071648 metered dose inhaler Drugs 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 238000010511 deprotection reaction Methods 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 102000000802 Galectin 3 Human genes 0.000 description 12
- 108010001517 Galectin 3 Proteins 0.000 description 12
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 12
- 102400000319 Oxyntomodulin Human genes 0.000 description 12
- 101800001388 Oxyntomodulin Proteins 0.000 description 12
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 239000003925 fat Substances 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 150000002338 glycosides Chemical class 0.000 description 12
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 108010060325 semaglutide Proteins 0.000 description 12
- 229950011186 semaglutide Drugs 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 208000004930 Fatty Liver Diseases 0.000 description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 11
- 208000018191 liver inflammation Diseases 0.000 description 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 108010011459 Exenatide Proteins 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 10
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 150000007942 carboxylates Chemical class 0.000 description 10
- 229960001519 exenatide Drugs 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000007863 steatosis Effects 0.000 description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 235000012631 food intake Nutrition 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 239000012730 sustained-release form Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 7
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 7
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 7
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 7
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 229960003082 galactose Drugs 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000006199 nebulizer Substances 0.000 description 7
- 229960003104 ornithine Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 6
- 108010019598 Liraglutide Proteins 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 150000002016 disaccharides Chemical class 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229960002701 liraglutide Drugs 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000036186 satiety Effects 0.000 description 6
- 235000019627 satiety Nutrition 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 5
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 230000008484 agonism Effects 0.000 description 5
- 108010068265 aspartyltyrosine Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 125000001165 hydrophobic group Chemical group 0.000 description 5
- 239000000859 incretin Substances 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 5
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 4
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 229940123464 Thiazolidinedione Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 238000007098 aminolysis reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 108010047857 aspartylglycine Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000000841 delta opiate receptor agonist Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 150000005828 hydrofluoroalkanes Chemical group 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- ZZWWXIBKLBMSCS-FQEVSTJZSA-N 2-[1-[(2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid Chemical compound COC1=CC=CC=C1[C@@H](OC1CCOCC1)CN1C(=O)N(C(C)(C)C(O)=O)C(=O)C2=C1SC(C=1OC=CN=1)=C2C ZZWWXIBKLBMSCS-FQEVSTJZSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 3
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 3
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 3
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 3
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000005480 Olmesartan Substances 0.000 description 3
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 3
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 3
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000002355 alkine group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000007240 daidzein Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 239000004026 insulin derivative Substances 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 3
- 229960005117 olmesartan Drugs 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VDWWLJRQDNTHJB-MXAMYCJDSA-N (2s)-2-[[(2s,3r)-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 VDWWLJRQDNTHJB-MXAMYCJDSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 2
- NDGUBXOBXSPVHJ-LXVLQKCJSA-N (4r)-4-[(3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-n,n-dimethylpentanamide Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(=O)N(C)C)C)[C@@]1(C)CC2 NDGUBXOBXSPVHJ-LXVLQKCJSA-N 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 description 2
- ZUGQWAYOWCBWGM-UHFFFAOYSA-N 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C(=CC(=CC=2)C(F)(F)F)F)SC=1CSC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZUGQWAYOWCBWGM-UHFFFAOYSA-N 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 description 2
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- GPPIDDWYKJPRES-YDHLFZDLSA-N Asp-Phe-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GPPIDDWYKJPRES-YDHLFZDLSA-N 0.000 description 2
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102100038495 Bile acid receptor Human genes 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical class C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
- AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- 102100038199 Desmoplakin Human genes 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- 108010043222 Exubera Proteins 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 2
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 description 2
- IIMZHVKZBGSEKZ-SZMVWBNQSA-N Gln-Trp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O IIMZHVKZBGSEKZ-SZMVWBNQSA-N 0.000 description 2
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000839025 Homo sapiens Hydroxymethylglutaryl-CoA synthase, cytoplasmic Proteins 0.000 description 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 101000642613 Homo sapiens Sterol O-acyltransferase 2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101710091439 Major capsid protein 1 Proteins 0.000 description 2
- HDNOQCZWJGGHSS-VEVYYDQMSA-N Met-Asn-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HDNOQCZWJGGHSS-VEVYYDQMSA-N 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 238000013234 NASH mouse model Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 108700027412 Pegbelfermin Proteins 0.000 description 2
- 102100029909 Peptide YY Human genes 0.000 description 2
- 108010088847 Peptide YY Proteins 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 108010058003 Proglucagon Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 108091006277 SLC5A1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 2
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 2
- 102100036673 Sterol O-acyltransferase 2 Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229960003345 empagliflozin Drugs 0.000 description 2
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 229940012151 exubera Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 150000002208 flavanones Chemical class 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005179 haloacetyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229950000991 ipragliflozin Drugs 0.000 description 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000006010 pyroptosis Effects 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 2
- 229950006544 saroglitazar Drugs 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 239000005458 thiazide-like diuretic Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ZBQKPDHUDKSCRS-UHFFFAOYSA-N $l^{1}-oxidanyl acetate Chemical group CC(=O)O[O] ZBQKPDHUDKSCRS-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- UGNVBODTSYDQPO-CMPLNLGQSA-N (1R,5S)-3-(hydroxymethyl)-1-(3-methylbut-2-enyl)-6-oxabicyclo[3.2.0]hept-2-en-7-one Chemical compound C1=C(CO)C[C@@H]2OC(=O)[C@@]21CC=C(C)C UGNVBODTSYDQPO-CMPLNLGQSA-N 0.000 description 1
- RZPAXNJLEKLXNO-UHFFFAOYSA-N (20R,22R)-3beta,22-Dihydroxylcholest-5-en Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C(O)CCC(C)C)C1(C)CC2 RZPAXNJLEKLXNO-UHFFFAOYSA-N 0.000 description 1
- RZPAXNJLEKLXNO-GFKLAVDKSA-N (22R)-22-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-GFKLAVDKSA-N 0.000 description 1
- IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 description 1
- FYHRJWMENCALJY-YSQMORBQSA-N (25R)-cholest-5-ene-3beta,26-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC[C@H](CO)C)[C@@]1(C)CC2 FYHRJWMENCALJY-YSQMORBQSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- HNODNXQAYXJFMQ-LQUSFLDPSA-N (2e,4e,6z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(\C(C)=C/C=C/C(/C)=C/C(O)=O)C(OCCC)=C2 HNODNXQAYXJFMQ-LQUSFLDPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 description 1
- OARALKHHLPKOLI-JTQLQIEISA-N (2s)-2-(2,4,6-trimethylanilino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=C(C)C=C(C)C=C1C OARALKHHLPKOLI-JTQLQIEISA-N 0.000 description 1
- PHHXKCQRPRQSKO-LURJTMIESA-N (2s)-2-(2-fluoroanilino)propanoic acid Chemical group OC(=O)[C@H](C)NC1=CC=CC=C1F PHHXKCQRPRQSKO-LURJTMIESA-N 0.000 description 1
- OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 description 1
- RPCLHYWMLWFFTE-VKTQGLPSSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamidopropanoyl]amino]-3-hydroxypropanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-amino-n-[(2s)-1-[[1-[[(2s)-6-amino-1-[[(2s)-1-[[(2s)-1-[[(2s Chemical compound CC(C)C[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(C)=O RPCLHYWMLWFFTE-VKTQGLPSSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- WLVXKTIBRNXBIF-KRWDZBQOSA-N (2s)-2-amino-3-[4-(2-ethyl-4-methoxyphenyl)phenyl]propanoic acid Chemical compound CCC1=CC(OC)=CC=C1C1=CC=C(C[C@H](N)C(O)=O)C=C1 WLVXKTIBRNXBIF-KRWDZBQOSA-N 0.000 description 1
- OGGWNIIHGPQQKO-INIZCTEOSA-N (2s)-2-amino-3-[4-(2-ethylphenyl)phenyl]propanoic acid Chemical group CCC1=CC=CC=C1C1=CC=C(C[C@H](N)C(O)=O)C=C1 OGGWNIIHGPQQKO-INIZCTEOSA-N 0.000 description 1
- LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical group CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 1
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- LDQKDRLEMKIYMC-XMMPIXPASA-N (3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine Chemical compound O=C([C@H]1CN(CCC1)C1CCN(CC1)C(=O)C=1C2=CC=CC=C2C=C2C=CC=CC2=1)N1CCOCC1 LDQKDRLEMKIYMC-XMMPIXPASA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- JICDBMXIQNEXKV-QFIPXVFZSA-N (3r)-3-(4-quinolin-6-ylphenyl)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound N1=CC=CC2=CC(C3=CC=C(C=C3)[C@@]3(C4CCN(CC4)C3)O)=CC=C21 JICDBMXIQNEXKV-QFIPXVFZSA-N 0.000 description 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RKFYYCKIHVEWHX-YOBICRQBSA-N (E)-trans-miyabenol C Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@H](C=1C=3[C@H]([C@@H](OC=3C=C(O)C=1)C=1C=CC(O)=CC=1)C=1C=C(O)C=C(O)C=1)[C@@H](C=1C=CC(O)=CC=1)O2 RKFYYCKIHVEWHX-YOBICRQBSA-N 0.000 description 1
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- LFQBDZIKMOOKIP-UHFFFAOYSA-N 1'-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]-5-(trifluoromethyl)spiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound C1CC=2C(C(F)(F)F)=CC=CC=2OC1(CC1)CCN1C(N=N1)=CC=C1C(O1)=NN=C1CC1=CC=CN=C1 LFQBDZIKMOOKIP-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- DSUNZEZCXUMUEH-UHFFFAOYSA-N 1-[3-[4-(3,3-dimethyl-1-oxo-2-oxa-9-azaspiro[4.5]decan-9-yl)piperidine-1-carbonyl]-1-benzothiophen-2-yl]-3-ethylurea Chemical compound CCNC(=O)NC=1SC2=CC=CC=C2C=1C(=O)N(CC1)CCC1N(C1)CCCC21CC(C)(C)OC2=O DSUNZEZCXUMUEH-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- SNDUAWDCUKVWFQ-UHFFFAOYSA-N 1-bis(2,2,2-trifluoroacetyl)boranyl-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)B(C(=O)C(F)(F)F)C(=O)C(F)(F)F SNDUAWDCUKVWFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
- HCZMHWVFVZAHCR-UHFFFAOYSA-N 2-[2-(2-sulfanylethoxy)ethoxy]ethanethiol Chemical compound SCCOCCOCCS HCZMHWVFVZAHCR-UHFFFAOYSA-N 0.000 description 1
- XTIXMPSOPHPWLE-VNXMGFANSA-N 2-[2-[(1s,2r,3as,7as)-2-hydroxy-1-[(3s)-3-hydroxy-4,4-dimethylnona-1,6-diynyl]-2,3,3a,6,7,7a-hexahydro-1h-inden-5-yl]ethoxy]acetic acid Chemical compound C1=C(CCOCC(O)=O)CC[C@@H]2[C@@H](C#C[C@@H](O)C(C)(C)CC#CCC)[C@H](O)C[C@@H]21 XTIXMPSOPHPWLE-VNXMGFANSA-N 0.000 description 1
- KCWJAXJEGXEZQC-JKVOQSHXSA-N 2-[2-[(2r,3as,4r,5r,6as)-5-hydroxy-4-[(e,3s,5s)-3-hydroxy-5-methylnon-1-enyl]-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]ethoxy]acetic acid Chemical compound C1[C@@H](CCOCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C[C@@H](C)CCCC)[C@H](O)C[C@@H]21 KCWJAXJEGXEZQC-JKVOQSHXSA-N 0.000 description 1
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 1
- WFOFPVXMPTVOTJ-UHFFFAOYSA-N 2-[6-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]pyridazin-3-yl]-5-methyl-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C1=CC=C(N2CCC(CC2)OC=2C(=CC=C(F)C=2)Cl)N=N1 WFOFPVXMPTVOTJ-UHFFFAOYSA-N 0.000 description 1
- 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 description 1
- KWOMLHIFHFWBSB-UHFFFAOYSA-N 2-azaniumyl-2-ethylbutanoate Chemical compound CCC(N)(CC)C(O)=O KWOMLHIFHFWBSB-UHFFFAOYSA-N 0.000 description 1
- OFYAYGJCPXRNBL-UHFFFAOYSA-N 2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IOWMKBFJCNLRTC-UHFFFAOYSA-N 24S-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(O)C(C)C)C1(C)CC2 IOWMKBFJCNLRTC-UHFFFAOYSA-N 0.000 description 1
- DKISDYAXCJJSLZ-UHFFFAOYSA-N 26-Hydroxy-cholesterin Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(CO)C)C1(C)CC2 DKISDYAXCJJSLZ-UHFFFAOYSA-N 0.000 description 1
- RMYKZOLKNAODDC-UHFFFAOYSA-N 3,3-dimethyl-7-[2-(4-propoxyphenyl)ethynyl]-2,4-dihydro-1,5-benzodioxepine Chemical compound C1=CC(OCCC)=CC=C1C#CC1=CC=C(OCC(C)(C)CO2)C2=C1 RMYKZOLKNAODDC-UHFFFAOYSA-N 0.000 description 1
- LBFDERUQORUFIN-UHFFFAOYSA-N 3-(1h-indol-3-yl)-4-[1-[2-(1-methylpyrrolidin-2-yl)ethyl]indol-3-yl]pyrrole-2,5-dione Chemical compound CN1CCCC1CCN1C2=CC=CC=C2C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C1 LBFDERUQORUFIN-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- VTQVXDHQCOTSNO-UHFFFAOYSA-N 3-(2-hydroxyethoxy)-4-methoxy-n-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide Chemical compound C1=C(OCCO)C(OC)=CC=C1C(=O)NC(S1)=NC=C1CC1=CC=CC(C(F)(F)F)=C1 VTQVXDHQCOTSNO-UHFFFAOYSA-N 0.000 description 1
- UQHKJRCFSLMWIA-UHFFFAOYSA-N 3-[1-(3-aminopropyl)-1h-indol-3-yl]-4-(1-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCN)C=2)C(=O)NC1=O UQHKJRCFSLMWIA-UHFFFAOYSA-N 0.000 description 1
- QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 1
- YDNMHDRXNOHCJH-UHFFFAOYSA-N 3-aminopyrrolidine-2,5-dione Chemical compound NC1CC(=O)NC1=O YDNMHDRXNOHCJH-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- DPYTYQFYDLYWHZ-UHFFFAOYSA-N 4-(2-chlorophenoxy)-n-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide Chemical compound CNC(=O)C1=CC=CC(NC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=C1 DPYTYQFYDLYWHZ-UHFFFAOYSA-N 0.000 description 1
- HYWPCURCNVJWBD-UHFFFAOYSA-N 4-(ethylamino)-3-(2-hydroxyethoxy)-n-[5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide Chemical compound C1=C(OCCO)C(NCC)=CC=C1C(=O)NC(S1)=NC=C1CC1=CC=CC(C(F)(F)F)=C1 HYWPCURCNVJWBD-UHFFFAOYSA-N 0.000 description 1
- CTPOHARTNNSRSR-NOQAJONNSA-N 4-[(1r,2r,3as,8bs)-2-hydroxy-1-[(e,3s,4s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1h-cyclopenta[b][1]benzofuran-5-yl]butanoic acid Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)[C@@H](C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-NOQAJONNSA-N 0.000 description 1
- MAUUNYHAXGTMMQ-AMXXQSRZSA-N 4-[(2e)-2-[(3as,4s,5r,6as)-5-hydroxy-4-[(3s,4s)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]ethoxy]butanoic acid Chemical compound C1\C(=C/COCCCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 MAUUNYHAXGTMMQ-AMXXQSRZSA-N 0.000 description 1
- ZZUKALQMHNSWTK-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=CC(=CC=2)C(O)=O)OCCO1 ZZUKALQMHNSWTK-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QPAMXNZWXFZISY-SDNWHVSQSA-N 5-[(e)-2-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]thiophene-2-carboxylic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(C)C=1C(/C)=C/C1=CC=C(C(O)=O)S1 QPAMXNZWXFZISY-SDNWHVSQSA-N 0.000 description 1
- ZEDKEKWGCXBKCJ-NTEUORMPSA-N 5-[(e)-2-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]thiophene-3-carboxylic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(C)C=1C(/C)=C/C1=CC(C(O)=O)=CS1 ZEDKEKWGCXBKCJ-NTEUORMPSA-N 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- YIEAVVIJPFEHCX-UHFFFAOYSA-N 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-4a,7a-dihydro-3H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound CCCOC1=CC=C(C=C1C1=NC2C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1 YIEAVVIJPFEHCX-UHFFFAOYSA-N 0.000 description 1
- ANTRYADYILUHOS-UHFFFAOYSA-N 5-fluoro-1'-[6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl]spiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound C1CC=2C(F)=CC=CC=2OC1(CC1)CCN1C(N=N1)=CC=C1C(O1)=NN=C1CC1=CC=CN=C1 ANTRYADYILUHOS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- WPUFSUFYEYOKFL-UHFFFAOYSA-N 6-[5-(cyclopropylmethyl)spiro[3,4-dihydro-1,5-benzoxazepine-2,4'-piperidine]-1'-yl]-n-(2-hydroxy-2-pyridin-3-ylethyl)pyridazine-3-carboxamide Chemical compound C=1C=CN=CC=1C(O)CNC(=O)C(N=N1)=CC=C1N(CC1)CCC1(OC1=CC=CC=C11)CCN1CC1CC1 WPUFSUFYEYOKFL-UHFFFAOYSA-N 0.000 description 1
- YRKFMPDOFHQWPI-UHFFFAOYSA-N 6-azaniumyl-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoate Chemical compound C1=CC=C2C(COC(=O)NC(CCCCN)C(O)=O)C3=CC=CC=C3C2=C1 YRKFMPDOFHQWPI-UHFFFAOYSA-N 0.000 description 1
- DQUHYEDEGRNAFO-UHFFFAOYSA-N 6-azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CCCCN DQUHYEDEGRNAFO-UHFFFAOYSA-N 0.000 description 1
- RCJYGWGQCPDYSL-HZPDHXFCSA-N 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1r,2r)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione Chemical compound C=1C=C(OC)C(Br)=CC=1CN1C=2C(=O)N(CC)C(=O)N(CCO)C=2N=C1N[C@@H]1CCC[C@H]1O RCJYGWGQCPDYSL-HZPDHXFCSA-N 0.000 description 1
- VCWMQNCMHOREFO-UHFFFAOYSA-N 7-sulfanyloxyheptane-1-thiol Chemical compound O(CCCCCCCS)S VCWMQNCMHOREFO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical class CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108010037611 ATI-5261 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 1
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
- 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 101100244969 Arabidopsis thaliana PRL1 gene Proteins 0.000 description 1
- USNSOPDIZILSJP-FXQIFTODSA-N Arg-Asn-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O USNSOPDIZILSJP-FXQIFTODSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010067611 BMS-962476 Proteins 0.000 description 1
- VYCMAAOURFJIHD-PJNXIOHISA-N BQ 123 Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@H]1CC1=CNC2=CC=CC=C12 VYCMAAOURFJIHD-PJNXIOHISA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 108010006931 CNTO 736 Proteins 0.000 description 1
- 108010068856 CS-6253 Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010040545 ETC 642 Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- JKNGELGDDBUFHG-UHFFFAOYSA-N Esterastin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)OC(=O)C(CC(N)=O)NC(C)=O)OC1=O JKNGELGDDBUFHG-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 239000005475 Fimasartan Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- AFPFGFUGETYOSY-HGNGGELXSA-N His-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AFPFGFUGETYOSY-HGNGGELXSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 description 1
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 description 1
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 1
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 description 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 1
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 1
- 101500028772 Homo sapiens Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 101100454448 Homo sapiens LGALS3 gene Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101500028776 Homo sapiens Oxyntomodulin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 1
- 101150051246 MAC2 gene Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- OBOUYBKGROJMIK-KOBVKWGYSA-N Miyabenol C Natural products Oc1ccc(C=Cc2cc(O)cc3O[C@H]([C@H](c4cc(O)c5O[C@@H]([C@@H](c6cc(O)cc(O)c6)c5c4)c7ccc(O)cc7)c23)c8ccc(O)cc8)cc1 OBOUYBKGROJMIK-KOBVKWGYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 206010035004 Pickwickian syndrome Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 108091006625 SLC10A6 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JKNGELGDDBUFHG-JJPNXARGSA-N [(2S,4Z,7Z)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]trideca-4,7-dien-2-yl] (2S)-2-acetamido-4-amino-4-oxobutanoate Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(N)=O)NC(C)=O)OC1=O JKNGELGDDBUFHG-JJPNXARGSA-N 0.000 description 1
- YYGLCPHONATYBU-FZDIXFNVSA-N [(2s,3s)-2,3-dihydroxy-3-[(1r,6s)-1-hydroxy-2-methylidene-7,9-dioxo-5-oxa-8,10-diazabicyclo[4.2.2]decan-6-yl]-2-methylpropyl] benzoate Chemical compound C([C@@](O)(C)[C@H](O)[C@]12C(N[C@](O)(C(=O)N1)C(=C)CCO2)=O)OC(=O)C1=CC=CC=C1 YYGLCPHONATYBU-FZDIXFNVSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- GWCQSPUAEOPDKF-UHFFFAOYSA-N amino octanoate Chemical compound CCCCCCCC(=O)ON GWCQSPUAEOPDKF-UHFFFAOYSA-N 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 1
- 229950000285 anacetrapib Drugs 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229940054733 arestin Drugs 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
- 229960000307 avanafil Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- ZISFCTXLAXIEMV-UHFFFAOYSA-N benzamidenafil Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC(C)CO ZISFCTXLAXIEMV-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 description 1
- RSMSFENOAKAUJU-UHFFFAOYSA-L bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RSMSFENOAKAUJU-UHFFFAOYSA-L 0.000 description 1
- APYXQTXFRIDSGE-UHFFFAOYSA-N bisindolylmaleimide III Chemical compound C12=CC=CC=C2N(CCCN)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O APYXQTXFRIDSGE-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 229950005341 bucindolol Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 1
- 229960002492 clobenzorex Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229950008441 clofibric acid Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical compound CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229950004181 dalcetrapib Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 229950003418 dasantafil Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 description 1
- 229960002551 dirlotapide Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 229950004394 ditiocarb Drugs 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950001279 elafibranor Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- RINBGYCKMGDWPY-UHFFFAOYSA-N epitizide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC(F)(F)F)NS2(=O)=O RINBGYCKMGDWPY-UHFFFAOYSA-N 0.000 description 1
- 229950010350 epitizide Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229950006293 eptaloprost Drugs 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- 229950004586 esuberaprost Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950011259 evogliptin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960000701 fenofibric acid Drugs 0.000 description 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000020680 filtered tap water Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003489 fimasartan Drugs 0.000 description 1
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- LZLGHWHSUZVUFZ-HZPDHXFCSA-N folerogenin Chemical compound C1([C@@H]2[C@H](O)C(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C=C1 LZLGHWHSUZVUFZ-HZPDHXFCSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229950005514 glycyclamide Drugs 0.000 description 1
- RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 description 1
- QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 description 1
- 229950005754 gosogliptin Drugs 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 108010050259 insulin degludec Proteins 0.000 description 1
- 229960004225 insulin degludec Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 description 1
- 229950009365 limaprost Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XXYTXQGCRQLRHA-UHFFFAOYSA-N metahexamide Chemical compound C1=C(N)C(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 XXYTXQGCRQLRHA-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- UQEOPLABKYFAJH-BUHFOSPRSA-N methyl 5-[5-hydroxy-4-[(e)-3-hydroxy-3-(4-propylcyclohexyl)prop-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]pentanoate Chemical compound C1CC(CCC)CCC1C(O)\C=C\C1C2CC(CCCCC(=O)OC)=NC2CC1O UQEOPLABKYFAJH-BUHFOSPRSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229950002245 mirodenafil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229950000884 mitratapide Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960003938 moxonidine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- QMZSSLLJQUFMHM-UHFFFAOYSA-N n-(2-cyclopropylethyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridazine-3-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C(C(=O)N2CCN(CC2)C=2N=NC(=CC=2)C(=O)NCCC2CC2)=C1 QMZSSLLJQUFMHM-UHFFFAOYSA-N 0.000 description 1
- OJLASFAHNJPVLA-UHFFFAOYSA-N n-(2-hydroxy-2-pyridin-3-ylethyl)-6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)C1CCN(C=2N=NC(=CC=2)C(=O)NCC(O)C=2C=NC=CC=2)CC1 OJLASFAHNJPVLA-UHFFFAOYSA-N 0.000 description 1
- WNDIAFXQKOHFLV-UHFFFAOYSA-N n-[2-(1h-1,2,4-triazol-5-ylmethyl)-3,4-dihydro-1h-isoquinolin-6-yl]-2-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1C(=O)NC1=CC=C(CN(CC2=NNC=N2)CC2)C2=C1 WNDIAFXQKOHFLV-UHFFFAOYSA-N 0.000 description 1
- PVTIQVJHZDSETN-UHFFFAOYSA-N n-[2-[6-[(3,4-dichlorophenyl)methylamino]-2-(4-methoxyphenyl)-3-oxopyrido[2,3-b]pyrazin-4-yl]ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(C(N(CCNC(C)=O)C1=N2)=O)=NC1=CC=C2NCC1=CC=C(Cl)C(Cl)=C1 PVTIQVJHZDSETN-UHFFFAOYSA-N 0.000 description 1
- WMTXYBPCCTYHRF-UHFFFAOYSA-N n-[4-[2-(4-propoxyphenoxy)-1,3-thiazol-5-yl]but-3-yn-2-yl]acetamide Chemical compound C1=CC(OCCC)=CC=C1OC1=NC=C(C#CC(C)NC(C)=O)S1 WMTXYBPCCTYHRF-UHFFFAOYSA-N 0.000 description 1
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229950001628 netoglitazone Drugs 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960001199 olmesartan medoxomil Drugs 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- MAGQQZHFHJDIRE-BNFZFUHLSA-N pellitorine Chemical compound CCCCC\C=C\C=C\C(=O)NCC(C)C MAGQQZHFHJDIRE-BNFZFUHLSA-N 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- UZUFPBIDKMEQEQ-UHFFFAOYSA-N perfluorononanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UZUFPBIDKMEQEQ-UHFFFAOYSA-N 0.000 description 1
- SNGREZUHAYWORS-UHFFFAOYSA-N perfluorooctanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- AZUIUVJESCFSLJ-UHFFFAOYSA-N phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C(C(F)(F)F)C=CC=1C=1C(OC)=CC=CC=1C(=O)NC(C=C1CC2)=CC=C1CN2C(=O)OC1=CC=CC=C1 AZUIUVJESCFSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940126844 remogliflozin Drugs 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 229960000804 ronifibrate Drugs 0.000 description 1
- AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical compound C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229950000737 sodelglitazar Drugs 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- SRVNVLSGXFMMLE-UVZUILRGSA-M sodium;(5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(1e,3s)-3-hydroxy-5,9-dimethyldeca-1,8-dienyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoate Chemical compound [Na+].C1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CC(CCC=C(C)C)C)[C@H](O)C[C@@H]21 SRVNVLSGXFMMLE-UVZUILRGSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 229950005268 sotagliflozin Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229950000584 tezosentan Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 229960000438 udenafil Drugs 0.000 description 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- WQAJKOXBERTWBK-UHFFFAOYSA-N verdine Natural products CC1CNC2C(C1)OC3(CCC4C5CCC6(O)CC(O)CC(O)C6(C)C5C(=O)C4=C3C)C2C WQAJKOXBERTWBK-UHFFFAOYSA-N 0.000 description 1
- UGNVBODTSYDQPO-UHFFFAOYSA-N vibralactone Natural products C1=C(CO)CC2OC(=O)C21CC=C(C)C UGNVBODTSYDQPO-UHFFFAOYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 1
- 229950005371 zaprinast Drugs 0.000 description 1
- 229930188494 zaragozic acid Natural products 0.000 description 1
- DFKDOZMCHOGOBR-UHFFFAOYSA-N zaragozic acid A Natural products O1C(C(O)(C(O2)C(O)=O)C(O)=O)(C(O)=O)C(OC(=O)C=CC(C)CC(C)CC)C(O)C21CCC(=C)C(OC(C)=O)C(C)CC1=CC=CC=C1 DFKDOZMCHOGOBR-UHFFFAOYSA-N 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
본 개시내용은 작용의 증가된 기간 및 생체이용률을 포함한 개선된 성질을 갖는 계면활성제 모이어티에 공유 결합된 펩티드를 포함하는 펩티드 생성물을 제공한다. 펩티드 생성물은 인슐린 내성, 당뇨병, 비만증, 대사 증후군 및 심혈관 질환 및 이와 관련된 병태, 예컨대 NASH 및 PCOS의 치료에 유용하다.
Description
관련 출원
본원은 2018년 1월 3일자로 출원된 미국 가출원 제62/613,396호를 우선권주장으로 하며, 이는 본원에 참조로 그 전문이 포함된다.
개시내용의 분야
진성 당뇨병의 증가하는 유병률은 환자 질병률 및 사망률의 주요 원인이 되며 주요한 경제적 부담이 되는 유행병 비율의 세계적인 보건 위기가 된다. 비만증은 2형 당뇨병에 대한 중요한 위험 요인이며, 2형 당뇨병 환자의 대략 90%는 과체중 또는 비만이다. 비만증은 급속하게 증가하고 있는 세계적인 문제이며, 미국에서는 성인의 65% 이상이 과체중이다. 본 개시내용은 비만증 또는/및 당뇨병, 예컨대 비알콜성 지방간염(NASH) 및 다낭성 난소 증후군(PCOS)과 관련된 질병의 치료를 위한 개선된 펩티드 약제를 제공한다.
개시내용의 개요
본원에는 펩티드 생성물 및, 인슐린 내성 또는/및 비만증, 예컨대 2형 당뇨병, 대사 증후군, 심혈관 질환(관상 동맥 질환, 예컨대 죽상경화증 및 심근경색증 포함), 고혈압, NASH 및 PCOS와 관련된 질병의 치료에서 및 상기 질환과 관련된 병태의 치료에서의 이의 용도가 기재되어 있다. 펩티드 생성물은 친수성 당류 기 및 소수성 기를 함유하는 계면활성제 모이어티에 공유 결합된 펩티드를 포함한다. 일부 실시양태에서, 펩티드는 대사 호르몬, 예컨대 GLP-1, 글루카곤, 옥신토모듈린 또는 엑센딘(예를 들어, 엑센딘-4) 또는 이들의 유사체 또는 변이체이다. 펩티드 생성물은 증가된 작용 기간 및 생체이용률을 포함한 개선된 성질을 갖는다.
참조 문헌 인용
본 명세서에 언급된 모든 공보, 특허 및 특허 출원은 본원에서 개개의 개별적인 공보, 특허 또는 특허 출원이 참조로 인용되는 것으로 구체적으로 및 개별적으로 나타내는 바와 동일한 정도로 참조로 포함된다.
도 1은 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 2는 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 3은 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 4는 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 5는 GLP-1 수용체의 N-말단 구역/세포외 도메인의 결합 부위의 X선 결정 구조를 도시하며, 이는 임계 소수성 리간드 결합 구역을 나타낸다(리간드 엑센딘-4의 Val19 *, Phe22 *, Trp25 * 및 Leu26 * 및, Glu15를 넘어선 엑센딘-4의 서열은 양친매성 헬릭스로서 상기 구역과 상호작용한다).
도 6은 펩티드의 위치 24에서 리신 잔기의 엡실론(측쇄) 아미노 기가 각각 1-O-옥틸 베타-D-글루쿠론산, 1-O-옥틸 베타-D-멜리비오우론산 또는 1-O-옥틸 알파-D-멜리비오우론산과의 아미드 결합을 형성하는, 3종의 대표적인 펩티드 생성물인 EU-A992, EU-A1022 및 EU-A1169의 구조를 도시한다.
도 7은 EU-A992의 구조의 보다 상세한 도시이다.
도 8은 인간 혈장 중에서 37℃에서 인큐베이션 중에 시간 경과에 따른 펩티드 생성물인 EU-A993 및 EU-A1023 및 천연 호르몬 GLP-1(7-36)의 농도를 도시한다.
도 9는 t = 0 및 7 시간에서 EU-A992, EU-A1167 및 EU-A1168(각각 250 nmol/㎏에서)의 피하 주사 후 db/db 마우스의 혈당 반응을 도시한다.
도 10은 1일차(T = 0 및 7 시간에서), 3, 6, 9, 12, 15, 18, 21 및 24일차에 2종의 상이한 투약에서 펩티드 생성물 EU-A1024의 피하 주사 후 식이 유발된 비만(DIO) 마우스에서의 체중 감량을 도시한다.
도 11은 1일차(투약전) 및 26일차에 NMR에 의하여 측정되도록 처치된 DIO 마우스에서 전신 지방 조직량 및 제지방 조직량에서의 변화를 도시한다.
도 12a-12b는 NASH의 식이 유발된 비만(DIO) 마우스 모델에서 체중에 대한 테스트 화합물의 효과를 도시한다.
도 13a-13b는 DIO-NASH 마우스에서 전신 지방 조직량에 대한 테스트 화합물의 효과를 도시한다.
도 14a-14b는 DIO-NASH 마우스에서 혈장 트리글리세리드(TG) 및 총 콜레스테롤(TC) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 15a-15b는 DIO-NASH 마우스에서 혈장 알라닌 트랜스아미나제(ALT) 및 아스파르테이트 트랜스아미나제(AST) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 16은 DIO-NASH 마우스에서 간 중량에 대한 테스트 화합물의 효과를 도시한다.
도 17a-17e는 DIO-NASH 마우스에서 헤마톡실린 및 에오신 염색을 사용한 간 지방증에 대한 테스트 화합물의 효과를 도시한다(도 17c에서 커다란 타원형 구조는 정맥임).
도 18a-18b는 DIO-NASH 마우스에서 조직학적 정량적 측정에 의하여 측정시 % 환부 면적 및 총 간 지질 함량에 관하여 생검후 간 지방증에 대한 테스트 화합물의 효과를 도시한다.
도 19a-19b는 DIO-NASH 마우스에서 간 트리글리세리드(TG) 및 총 콜레스테롤(TC) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 20은 DIO-NASH 마우스에서 면역조직화학적으로 측정시 총 간 콜라겐 1형 알파 1(col1a1) 함량에 대한 테스트 화합물의 효과를 도시한다.
도 21은 DIO-NASH 마우스에서 면역조직화학적으로 측정시 총 간 갈렉틴-3 함량에 대한 테스트 화합물의 효과를 도시한다.
도 22a-22e는 DIO-NASH 마우스에서 간 지방증 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 23a-23e는 DIO-NASH 마우스에서 간 염증 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 24a-24e는 DIO-NASH 마우스에서 간세포 확대 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 25a-25e는 DIO-NASH 마우스에서 NAS(비알콜성 지방간 질환 활성 스코어) 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 26a-26e는 DIO-NASH 마우스에서 간 섬유증 스코어에 대한 테스트 화합물의 효과를 도시하며, 여기서 간 섬유증은 피크로시리우스 레드 염색에 의하여 평가하였다.
도 27a-27f는 DIO-NASH 마우스에서의 섬유증, 염증 및, 단핵구 동원 및 분화에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 28a-28f는 DIO-NASH 마우스에서 단핵구 동원 및 분화에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 29a-29i는 DIO-NASH 마우스에서 섬유증 섬유 형성에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 30a-30f는 DIO-NASH 마우스에서 간 성상 세포 활성화 및 근섬유모세포 증식에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 31a-31f는 DIO-NASH 마우스에서 파이롭토시스에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 2는 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 3은 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 4는 모두 본 개시내용에 포함되는 구체적인 펩티드 생성물을 도시한다.
도 5는 GLP-1 수용체의 N-말단 구역/세포외 도메인의 결합 부위의 X선 결정 구조를 도시하며, 이는 임계 소수성 리간드 결합 구역을 나타낸다(리간드 엑센딘-4의 Val19 *, Phe22 *, Trp25 * 및 Leu26 * 및, Glu15를 넘어선 엑센딘-4의 서열은 양친매성 헬릭스로서 상기 구역과 상호작용한다).
도 6은 펩티드의 위치 24에서 리신 잔기의 엡실론(측쇄) 아미노 기가 각각 1-O-옥틸 베타-D-글루쿠론산, 1-O-옥틸 베타-D-멜리비오우론산 또는 1-O-옥틸 알파-D-멜리비오우론산과의 아미드 결합을 형성하는, 3종의 대표적인 펩티드 생성물인 EU-A992, EU-A1022 및 EU-A1169의 구조를 도시한다.
도 7은 EU-A992의 구조의 보다 상세한 도시이다.
도 8은 인간 혈장 중에서 37℃에서 인큐베이션 중에 시간 경과에 따른 펩티드 생성물인 EU-A993 및 EU-A1023 및 천연 호르몬 GLP-1(7-36)의 농도를 도시한다.
도 9는 t = 0 및 7 시간에서 EU-A992, EU-A1167 및 EU-A1168(각각 250 nmol/㎏에서)의 피하 주사 후 db/db 마우스의 혈당 반응을 도시한다.
도 10은 1일차(T = 0 및 7 시간에서), 3, 6, 9, 12, 15, 18, 21 및 24일차에 2종의 상이한 투약에서 펩티드 생성물 EU-A1024의 피하 주사 후 식이 유발된 비만(DIO) 마우스에서의 체중 감량을 도시한다.
도 11은 1일차(투약전) 및 26일차에 NMR에 의하여 측정되도록 처치된 DIO 마우스에서 전신 지방 조직량 및 제지방 조직량에서의 변화를 도시한다.
도 12a-12b는 NASH의 식이 유발된 비만(DIO) 마우스 모델에서 체중에 대한 테스트 화합물의 효과를 도시한다.
도 13a-13b는 DIO-NASH 마우스에서 전신 지방 조직량에 대한 테스트 화합물의 효과를 도시한다.
도 14a-14b는 DIO-NASH 마우스에서 혈장 트리글리세리드(TG) 및 총 콜레스테롤(TC) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 15a-15b는 DIO-NASH 마우스에서 혈장 알라닌 트랜스아미나제(ALT) 및 아스파르테이트 트랜스아미나제(AST) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 16은 DIO-NASH 마우스에서 간 중량에 대한 테스트 화합물의 효과를 도시한다.
도 17a-17e는 DIO-NASH 마우스에서 헤마톡실린 및 에오신 염색을 사용한 간 지방증에 대한 테스트 화합물의 효과를 도시한다(도 17c에서 커다란 타원형 구조는 정맥임).
도 18a-18b는 DIO-NASH 마우스에서 조직학적 정량적 측정에 의하여 측정시 % 환부 면적 및 총 간 지질 함량에 관하여 생검후 간 지방증에 대한 테스트 화합물의 효과를 도시한다.
도 19a-19b는 DIO-NASH 마우스에서 간 트리글리세리드(TG) 및 총 콜레스테롤(TC) 농도에 대한 테스트 화합물의 효과를 도시한다.
도 20은 DIO-NASH 마우스에서 면역조직화학적으로 측정시 총 간 콜라겐 1형 알파 1(col1a1) 함량에 대한 테스트 화합물의 효과를 도시한다.
도 21은 DIO-NASH 마우스에서 면역조직화학적으로 측정시 총 간 갈렉틴-3 함량에 대한 테스트 화합물의 효과를 도시한다.
도 22a-22e는 DIO-NASH 마우스에서 간 지방증 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 23a-23e는 DIO-NASH 마우스에서 간 염증 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 24a-24e는 DIO-NASH 마우스에서 간세포 확대 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 25a-25e는 DIO-NASH 마우스에서 NAS(비알콜성 지방간 질환 활성 스코어) 스코어에 대한 테스트 화합물의 효과를 도시한다.
도 26a-26e는 DIO-NASH 마우스에서 간 섬유증 스코어에 대한 테스트 화합물의 효과를 도시하며, 여기서 간 섬유증은 피크로시리우스 레드 염색에 의하여 평가하였다.
도 27a-27f는 DIO-NASH 마우스에서의 섬유증, 염증 및, 단핵구 동원 및 분화에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 28a-28f는 DIO-NASH 마우스에서 단핵구 동원 및 분화에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 29a-29i는 DIO-NASH 마우스에서 섬유증 섬유 형성에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 30a-30f는 DIO-NASH 마우스에서 간 성상 세포 활성화 및 근섬유모세포 증식에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
도 31a-31f는 DIO-NASH 마우스에서 파이롭토시스에 연관된 mRNA의 간 발현에 대한 테스트 화합물의 효과를 도시한다.
정의
본원에서 이들의 사용에 의하여 달리 정의하거나 또는 달리 명백하게 나타내지 않는다면, 본원에 사용된 모든 기술적 및 과학적 용어는 본원이 속하는 분야의 통상의 기술자에 의하여 통상적으로 이해되는 바와 동일한 의미를 갖는다.
명세서 및 첨부된 청구범위에서 사용된 바와 같이, 단수형은 하나 이상을 의미한다. 본원에서 사용된 바와 같이, 용어 "또 다른"은 제2의 또는 그 이상을 의미한다.
약어 "aka"는 "~로도 알려진"을 의미한다.
용어 "예시적인"은 본원에서 사용된 바와 같이 "예, 사례 또는 예시로서 작용한다"는 것을 의미한다. 본원에서 "예시적인"으로 특징화된 임의의 실시양태 또는 특징은 반드시 다른 실시양태 또는 특징에 비하여 바람직하거나 또는 이로운 것으로 간주될 필요는 없다.
일부 실시양태에서, 용어 "약" 또는 "대략"은 명시된 값의 ±10% 또는 5% 이내라는 것을 의미한다. 용어 "약" 또는 "대략"이 연속하는 2종 이상의 수치에서 또는 수치의 연속하는 2종 이상의 범위에서 제1의 수치에 선행할 때마다, 용어 "약" 또는 "대략"은 연속하는 상기 수치 또는 수치의 연속하는 상기 범위에서 수치 중 각각의 하나에 적용된다.
"펩티드"는 통상적으로 펩티드 결합을 통하여 연결된 2종 이상의 천연 또는/및 비천연 아미노산 잔기를 포함한다. 상기 아미노산은 천연 발생 구조 변이체, 천연 발생 비단백질성 아미노산 또는/및 천연 아미노산의 합성 비천연 발생 유사체를 포함할 수 있다. 용어 "펩티드" 및 "폴리펩티드"는 본원에서 상호교환적으로 사용된다. 펩티드는 짧은 펩티드(약 2-20종의 아미노산), 중간 길이 펩티드(약 21-50종의 아미노산) 및 긴 펩티드(>약 50종의 아미노산, 또한 "단백질"로도 지칭될 수 있음)를 포함한다. 일부 실시양태에서, 펩티드 생성물은 약 50, 40 또는 30종 이하의 아미노산의 펩티드에 공유 결합된 계면활성제 모이어티를 포함한다. 합성 펩티드는 예를 들면 자동화된 펩티드 합성기를 사용하여 합성될 수 있다. 펩티드는 또한 펩티드를 코딩하는 핵산 서열을 발현시키는 세포에서 재조합 생성될 수 있다. 통상의 표기는 본원에서 펩티드 서열을 나타내는데 사용된다: 펩티드 서열의 좌측 단부는 아미노 (N)-말단이며, 펩티드 서열의 우측 단부는 카르복실 (C)-말단이다.
통상의 아미노산에 대한 표준 1문자 및 3문자 약어를 본원에서 사용한다. 본원에 개시된 아미노산 서열에 사용된 약어가 D- 또는 DL-로서 달리 지정하지 않을 경우 L-아미노산을 나타내거나 또는 아미노산이 아키랄이더라도, 대응부 D-이성질체는 일반적으로 임의의 위치에서 사용될 수 있다(예를 들어, 단백분해성 분해를 저지하기 위하여). 본원에 사용된 다른 아미노산에 대한 약어는 하기를 포함한다: Ac3c = 1-아미노시클로프로판-1-카르복실산; Ac4c = 1-아미노시클로부탄-1-카르복실산; Ac5c = 1-아미노시클로펜탄-1-카르복실산; Ac6c = 1-아미노시클로헥산-1-카르복실산; Aib = α-아미노이소부티르산(또는 2-메틸알라닌 또는 Cα-메틸알라닌); Bip = 3-(비페닐-4-일)알라닌; Bip2Et = 3-(2'-에틸비페닐-4-일)알라닌; Bip2EtMeO = 3-(2'-에틸-4'-메톡시비페닐-4-일)알라닌; Cit = 시트룰린; Deg = 2,2-디에틸글리신; Dmt = (2,6-디메틸)티로신; 2FPhe = (2-플루오로페닐)알라닌; 2FMePhe 또는 2FαMePhe = Cα-메틸-(2-플루오로페닐)알라닌; hArg = 호모아르기닌; MeLys 또는 αMeLys = Cα-메틸리신; MePhe 또는 αMePhe = Cα-메틸페닐알라닌; MePro 또는 αMePro = Cα-메틸프롤린; Nal1 또는 Nal(1) = 3-(1-나프틸)알라닌; Nal2 또는 Nal(2) = 3-(2-나프틸)알라닌; Nle = 노르류신; Orn = 오르니틴; 및 Tmp = (2,4,6-트리메틸페닐)알라닌. 잔기 사이에서 감소된 아미드 결합을 갖는 1,2,3,4-테트라히드로이소퀴놀린-3-카르복실산(Tic) 및 Tic-Phe 디펩티드 모이어티(Tic-Ψ[CH2-NH]-Ψ-Phe로 지정함)는 하기 구조를 갖는다:
구체적으로 달리 명시하거나 또는 문맥이 명백하게 달리 나타내지 않는다면, 본 개시내용은 펩티드가 합성에 의하여(예를 들어, 펩티드 합성기를 사용하여) 또는 세포에 의하여(예를 들어, 재조합 생성에 의하여) 생성될 수 있는 펩티드의 임의의 및 모든 형태를 포함한다. 상기 형태의 펩티드는 하나 이상의 변경이 고려되든 고려되지 않든, 펩티드의 합성 또는 세포성 생성의 과정 중에 생성될 수 있는 하나 이상의 변경, 예컨대 하나 이상의 번역후 변경을 포함할 수 있다. 펩티드는 2종 이상의 상이한 위치에서 동일한 유형의 변경을 가질 수 있거나/있고 2종 이상의 상이한 유형의 변경을 가질 수 있다. 화학적 및 번역후 변경을 포함한 펩티드의 합성 또는 세포성 생성의 과정 중에 생성될 수 있는 변경은 글리코실화(예를 들어, N-연결된 글리코실화 및 O-연결된 글리코실화), 지질화, 인산화, 황산화, 아세틸화(예를 들어, N-말단의 아세틸화), 아미드화(예를 들어, C-말단의 아미드화), 히드록실화, 메틸화, 분자내 또는 분자간 디술피드 결합의 형성, 2개의 측쇄 사이의 락탐의 형성, 피로글루타메이트의 형성 및 유비퀴틴화를 포함하나 이에 제한되지 않는다. 펩티드는 어느 곳에서나, 예컨대 N-말단, C-말단, 하나 이상의 아미노산 측쇄 또는 펩티드 백본 또는 이들의 임의의 조합에서 하나 이상의 변경을 가질 수 있다. 일부 실시양태에서, 펩티드는 N-말단에서 아세틸화되거나 또는/및 C-말단에서 카르복스아미드(-CONH2) 기를 가져서 펩티드의 안정성을 증가시킬 수 있다.
펩티드의 잠재적 변경은 또한 하나 이상의 아미노산의 결실, 하나 이상의 천연 또는/및 비천연 아미노산의 첨가/삽입 또는 하나 이상의 천연 또는/및 비천연 아미노산에의 치환 또는 이들의 임의의 또는 전부의 조합을 포함한다. 치환은 보존적이거나 또는 비보존적일 수 있다. 상기 변경은 예컨대 부위 지향된 돌연변이를 통하여 또는 펩티드의 화학적 합성에서 고려될 수 있거나 또는 우발적일 수 있으며, 예컨대 펩티드를 생성하는 숙주 세포에서 발생하는 돌연변이에 의하여 또는 PCR 증폭으로 인한 오차에 의할 수 있다. 비천연 아미노산은 D 입체화학을 갖는 것을 제외하고 대응부 천연 아미노산과 동일한 화학적 구조를 가질 수 있거나 또는 상이한 화학적 구조 및 D 또는 L 입체화학을 가질 수 있다. 비천연 아미노산은 예를 들면 α-헬릭스 형성을 촉진시키기 위하여 또는/및 펩티드의 안정성을 증가시키기 위하여(예를 들어, 단백분해성 분해를 저지시키기 위하여) 사용될 수 있다.
기준 펩티드에 대한 하나 이상의 변경을 갖는 펩티드는 적절히 기준 펩티드의 "유사체" 또는 "변이체"로 지칭될 수 있다. "유사체"는 통상적으로 기준 펩티드의 하나 이상의 필수 성질(예를 들어, 수용체 결합, 수용체 또는 효소의 활성화, 수용체 또는 효소의 억제 또는 다른 생물학적 활성)을 보유한다. "변이체"는 기준 펩티드의 생물학적 활성을 보유할 수 있거나 또는 보유하지 않을 수 있으며 또는/및 상이한 생물학적 활성을 가질 수 있다. 일부 실시양태에서, 기준 펩티드의 유사체 또는 변이체는 기준 펩티드와는 상이한 아미노산 서열을 갖는다.
용어 "보존적 치환"은 펩티드에서의 아미노산을 작용적, 구조적 또는 화학적으로 유사한 천연 또는 비천연 아미노산으로 치환하는 것을 지칭한다. 특정한 실시양태에서, 하기 기 각각은 서로에 대하여 보존적 치환인 천연 아미노산을 함유한다:
1) 글리신(Gly/G), 알라닌(Ala/A);
2) 이소류신(Ile/I), 류신(Leu/L), 메티오닌(Met/M), 발린(Val/V);
3) 페닐알라닌(Phe/F), 티로신(Tyr/Y), 트립토판(Trp/W);
4) 세린(Ser/S), 트레오닌(Thr/T), 시스테인(Cys/C);
5) 아스파라긴(Asn/N), 글루타민(Gln/Q);
6) 아스파르트산(Asp/D), 글루탐산(Glu/E); 및
7) 아르기닌(Arg/R), 리신(Lys/K), 히스티딘(His/H).
추가의 실시양태에서, 하기 기 각각은 서로에 대하여 보존적 치환인 천연 아미노산을 함유한다:
1) 비극성: Ala, Val, Leu, Ile, Met, Pro(프롤린/P), Phe, Trp;
2) 소수성: Val, Leu, Ile, Phe, Trp;
3) 지방족: Ala, Val, Leu, Ile;
4) 방향족: Phe, Tyr, Trp, His;
5) 비하전된 극성 또는 친수성: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln, Tyr;
6) 지방족 히드록실- 또는 술프히드릴 함유: Ser, Thr, Cys;
7) 아미드 함유: Asn, Gln;
8) 산성: Asp, Glu;
9) 염기성: Lys, Arg, His; 및
10) 작은: Gly, Ala, Ser, Cys.
다른 실시양태에서, 아미노산은 하기 명시된 바와 같이 그룹화될 수 있다:
1) 소수성: Val, Leu, Ile, Met, Phe, Trp;
2) 방향족: Phe, Tyr, Trp, His;
3) 중성 친수성: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln;
4) 산성: Asp, Glu;
5) 염기성: Lys, Arg, His; 및
6) 백본 배향에 영향을 미치는 잔기: Pro.
비천연 또는 비단백질성 아미노산의 예는 알라닌 유사체(예를 들어, α-에틸Gly[α-아미노부티르산 또는 Abu], α-n-프로필Gly[노르발린 또는 Nva], α-tert-부틸Gly[Tbg], α-비닐Gly[Vg 또는 Vlg], α-알릴Gly[Alg], α-프로파르길Gly[Prg], 3-시클로프로필Ala[Cpa] 및 Aib), 류신 유사체(예를 들어, Nle), 프롤린 유사체(예를 들어, α-MePro), 페닐알라닌 유사체{예를 들어, Phe(2-F), Phe(2-Me), Tmp, Bip, Bip(2'-Et-4'-OMe), Nal1, Nal2, Tic, α-MePhe, α-MePhe(2-F) 및 α-MePhe(2-Me)}, 티로신 유사체(예를 들어, Dmt 및 α-MeTyr), 세린 유사체(예를 들어, 호모세린[이소트레오닌 또는 hSer]), 글루타민 유사체(예를 들어, Cit), 아르기닌 유사체(예를 들어, hArg), 리신 유사체(예를 들어, 호모리신[hLys], Orn 및 α-MeLys), α,α-이치환된 아미노산(예를 들어, Aib, α,α-디에틸Gly[Deg], α-시클로헥실Ala[2-Cha], Ac3c, Ac4c, Ac5c 및 Ac6c) 및 문헌[A. Santoprete et al., J. Pept. Sci., 17:270-280 (2011)]에 개시된 다른 비천연 아미노산을 포함하나 이에 제한되지 않는다. α,α-이치환된 아미노산은 형태적 제약 또는/및 α-헬릭스 안정화를 제공할 수 있다. 2개의 잔기 사이의 감소된 아미드 결합(예를 들면 Tic-Ψ[CH2-NH]-Ψ-Phe에서와 같이)은 프로테아제 내성을 증가시키며, 또한 예를 들면 수용체 결합을 변경시킬 수 있다.
본 개시내용은 양의 알짜 전하를 갖는 것, 음의 알짜 전하를 갖는 것 및 알짜 전하를 갖지 않는 것을 포함한 펩티드의 모든 약학적으로 허용되는 염을 포함한다.
당류는 단당류, 이당류 및 올리고당류(예를 들어, 삼당류, 사당류 등)를 포함한다. 환원 당류는 고리 형태 및 개방쇄 형태로 평형 상태로 존재하며, 이는 일반적으로 고리 형태를 선호한다. 계면활성제 모이어티의 작용화된 당류는 펩티드의 아미노산과의 공유 결합을 형성하기에 적절한 작용기를 갖는다.
"알킬" 기는 지방족 탄화수소 기를 지칭한다. 알킬 기는 포화 또는 불포화일 수 있으며, 직쇄형(선형), 분지형 또는 시클릭일 수 있다. 일부 실시양태에서, 알킬 기는 시클릭이 아니다. 일부 실시양태에서, 알킬 기는 1-30, 6-30, 6-20 또는 8-20개의 탄소 원자를 함유한다. "치환된" 알킬 기는 하나 이상의 치환기로 치환된다. 일부 실시양태에서, 하나 이상의 치환기는 할로겐, 니트로, 시아노, 옥소, 히드록시, 알콕시, 할로알콕시, 아릴옥시, 티올, 알킬티오, 아릴티오, 알킬술폭시드, 아릴술폭시드, 알킬술폰, 아릴술폰, 아미노, 알킬아미노, 디알킬아미노, 아릴아미노, 알코일, 카르복실, 카르복실레이트, 에스테르, 아미드, 카르보네이트, 카르바메이트, 우레아, 알킬, 할로알킬, 플루오로알킬, 아랄킬, 아실 기를 함유하는 알킬 쇄, 헤테로알킬, 헤테로알리시클릭, 아릴, 알콕시아릴, 헤테로아릴, 소수성 천연 화합물(예를 들어, 스테로이드) 등으로부터 독립적으로 선택된다.
일부 실시양태에서, 치환기로서 알킬 기는 "저급 알킬"로 지칭될 수 있는 선형 또는 분지형 C1-C6 알킬이다. 저급 알킬 기의 비제한적인 예는 메틸, 에틸, 프로필(n-프로필 및 이소프로필 포함), 부틸(모든 이성질체 형태, 예컨대 n-부틸, 이소부틸, sec-부틸 및 tert-부틸 포함), 펜틸(모든 이성질체 형태, 예컨대 n-펜틸 포함) 및 헥실(모든 이성질체 형태, 예컨대 n-헥실 포함)을 포함한다.
일부 실시양태에서, 알킬 기는 펩티드의 잔기(예를 들어, Tyr 또는 Dmt)의 Nα-원자에 연결된다. 특정한 실시양태에서, N-알킬 기는 직쇄형 또는 분지형 C1-C10 알킬 또는 아릴-치환된 알킬, 예컨대 벤질, 페닐에틸 등이다. 1 또는 2개의 알킬 기는 N-말단 잔기의 Nα-원자에 연결될 수 있다.
일부 실시양태에서, 알킬 기는 당류(예를 들어, 글루코스)의 C-1 위치에 글리코시드 결합(예를 들어, O-, S-, N- 또는 C-글리코시드 결합)을 통하여 연결되는 1-알킬 기이다. 일부 실시양태에서, 상기 1-알킬 기는 비치환된 또는 치환된 C1-C30, C6-C30, C6-C20 또는 C8-C20 알킬 기이다.
일부 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 아릴, -OH, -OR1, -SH, -SR1, -NH2, -NHR1, -N(R1)2, 옥소 (=O), -C(=O)R2, 카르복실(-CO2H), 카르복실레이트(-CO2 -), -C(=O)OR1, -OC(=O)R3, -C(=O)N(R1)2, -NR4C(=O)R3, -OC(=O)OR5, -OC(=O)N(R1)2, -NR4C(=O)OR5 및 -NR4C(=O)N(R1)2로부터 독립적으로 선택된 기 하나 이상(예를 들어, 2 또는 3개)으로 치환되며, 여기서
R1은 각각의 경우에 독립적으로 수소, 알킬 또는 아릴이거나 또는 R1 및 이들이 연결되어 있는 질소 원자의 둘 다의 발생은 헤테로시클릴 또는 헤테로아릴 고리를 형성하며;
R2는 각각의 경우에 독립적으로 알킬, 헤테로시클릴, 아릴 또는 헤테로아릴이며;
R3은 각각의 경우에 독립적으로 수소, 알킬, 헤테로시클릴, 아릴 또는 헤테로아릴이며;
R4는 각각의 경우에 독립적으로 수소 또는 알킬이며;
R5는 각각의 경우에 독립적으로 알킬 또는 아릴이다.
일부 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 카르복실/카르복실레이트 기, 아릴 기 또는 -O-아릴 기로 내부에 또는/및 말단에 치환된다. 특정한 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 알킬 기의 원위 단부에서 카르복실 또는 카르복실레이트 기로 치환된다. 추가의 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 알킬 기의 원위 단부에서 아릴 기로 치환된다. 다른 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 알킬 기의 원위 단부에서 -O-아릴 기로 치환된다.
용어 "할로겐", "할라이드" 및 "할로"는 플루오라이드, 클로라이드, 브로마이드 및 요오다이드를 지칭한다.
용어 "아실"은 -C(=O)R을 지칭하며, 여기서 R은 포화 또는 불포화될 수 있으며, 선형, 분지형 또는 시클릭일 수 있는 지방족 기이다. 특정한 실시양태에서, R은 1-20개, 1-10개 또는 1-6개의 탄소 원자를 함유한다. 아실 기는 하나 이상의 기, 예컨대 할로겐, 옥소, 히드록실, 알콕시, 티올, 알킬티오, 아미노, 알킬아미노, 디알킬아미노, 시클로알킬, 아릴, 아실, 카르복실, 에스테르, 아미드, 소수성 천연 화합물(예를 들어, 스테로이드) 등으로 임의로 치환될 수 있다.
용어 "헤테로시클릴" 및 "헤테로시클릭"은 적어도 1종의 비방향족 고리를 함유하는 모노시클릭 비방향족 기 또는 멀티시클릭 기를 지칭하며, 여기서 적어도 1종의 비방향족 고리는 O, N 및 S로부터 독립적으로 선택된 1종 이상의 헤테로원자를 함유한다. 1종 이상의 헤테로원자를 함유하는 비방향족 고리는 하나 이상의 포화, 부분 불포화 또는 방향족 고리에 연결 또는 융합될 수 있다. 특정한 실시양태에서, 헤테로시클릴 또는 헤테로시클릭 기는 3 내지 15 또는 3 내지 12 또는 3 내지 10 또는 3 내지 8 또는 3 내지 6개의 고리 원자를 갖는다. 헤테로시클릴 또는 헤테로시클릭 기는 아지리디닐, 아제티디닐, 피롤리디닐, 피페리디닐, 모르폴리닐, 피페라지닐, 아제파닐, 아조카닐, 옥시라닐, 옥세타닐, 테트라히드로푸라닐(옥솔라닐), 테트라히드로피라닐, 옥세파닐 및 옥소카닐을 포함하나 이에 제한되지 않는다.
용어 "아릴"은 적어도 1종의 방향족 탄화수소 고리를 함유하는 모노시클릭 방향족 탄화수소 기 또는 멀티시클릭 기를 지칭한다. 특정한 실시양태에서, 아릴 기는 6 내지 15 또는 6 내지 12 또는 6 내지 10개의 고리 원자를 갖는다. 아릴 기는 페닐, 나프탈레닐(나프틸), 플루오레닐, 아줄레닐, 안트릴, 페난트릴, 비페닐 및 터페닐을 포함하나 이에 제한되지 않는다. 아릴 기의 방향족 탄화수소 고리는 하나 이상의 포화, 부분 불포화 또는 방향족 고리에 연결 또는 융합될 수 있으며, 예를 들면 디히드로나프틸, 인데닐, 인다닐 및 테트라히드로나프틸(테트랄리닐)이다. 아릴 기는 할로겐(-F 및 -Cl 포함), 시아노, 니트로, 히드록실, 알콕시, 티올, 알킬티오, 알킬술폭시드, 알킬술폰, 아미노, 알킬아미노, 디알킬아미노, 알킬, 할로알킬(플루오로알킬, 예컨대 트리플루오로메틸 포함), 아실, 카르복실, 에스테르, 아미드 등으로부터 독립적으로 선택된 치환기 하나 이상(예를 들어, 2 또는 3종)으로 임의로 치환될 수 있다.
용어 "헤테로아릴"은 적어도 1종의 방향족 고리를 함유하는 모노시클릭 방향족 기 또는 멀티시클릭 기를 지칭하며, 여기서 적어도 1종의 방향족 고리는 O, N 및 S로부터 독립적으로 선택된 헤테로원자 1종 이상을 함유한다. 헤테로방향족 고리는 탄소 원자만을 함유할 수 있으며, 1종 이상의 헤테로원자를 함유할 수 있는 하나 이상의 포화, 부분 불포화 또는 방향족 고리에 연결 또는 융합될 수 있다. 특정한 실시양태에서, 헤테로아릴 기는 5 내지 15 또는 5 내지 12 또는 5 내지 10개의 고리 원자를 갖는다. 모노시클릭 헤테로아릴 기는 피롤릴, 피라졸릴, 피라졸리닐, 이미다졸릴, 옥사졸릴, 이속사졸릴, 티아졸릴, 티아디아졸릴, 이소티아졸릴, 푸라닐, 티에닐(티오페닐), 옥사디아졸릴, 트리아졸릴, 테트라졸릴, 피리딜, 피리도닐, 피라지닐, 피리미디닐, 피리다지닐, 피리다지노닐 및 트리아지닐을 포함하나 이에 제한되지 않는다. 비시클릭 헤테로아릴 기의 비제한적인 예는 인돌릴, 벤조티아졸릴, 벤조티아디아졸릴, 벤족사졸릴, 벤즈이속사졸릴, 벤조티에닐(벤조티오페닐), 퀴놀리닐, 테트라히드로이소퀴놀리닐, 이소퀴놀리닐, 벤즈이미다졸릴, 벤조트리아졸릴, 인돌리지닐, 벤조푸라닐, 이소벤조푸라닐, 크로모닐, 쿠마리닐, 신놀리닐, 퀴나졸리닐, 퀴녹살리닐, 인다졸릴, 나프티리디닐, 프탈라지닐, 퀴나졸리닐, 푸리닐, 피롤로피리디닐, 푸로피리디닐, 티에노피리디닐, 디히드로이소인돌릴 및 테트라히드로퀴놀리닐을 포함한다.
용어 "스테로이드 핵"은 하기 제시된 바와 같은 A, B, C 및 D로 지정된 융합된 고리 4종의 배열을 포함하는 스테로이드의 코어를 지칭한다:
스테로이드 핵은 하나 이상의 기, 예컨대 할로겐, 히드록실, 옥소, 알킬, 아실, 카르복실, 에스테르, 아미드 등을 지닐 수 있다. 스테로이드 핵 함유 모이어티는 콜레스테롤 등을 포함하나 이에 제한되지 않는다.
용어 "약학적으로 허용되는"은 과도한 자극, 알러지 반응, 면역원성 및 독성 없이 대상체의 조직 및 기관과 접촉에 사용하기 적절하며, 타당한 이득/위험비와 적합하며, 이들의 의도한 용도에 효과적인 물질(예를 들어, 활성 성분 또는 부형제)을 지칭한다. 약학 조성물의 "약학적으로 허용되는" 부형제 또는 담체는 또한 조성물의 다른 성분과 적합성을 갖는다.
용어 "치료 유효량"은 대상체에게 투여시 처치되는 의학적 병태를 예방하고, 병태의 발생 우려를 감소시키고, 병태의 개시를 지연시키고, 병태의 진행을 서행시키거나 또는 병태의 퇴행을 유발하거나 또는 상기 화합물을 취한 대상체의 적어도 일부 분율로 의학적 병태 또는 그러한 병태의 하나 이상의 증상 또는 합병증을 어느 정도로 완화시키기에 충분한 화합물의 양을 지칭한다. 용어 "치료 유효량"은 또한 의사 또는 임상의가 추구하는 세포, 조직, 장기 또는 인간의 생물학적 또는 의학적 반응을 유도하기에 충분한 화합물의 양을 지칭한다.
용어 "치료하다", "치료하는" 및 "치료"는 의학적 병태 또는 그러한 병태와 관련된 하나 이상의 증상 또는 합병증을 완화, 개선, 이들의 진행을 억제, 병태를 역전 또는 저지하며, 병태의 하나 이상의 원인을 완화, 개선 또는 근절시키는 것을 포함한다. 의학적 병태의 "치료"에 대한 언급은 병태의 예방을 포함한다. 용어 "예방하다", "예방하는" 및 "예방"은 의학적 병태 또는 상기 병태와 관련된 하나 이상의 증상 또는 합병증을 배제, 이들의 발생 위험을 감소 및 이들의 개시를 지연시키는 것을 포함한다.
용어 "의학적 병태"(또는 간략하게 "병태")는 질환 및 질병을 포함한다. 용어 "질환" 및 "질병"은 본원에서 상호교환적으로 사용된다.
비만증 및 인슐린 내성
비만증은 인슐린 수용체의 감소된 개수 및 인슐린 수용체의 임계 세포내 신호계로의 감소된 커플링을 통하여 인슐린 자극에 반응하는 체내 세포의 감소된 능력인 인슐린 내성을 초래한다. 비만 상태는 또한 인슐린 내성, 고혈압, 죽상경화증 등을 포함한 질병의 무리인 대사 증후군을 초래한다. 인슐린 내성은 종종 2형 당뇨병을 초래한다. 연장된 고혈당증은 미세혈관 및 대혈관 합병증, 감각 신경병증, 심근경색증, 뇌졸중, 대혈관 사망률 및 총 사망률의 위험을 증가시킨다. 2형 당뇨병, 대사 증후군 및 다른 비만증- 및 인슐린 내성-관련 질환은 세계적으로 커다란 재정적 및 의료 부담이 된다.
대사 호르몬
인크레틴은 혈당 수치 감소를 유발하는 대사 호르몬이다. 인크레틴은 식사 후 배출되며, 인슐린 생성 및 혈당 의존성 기전에 의하여 랑게르한스섬의 췌장 베타 세포로부터의 분비를 자극한다. 인크레틴은 또한 위 배출을 지연시켜 혈류로의 영양분의 흡수 속도를 지연시키며, 이는 포만감을 유발하여 식욕을 억제한다. 더욱이, 인크레틴은 랑게르한스섬의 알파 세포로부터 글루카곤 배출을 억제한다. 주요 인크레틴 2종은 장 L-세포에 의하여 분비되며, 글루카곤 펩티드 슈퍼패밀리의 구성원인 글루카곤 유사 펩티드-1(GLP-1) 및 위 억제 펩티드(GIP, 또한 글루코스 의존성 인슐린자극 폴리펩티드로도 알려짐)이다. GLP-1 및 GIP는 디펩티딜 펩티다제 4(DPP-4)에 의하여 급속하게 분해된다. 2형 당뇨병을 갖는 인간은 GLP-1에 반응하여 췌장 베타 세포로부터 인슐린 분비를 손상시켰다.
GLP-1은 다른 이로운 효과를 갖는다. 예를 들면, GLP-1은 췌장 베타-세포 증식을 자극하며, 말초 인슐린 민감도 및 간 글루코스 흡수 및 글리코겐 생성을 증가시키며, 심장 기능(예를 들어, 좌심실 기능)을 개선시킨다.
GLP-1과 같이, 옥신토모듈린(OXM)은 프리프로글루카곤으로부터 유도되며, 식사에 반응하여 창자에서 L-세포로부터 분비된다. OXM은 본질적으로 8종의 아미노산 잔기의 C-말단 확대를 갖는 글루카곤이다. OXM은 글루카곤 수용체(GCGR) 및 GLP-1 수용체(GLP1R) 둘 다를 활성화시키지만, 글루카곤 및 GLP-1보다 10 내지 100배 더 낮은 효력을 갖는다. OXM은 포만감을 유발하며, 체지방(예를 들어, 백색 지방 조직)을 감소시킨다. OXM은 음식 섭취 및 체지방을 감소시켜 체중 감량을 유발한다.
글루카곤은 랑게르한스섬의 췌장 알파 세포에서 프리프로글루카곤으로부터 생성된다. 글루카곤은 포만감을 유발하며, 지방 조직에서 지방분해를 유발하며, 에너지 소비를 증가시킨다. 글루카곤은 음식 섭취를 감소시키고, 지방 연소를 자극하여 체중을 감소시킨다.
인간 GLP-1, 글루카곤 및 옥신토모듈린의 생물학적 활성 형태의 아미노산 서열을 하기 제시한다:
GLP-1(글루카곤 넘버링 사용):
His1-Ala2-Glu3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Val10-Ser11-Ser12-Tyr13-Leu14-Glu15-Gly16-Gln17-Ala18-Ala19-Lys20-Glu21-Phe22-Ile23-Ala24-Trp25-Leu26-Val27-Lys28-Gly29-Arg30(서열 번호 1)
글루카곤:
His1-Ser2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Ser16-Arg17-Arg18-Ala19-Gln20-Asp21-Phe22-Val23-Gln24-Trp25-Leu26-Met27-Asn28-Thr29(서열 번호 2)
옥신토모듈린:
His1-Ser2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Ser16-Arg17-Arg18-Ala19-Gln20-Asp21-Phe22-Val23-Gln24-Trp25-Leu26-Met27-Asn28-Thr29-Lys30-Arg31-Asn32-Arg33-Asn34-Asn35-Ile36-Ala37(서열 번호 3)
GLP-1 및 글루카곤의 서열 전체에서 아미노산 잔기는 생물학적 활성을 보유하면서 대체될 수 있다. 예를 들면, Ala에 의한 대체는 GLP-1의 N-말단 구역에서, 특히 위치 2, 3, 5, 8, 11 및 12에서 잘 허용된다(Adelhorst et al., J. Biol . Chem., 269:6275-6278 [1994]). 더욱이, GLP-1의 짧은 N-말단 유사체는 강력하게 결합되어 GLP1R을 활성화시킬 수 있다(Mapelli et al., J. Med . Chem., 52:7788-7799 [2009]; 및 Haque et al., Peptides, 31:950-955 and 1353-1360 [2010]). GLP1R 및 GCGR 둘 다에 결합될 수 있는 키메라 유사체는 C-말단 잔기를 GLP-1로부터 글루카곤의 N-말단 잔기 상에 그래프팅하여 생성될 수 있다(Hjorth et al., J. Biol. Chem., 269:30121-30124 [1994]).
본 개시내용은 계면활성제 모이어티에 공유 결합되는 펩티드 장 호르몬(예를 들어, GLP-1, GIP, 글루카곤, 옥신토모듈린 또는 엑센딘[예를 들어, 엑센딘-4]) 또는 이들의 유사체 또는 변이체를 포함하는 펩티드 생성물을 제공한다. 펩티드 생성물은 근본적인 펩티드의 수용체(들)의 강력한 효능제이며, 대사 항상성을 촉진하며, 긴 작용 기간 및 향상된 생체이용률을 갖는다. 일부 실시양태에서, 펩티드 생성물은 GLP-1 수용체(GLP1R)의 효능제이다. GLP1R 효능제는 혈당 의존성 인슐린 분비를 자극하며, 저혈당증의 감소된 위험과 함께 인슐린 민감도를 증가시키며, 포만감을 유발하여 음식 섭취를 감소시키며, 체중 증가를 감소시키거나 또는 체중 감량을 야기한다. 추가의 실시양태에서, 펩티드 생성물은 GLP1R 및 글루카곤 수용체(GCGR)의 2중 효능제이며, 이는 지방 연소의 자극, 체지방량 손실 및 저혈당증의 예방을 포함한 GCGR 활성화의 이득을 추가한다.
펩티드 생성물
펩티드 및 단백질은 종종 제제 중의 불안정성, 응집, 짧은 작용 기간 및 불량한 생체이용률을 포함한, 의약으로서 이들의 용도에서의 단점을 갖는다. 본원에는 증가된 안정성, 반감기, 작용 기간 및 생체이용률 및 감소된 면역원성을 포함한 약제로서 개선된 성질을 갖는 펩티드 생성물이 개시되어 있다. 펩티드 생성물은 친수성 당류 기 및 소수성 기를 함유하는 계면활성제 모이어티에 공유 결합된 펩티드를 포함한다. 일부 실시양태에서, 펩티드는 당류 기에 연결되며, 이는 다시 소수성 기에 연결된다. 일부 실시양태에서, 펩티드는 대사 호르몬, 예컨대 GLP-1, 글루카곤, 옥신토모듈린 또는 엑센딘(예를 들어, 엑센딘-4) 또는 이들의 유사체 또는 변이체이다. 펩티드 생성물은 예를 들면 인슐린 내성, 당뇨병, 비만증, 대사 증후군 및 심혈관 질환 및 그와 연관된 병태, 예컨대 NASH 및 PCOS를 치료하는데 유용하다.
일부 실시양태에서, 펩티드 생성물은 계면활성제 모이어티(예를 들어, 알킬 글리코시드, 예컨대 1-알킬 글리코시드)에 공유 결합된 GLP-1 또는 이들의 유사체 또는 변이체를 포함한다. GLP-1 펩티드는 천연 또는 비천연 아미노산 서열 또는 구조를 가질 수 있다. 알킬 기는 비치환될 수 있거나 또는 (예를 들어, 카르복실/카르복실레이트, 아릴 또는 옥시아릴 기로) 치환될 수 있다. 특정한 실시양태에서, 알킬 글리코시드는 1-O-알킬 β-D-글루쿠론산이다.
추가의 실시양태에서, 펩티드 생성물은 계면활성제 모이어티(예를 들어, 알킬 글리코시드, 예컨대 1-알킬 글리코시드)에 공유 결합된 글루카곤 또는 이들의 유사체 또는 변이체를 포함한다. 글루카곤 펩티드는 천연 또는 비천연 아미노산 서열 또는 구조를 가질 수 있다. 알킬 기는 비치환될 수 있거나 또는 (예를 들어, 카르복실/카르복실레이트, 아릴 또는 옥시아릴 기로) 치환될 수 있다. 특정한 실시양태에서, 알킬 글리코시드는 1-O-알킬 β-D-글루쿠론산이다.
추가적인 실시양태에서, 펩티드 생성물은 계면활성제 모이어티(예를 들어, 알킬 글리코시드, 예컨대 1-알킬 글리코시드)에 공유 결합된 옥신토모듈린 또는 이들의 유사체 또는 변이체를 포함한다. 옥신토모듈린 펩티드는 천연 또는 비천연 아미노산 서열 또는 구조를 가질 수 있다. 알킬 기는 비치환될 수 있거나 또는 (예를 들어, 카르복실/카르복실레이트, 아릴 또는 옥시아릴 기로) 치환될 수 있다. 특정한 실시양태에서, 알킬 글리코시드는 1-O-알킬 β-D-글루쿠론산이다.
다른 실시양태에서, 펩티드 생성물은 계면활성제 모이어티(예를 들어, 알킬 글리코시드, 예컨대 1-알킬 글리코시드)에 공유 결합된 엑센딘(예를 들어, 엑센딘-4) 또는 이들의 유사체 또는 변이체를 포함한다. 엑센딘 펩티드는 천연 또는 비천연 아미노산 서열 또는 구조를 가질 수 있다. 알킬 기는 비치환될 수 있거나 또는 (예를 들어, 카르복실/카르복실레이트, 아릴 또는 옥시아릴 기로) 치환될 수 있다. 특정한 실시양태에서, 알킬 글리코시드는 1-O-알킬 β-D-글루쿠론산이다.
일부 실시양태는 링커 아미노산 U 및 적어도 1종의 다른 아미노산을 포함하는 펩티드에 공유 결합된 계면활성제 X를 포함하는, 하기 화학식 I-A의 펩티드 생성물에 관한 것이다:
상기 식에서,
계면활성제 X는 하기 화학식 I의 모이어티이며:
상기 식에서,
R1a는 각각의 경우에 독립적으로 결합, H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬(-알킬아릴) 기, 비치환된 또는 치환된 알킬옥시아릴 기, 또는 스테로이드 핵 함유 기이며;
R1b, R1c 및 R1d는 각각의 경우에 독립적으로 결합, H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬 기, 비치환된 또는 치환된 알킬옥시아릴 기, 또는 스테로이드 핵 함유 기이며;
R2는 각각의 경우에 독립적으로 결합, U에의 결합, H, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬 기, 비치환된 또는 치환된 알킬옥시아릴 기, 스테로이드 핵 함유 기, -NH-, -S-, -O-NH-, 스페이서, -트리아졸로-, -NH(C=O)-CH2- 또는 -(CH2)m-말레이미드-이며;
W1은 각각의 경우에 독립적으로 -CH2-, -CH2-O-, -CH2-S-, -CH2-NH-, -(C=O)-, -(C=O)-NH-, -(C=S)- 또는 -(C=S)-NH-이며;
W2는 각각의 경우에 독립적으로 -O-, -S-, -NH- 또는 -CH2-이며;
R1a, R1b, R1c, R1d 또는 R2 중 적어도 하나의 경우는 비치환된 또는 치환된 C1-C30 알킬, 아랄킬, 알킬옥시아릴 또는 스테로이드 핵 함유 기이며;
m은 1 내지 10의 정수이며;
n은 1, 2 또는 3이며;
펩티드는 하기 화학식 II를 가지며:
aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-aa30-aa31-aa32-aa33-aa34-aa35-aa36-aa37-Z 화학식 II(서열 번호 1108)
상기 식에서,
Z는 -OH, -NHR3 또는 -N(R4)His이며, 여기서
R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
R4는 H, C2-C10 아실(예를 들어, 아세틸) 또는 -C(=O)-아릴(예를 들어, 벤조일)이며;
aa1은 His, N(R3)His, N(R4)His 또는 pGlu-His이며;
aa2는 Ser, D-Ser, Ala, Gly, Pro, MePro, Aib, Ac4c 또는 Ac5c이며;
aa3은 Gln 또는 Cit이며;
aa4는 Gly 또는 D-Ala이며;
aa5는 Thr 또는 Ser이며;
aa6은 Phe, Trp, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa7은 Thr 또는 Ser이며;
aa8은 Ser 또는 Asp이며;
aa9은 Asp 또는 Glu이며;
aa10은 Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser, Arg 또는 U이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U이며;
aa14는 존재하지 않거나 또는 Leu, Met, Nle, Glu, Lys 또는 U이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg 또는 U이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Cit, Aib, Ac4c, Ac5c, Lys 또는 U이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U이며;
aa19는 존재하지 않거나 또는 Ala, Val, Aib, Ac4c, Ac5c 또는 U이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c 또는 U이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib, Ac4c, Ac5c 또는 U이며;
aa22는 존재하지 않거나 또는 Phe, Trp, Nal2, Aib, Ac4c, Ac5c 또는 U이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib, Ac4c, Ac5c 또는 U이며;
aa24는 존재하지 않거나 또는 Ala, Gln, Glu, Cit 또는 U이며;
aa25는 존재하지 않거나 또는 Trp, Nal2 또는 U이며;
aa26은 존재하지 않거나 또는 Leu 또는 U이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U이며;
aa28은 존재하지 않거나 또는 Asn, Lys, Glu, Gln, Cit 또는 U이며;
aa29는 존재하지 않거나 또는 Thr, Gly, Aib, Ac4c, Ac5c 또는 U이며;
aa30은 존재하지 않거나 또는 Lys, Aib, Ac4c, Ac5c, Arg 또는 U이며;
aa31은 존재하지 않거나 또는 Arg, Aib, Ac4c, Ac5c 또는 U이며;
aa32는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa33은 존재하지 않거나 또는 Arg, Aib, Ac4c, Ac5c 또는 U이며;
aa34는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa35는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa36은 존재하지 않거나 또는 Ala, Ile, Aib, Ac4c, Ac5C 또는 U이며;
aa37은 존재하지 않거나 또는 U이며;
U는 계면활성제 X에의 공유 결합에 사용된 작용기를 포함하는 천연 또는 비천연 아미노산이며;
aa1-aa37 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa37 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 링커 아미노산 U이다.
계면활성제 모이어티는 또한 펩티드의 링커 아미노산 U에 R1a, R1b, R1c 또는 R1d를 통하여 연결될 수 있다. 예를 들면, W2는 -O-일 수 있으며, R1a 중 하나의 존재는 히드록실 함유 천연 또는 비천연 아미노산(예를 들어, 세린, 호모세린 또는 트레오닌)에의 결합일 수 있거나 또는 W2는 -S-일 수 있으며, R1a 중 하나의 존재는 티올/술프히드릴 함유 천연 또는 비천연 아미노산(예를 들어, 시스테인 또는 호모시스테인)에의 결합일 수 있거나 또는 W2는 -NH-일 수 있으며, R1a 중 하나의 존재는 아미노 함유 천연 또는 비천연 아미노산(예를 들어, 리신 또는 오르니틴)에의 결합일 수 있다. 특정한 실시양태에서, R1a를 통하여 계면활성제 모이어티에 연결된 U는 비천연 아미노산이다. R1a를 통하여 계면활성제 모이어티에 연결된 링커 아미노산 U는 L- 또는 D-이성질체일 수 있다. 특정한 실시양태에서, U는 D-이성질체일 수 있다.
일부 실시양태에서, n은 1이다. 다른 실시양태에서, n은 2이며, 제1의 글리코시드는 제1의 글리코시드의 W2 및 제2의 글리코시드의 -OR1b, -OR1c 또는 -OR1d 사이의 결합을 통하여 제2의 글리코시드에 연결된다. 다른 실시양태에서, n은 3이며, 제1의 글리코시드는 제1의 글리코시드의 W2 및 제2의 글리코시드의 -OR1b, -OR1c 또는 -OR1d 사이의 결합을 통하여 제2의 글리코시드에 연결되며, 제2의 글리코시드는 제2의 글리코시드의 W2 및 제3의 글리코시드 -OR1b, -OR1c 또는 OR1d 사이의 결합을 통하여 제3의 글리코시드에 연결된다.
화학식 I-A의 펩티드 생성물의 일부 실시양태에서, 계면활성제 X는 하기이다:
상기 식에서,
R1a는 H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기 또는 스테로이드 핵 함유 기이며;
R1b, R1c 및 R1d는 독립적으로 H, 보호기, 당류 또는 비치환된 또는 치환된 C1-C30 알킬 기이며;
R2는 U에의 결합, -NH-, -S-, -트리아졸로-, -NH(C=O)-CH2- 또는 -(CH2)m-말레이미드-이며;
W1은 -CH2-, -CH2-O-, -CH2-S-, -(C=O)-, -(C=O)-NH-, -(C=S)- 또는 -(C=S)-NH-이며;
W2는 -O- 또는 -S-이며;
m은 1-10이며;
R1a, R1b, R1c 및 R1d 중 적어도 1종은 비치환된 또는 치환된 C1-C30 알킬 기 또는 스테로이드 핵 함유 기이다.
특정한 실시양태에서, 계면활성제 X는 구조 
를 가지며, 여기서 R2는 U에의 결합이다. 특정한 실시양태에서, W1은 -C(=O)NH-이며, R2는 펩티드의 W1 및 아미노산 잔기 U(예를 들어, 리신 잔기의 측쇄 아미노 기) 사이의 결합이다.
다른 실시양태에서, 계면활성제 X는 
이다. 특정한 실시양태에서, W1은 -CH2-O-, -CH2-S- 또는 -(C=O)-NH-이며, R2는 펩티드의 아미노산 잔기 U의 적절한 작용기와 함께 결합을 형성하는 -(CH2)m-말레이미드- 기이다(예를 들어, 시스테인 잔기의 티올 기는 말레이미드 기와 함께 티오에테르 결합을 형성한다).
추가의 실시양태에서, 계면활성제 X는 하기 구조를 갖는다:
상기 식에서,
R1a는 H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기 또는 스테로이드 핵 함유 기이며;
R1b, R1c 및 R1d는 독립적으로 H, 보호기 또는 비치환된 또는 치환된 C1-C30 알킬 기이며;
R2는 U에의 결합이며;
W1은 -(C=O)-NH-이며;
W2는 -O-이며;
R1a, R1b, R1c 및 R1d 중 적어도 1종은 비치환된 또는 치환된 C1-C30 알킬 기 또는 스테로이드 핵 함유 기이다.
특정한 실시양태에서, 계면활성제 X는 하기 구조를 갖는다:
상기 식에서,
R1a는 비치환된 또는 치환된 C1-C30 알킬 기이며;
R1b, R1c 및 R1d는 H이며;
R2는 U에의 결합이며;
W1은 -(C=O)-NH-이며;
W2는 -O-이다.
일부 실시양태에서, 계면활성제 X는 1-O-알킬 베타-D-글루쿠로닐 모이어티이다:
상기 식에서, R1a는 비치환된 또는 치환된 C1-C30, C1-C20 또는 C6-C20 알킬 기이며, R'는 N-말단 알파 아미노 기 또는 천연 또는 비천연 아미노산(예를 들어, 리신 또는 오르니틴)의 측쇄 아미노 기를 통하여 계면활성제 모이어티에 연결되는 펩티드이다. 특정한 실시양태에서, R1a는 비치환된 또는 치환된 C8-C20, C12-C20 또는 C12-C16 알킬 기이다.
일부 실시양태에서, 당류에 연결된 알킬 기는 비치환된 또는 치환된 C1-C30, C1-C20, C6-C30 또는 C6-C20 알킬 기이다. 특정한 실시양태에서, 당류에 연결된 알킬 기는 비치환된 또는 치환된 C8-C20, C6-C18 또는 C12-C18 알킬 기이다.
일부 실시양태에서, R1a, R1b, R1c, R1d 또는 R2 중 적어도 하나의 경우는 비치환된 또는 치환된 C1-C30 알킬 기이다. 특정한 실시양태에서, 알킬 기는 에테르 결합(-O-알킬)을 통하여 R1b, R1c 또는 R1d 중 적어도 1종의 존재에 연결된다. 추가의 실시양태에서, 알킬 기는 에테르 결합(-O-알킬) 또는 아미드 결합[-C(=O)NH-알킬]을 통하여 R2 중 적어도 1종의 존재에 연결된다.
일부 실시양태에서, R1a 중 적어도 하나의 존재 또는 단독 존재는 비치환된 또는 치환된 C1-C30, C6-C30, C6-C20 또는 C8-C20 알킬 기이다. 특정한 실시양태에서, R1a 중 적어도 하나의 존재 또는 단독 존재는 비치환된 또는 치환된 C12-C20 알킬 기이다.
일부 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 카르복실 또는 카르복실레이트 기로 내부에 또는/및 말단에 치환된다. 특정한 실시양태에서, 알킬 기(예를 들어, 1-알킬 기)는 알킬 기의 원위 단부에서 카르복실 또는 카르복실레이트 기로 치환된다.
추가적인 실시양태에서, R1a 중 적어도 하나의 존재 또는 단독 존재는 당류이다. 특정한 실시양태에서, 당류는 갈락토스이다. 갈락토스는 알파- 또는 베타-연결될 수 있다. 일부 실시양태에서, 갈락토스는 알파-연결된 갈락토피라노스, 베타-연결된 갈락토피라노스, 알파-연결된 갈락토푸라노스 또는 베타-연결된 갈락토푸라노스이다.
일부 실시양태에서, 계면활성제 모이어티의 당류 기는 단당류이다. 특정한 실시양태에서, 단당류는 적절하게 작용화된 글루코스, 갈락토스 또는 만노스, 예컨대 글루쿠론산, 갈락투론산 또는 만노우론산이다. 다른 실시양태에서, 당류는 이당류이다. 일부 실시양태에서, 이당류는 2개의 글루코스 분자 또는 1개의 글루코스 분자 및 1개의 갈락토스 분자를 함유한다. 특정한 실시양태에서, 이당류는 디글루쿠론산 또는 적절하게 작용화된 멜리비오스, 말토스, 이소말토스, 겐티오비오스 또는 락토스, 예컨대 멜리비오우론산, 말토우론산, 이소말토우론산, 겐티오비오우론산 또는 락토우론산이다. 용어 "-우론산" 및 "-우로닐"은 계면활성제 모이어티의 당류 기에 관하여 본원에서 상호교환적으로 사용된다.
일부 실시양태에서, 계면활성제 X는 1-알킬 글리코시드이며, 여기서 비치환된 또는 치환된 알킬 기는 글리코시드 결합을 통하여 당류의 C-1 위치에 연결된다. 글리코시드 결합은 O-, S-, N- 또는 C-글리코시드 결합일 수 있다. 특정한 실시양태에서, 글리코시드 결합은 O-글리코시드 결합이다. 1-알킬 기는 베타- 또는 알파-아노머일 수 있다. 특정한 실시양태에서, 1-알킬 기는 베타-아노머이다.
일부 실시양태에서, 계면활성제 X는 1-에이코실 베타-D-글루쿠론산, 1-옥타데실 베타-D-글루쿠론산, 1-헥사데실 베타-D-글루쿠론산, 1-테트라데실 베타-D-글루쿠론산, 1-도데실 베타-D-글루쿠론산, 1-데실 베타-D-글루쿠론산, 1-옥틸 베타-D-글루쿠론산, 1-에이코실 베타-D-디글루쿠론산, 1-옥타데실 베타-D-디글루쿠론산, 1-헥사데실 베타-D-디글루쿠론산, 1-테트라데실 베타-D-디글루쿠론산, 1-도데실 베타-D-디글루쿠론산, 1-데실 베타-D-디글루쿠론산, 1-옥틸 베타-D-디글루쿠론산, 1-에이코실 베타-D-이소말토우론산, 1-옥타데실 베타-D-이소말토우론산, 1-헥사데실 베타-D-이소말토우론산, 1-테트라데실 베타-D-이소말토우론산, 1-도데실 베타-D-이소말토우론산, 1-데실 베타-D-이소말토우론산, 1-옥틸 베타-D-이소말토우론산, 1-에이코실 베타-D-겐티오비오우론산, 1-옥타데실 베타-D-겐티오비오우론산, 1-헥사데실 베타-D-겐티오비오우론산, 1-테트라데실 베타-D-겐티오비오우론산, 1-도데실 베타-D-겐티오비오우론산, 1-데실 베타-D-겐티오비오우론산, 1-옥틸 베타-D-겐티오비오우론산, 1-에이코실 베타-D-멜리비오우론산, 1-옥타데실 베타-D-멜리비오우론산, 1-헥사데실 베타-D-멜리비오우론산, 1-테트라데실 베타-D-멜리비오우론산, 1-도데실 베타-D-멜리비오우론산, 1-데실 베타-D-멜리비오우론산, 1-옥틸 베타-D-멜리비오우론산, 작용화된 1-에이코실 베타-D-글루코스, 1-옥타데실 베타-D-글루코스, 1-헥사데실 베타-D-글루코스, 1-테트라데실 베타-D-글루코스, 1-도데실 베타-D-글루코스, 1-데실 베타-D-글루코스, 1-옥틸 베타-D-글루코스, 1-에이코실 베타-D-말토시드, 1-옥타데실 베타-D-말토시드, 1-헥사데실 베타-D-말토시드, 1-테트라데실 베타-D-말토시드, 1-도데실 베타-D-말토시드, 1-데실 베타-D-말토시드, 1-옥틸 베타-D-말토시드, 1-에이코실 베타-D-멜리비오시드, 1-옥타데실 베타-D-멜리비오시드, 1-헥사데실 베타-D-멜리비오시드, 1-테트라데실 베타-D-멜리비오시드, 1-도데실 베타-D-멜리비오시드, 1-데실 베타-D-멜리비오시드, 1-옥틸 베타-D-멜리비오시드, 6-카르복실 기 또는 6,6'-디카르복실 기를 갖는 상응하는 1-알킬 글리코시드, 상응하는 1-알킬 알파-아노머 등으로부터 선택된다. 특정한 실시양태에서, 계면활성제 X는 1-알킬 베타-D-글루쿠론산이다.
예시적인 예로서, 하기에는 1-O-옥틸 베타-D-멜리비오우로닐 모이어티(좌측 위), 1-O-헥사데실 베타-D-겐티오비오우로닐 모이어티(우측 위), 1-O-도데실 베타-D-말토우로닐 모이어티(좌측 아래, 카르복실 기 중 어느 하나 또는 둘 다는 펩티드에 연결될 수 있음) 및 펩티드의 아미노 기(예를 들어, 리신 잔기의 측쇄 아미노 기)에 연결된 1-O-테트라데실 베타-D-이소말토우로닐 모이어티(우측 아래)를 제시한다.
일부 실시양태에서, 계면활성제 모이어티는 아미드 결합을 통하여 펩티드의 링커 아미노산 U에 연결된다.
펩티드 생성물의 펩티드는 하나 이상의 계면활성제 모이어티에 공유 결합될 수 있다. 특정한 실시양태에서, 펩티드 생성물은 1종의 계면활성제 모이어티를 갖는다. 추가의 실시양태에서, 펩티드 생성물은 동일하거나 또는 상이할 수 있는 2종의 계면활성제 모이어티를 갖는다. 다른 실시양태에서, 펩티드 생성물은 동일하거나 또는 상이할 수 있는 3종의 계면활성제 모이어티를 갖는다.
링커 아미노산 U는 계면활성제 모이어티에 공유 결합하기에 적절한 작용기를 갖는 임의의 천연 또는 비천연 아미노산일 수 있다. 일부 실시양태에서, U는 2가 염기성 천연 또는 비천연 아미노산(예를 들어, 측쇄 아미노 기를 갖는 것, 예컨대 리신 또는 오르니틴), 2가 산성 천연 또는 비천연 아미노산(예를 들어, 측쇄 카르복실 기를 갖는 것, 예컨대 글루탐산 또는 아스파르트산), 티올/술프히드릴 기를 갖는 천연 또는 비천연 아미노산(예를 들어, 시스테인), 히드록실 기를 갖는 천연 또는 비천연 아미노산(예를 들어, 세린 또는 트레오닌) 또는 -N3 기, 아세틸렌 기, 할로아세틸 기(예를 들어, -NHC(=O)CH2Br) 또는 -(CH2)m-말레이미드 기를 가지며, m이 1-10인 비천연 아미노산이다. 링커 아미노산의 할로아세틸 기 또는 말레이미드 기는 예를 들면 계면활성제 모이어티의 당류 기의 티올 기와 커플링될 수 있거나 또는 그 반대도 가능하다. 링커 아미노산의 아지드 기 또는 알킨 기는 예를 들면 구리 촉매를 사용하여 계면활성제 모이어티의 당류 기의 알킨 기 또는 아지드 기 각각과 함께 1,3-2극성 시클로첨가하여 트리아졸을 형성할 수 있다. 특정한 실시양태에서, U는 리신, 오르니틴 (Orn), 시스테인 또는 글루탐산 잔기이다. 펩티드의 임의의 아미노산 잔기와 같이, U는 L- 또는 D-아미노산일 수 있다.
링커 아미노산 U는 펩티드의 내부 또는/및 말단 아미노산 잔기일 수 있다. 계면활성제 모이어티와의 공유 결합을 형성하는 U의 작용기는 내부 또는 말단 아미노산 잔기의 측쇄 작용기일 수 있거나 또는 N-말단 아미노산 잔기의 알파 아미노 기 또는 C-말단 아미노산 잔기의 알파 카르복실 기일 수 있다.
일부 실시양태에서, 펩티드의 2종의 아미노산 잔기(별표로 표시함), 예컨대 리신 잔기 및 글루탐산 잔기의 측쇄 작용기는 연결되어 시클릭 구조, 예컨대 락탐을 형성한다. 리신 잔기 및 글루탐산 잔기의 측쇄 작용기 사이에 형성된 락탐은 펩티드의 α-헬릭스 구조를 안정화시킬 수 있다. 시클릭 구조는 또한 형태를 제한하며, α-헬릭스 형성을 촉진할 수 있는 2종의 시스테인 잔기의 티올 기 사이의 디술피드 결합에 의하여 형성될 수 있다. 2개의 비천연 아미노산 잔기의 알킨 기 및 측쇄 아지드 사이의 "클릭 반응"은 또한 형태를 제한하며, α-헬릭스를 안정화시키는 헤테로시클릭 구조(트리아졸)를 형성할 수 있다(Le Chevalier et al., J. Peptide Sci., 15:451-454 [2009]). 더욱이, 2종의 비천연 아미노산 잔기의 측쇄 알켄 기는 올레핀 복분해에 의하여 고리화되어 C=C 이중 결합을 형성할 수 있으며, 그 후 C-C 단일 결합으로 환원될 수 있다(Verdine and Hilinski, Meth . Enzymol ., 503:3-33 [2011]).
일부 실시양태에서, 화학식 I-A의 펩티드 생성물은 서열 번호 1108의 적어도 아미노산 잔기 aa1-aa17, aa1-aa18, aa1-aa19 또는 aa1-aa20을 포함한다. 추가의 실시양태에서, 화학식 I-A의 펩티드 생성물은 서열 번호 1108의 적어도 아미노산 잔기 aa1-aa27, aa1-aa28, aa1-aa29 또는 aa1-aa30을 포함한다.
일부 실시양태에서, 화학식 I-A의 펩티드 생성물은 하기 화학식 III-A를 갖는다:
aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-Z 화학식 III-A(서열 번호 1109)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
aa1은 His, N(R3)His, N(Ac)His 또는 pGlu-His이며;
aa2는 Ser, Ala, Gly, MePro, Aib, Ac4c 또는 Ac5c이며;
aa3은 Gln 또는 Cit이며;
aa4는 Gly 또는 D-Ala이며;
aa5는 Thr 또는 Ser이며;
aa6은 Phe, Trp, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa7은 Thr 또는 Ser이며;
aa8은 Ser 또는 Asp이며;
aa9는 Asp 또는 Glu이며;
aa10은 Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U(X)이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U(X)이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser, Arg 또는 U(X)이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U(X)이며;
aa14는 존재하지 않거나 또는 Leu, Met, Nle, Glu, Lys 또는 U(X)이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U(X)이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg 또는 U(X)이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Lys, Cit, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa19는 존재하지 않거나 또는 Ala, Val, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa22는 존재하지 않거나 또는 Phe, Trp, Nal2, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa24는 존재하지 않거나 또는 Ala, Gln, Glu, Cit 또는 U(X)이며;
aa25는 존재하지 않거나 또는 Trp, Nal2 또는 U(X)이며;
aa26은 존재하지 않거나 또는 Leu 또는 U(X)이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U(X)이며;
aa28은 존재하지 않거나 또는 Asn, Lys, Glu, Gln 또는 U(X)이며;
aa29는 존재하지 않거나 또는 Thr, Gly, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa1-aa29 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa12 및 aa16-aa29 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 천연 또는 비천연 아미노산 U이다.
특정한 실시양태에서, 화학식 III-A의 펩티드 생성물은 하기 구조를 갖는다:
aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-Z 화학식 III-A(서열 번호 1110)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
aa1은 His이며;
aa2는 Aib이며;
aa3은 Gln이며;
aa4는 Gly이며;
aa5는 Thr이며;
aa6은 Phe이며;
aa7은 Thr이며;
aa8은 Ser이며;
aa9는 Asp이며;
aa10은 Tyr, Glu, Lys 또는 U(X)이며;
aa11은 Ser이며;
aa12는 Lys 또는 Glu이며;
aa13은 Tyr이며;
aa14는 Leu, Glu 또는 Lys이며;
aa15는 Asp이며;
aa16은 Glu 또는 Lys이며;
aa17은 Gln, Glu 또는 U(X)이며;
aa18은 Ala이며;
aa19는 Ala이며;
aa20은 Glu, Lys 또는 U(X)이며;
aa21은 Glu이며;
aa22는 Phe이며;
aa23은 Ile이며;
aa24는 Gln, Glu 또는 U(X)이며;
aa25는 Trp이며;
aa26은 Leu이며;
aa27은 Leu이며;
aa28은 Glu 또는 Gln이며;
aa29는 Thr이며;
aa10와 aa14 또는 aa12와 aa16 또는 aa16과 aa20은 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10, aa17, aa20 및 aa24 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 천연 또는 비천연 아미노산 U이다.
추가의 실시양태에서, 화학식 I-A의 펩티드 생성물은 하기 화학식 III-B를 갖는다:
His1-aa2-aa3-Gly4-Thr5-aa6-Thr7-Ser8-Asp9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-aa30-Z 화학식 III-B(서열 번호 1111)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
aa2는 Gly, MePro 또는 Aib이며;
aa3은 Gln 또는 Cit이며;
aa6은 Phe, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa10은 Tyr, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U(X)이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U(X)이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser 또는 U(X)이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U(X)이며;
aa14는 존재하지 않거나 또는 Leu, Nle, Glu, Lys 또는 U(X)이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U(X)이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Lys, Arg 또는 U(X)이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Lys, Cit, Aib 또는 U(X)이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa19는 존재하지 않거나 또는 Ala, Aib 또는 U(X)이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib 또는 U(X)이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib 또는 U(X)이며;
aa22는 존재하지 않거나 또는 Phe 또는 U(X)이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib 또는 U(X)이며;
aa24는 존재하지 않거나 또는 Ala, Glu, Gln 또는 U(X)이며;
aa25는 존재하지 않거나 또는 Trp 또는 U(X)이며;
aa26은 존재하지 않거나 또는 Leu 또는 U(X)이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U(X)이며;
aa28은 존재하지 않거나 또는 Asn, Glu, Gln, Cit 또는 U(X)이며;
aa29는 존재하지 않거나 또는 Thr, Aib 또는 U(X)이며;
aa30은 존재하지 않거나 또는 Arg 또는 U(X)이며;
aa1-aa23 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa12, aa16-aa24 및 aa28 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 천연 또는 비천연 아미노산 U이다.
화학식 I-A, III-A 또는 III-B의 펩티드 생성물의 일부 실시양태에서:
aa2는 Gly, Aib 또는 Ac4c이거나; 또는
aa12는 리신이거나; 또는
aa14는 류신이거나; 또는
aa17은 글리신 또는 호모아르기닌(hArg)이거나; 또는
aa17, aa18, aa20, aa24 또는 aa28 또는 이들의 임의의 조합은 계면활성제 X에 결합된 리신이거나; 또는
aa16 및 aa20은 이들의 측쇄를 통하여 고리화되어 락탐을 형성하거나; 또는
계면활성제 X는 비치환된 또는 치환된 도데실, 테트라데실, 헥사데실 또는 옥타데실 알킬 기를 포함하거나; 또는
상기 중 임의의 조합 또는 전부이다.
일부 실시양태에서, 본원에 기재된 펩티드 생성물의 펩티드는 N-말단에서 또는 부근에서, C-말단에서 또는 부근에서 또는 내부에서 또는 이들의 임의의 조합 또는 전부에서 하나 이상의 Aib 잔기를 포함한다. Aib 잔기는 프로테아제, 예컨대 디펩티딜 펩티다제 4(DPP-4)에 의하여 분해로부터 펩티드를 보호할 수 있다. 특정한 실시양태에서, aa2는 Aib이다.
일부 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Ala18-Ala19-aa20-Glu21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 1126)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ser, Ala, Lys 또는 Aib이며;
aa17은 Gln, Lys 또는 U(X)이며;
aa20은 Lys, Glu 또는 Arg이며;
aa23은 Ile 또는 Val이며;
aa24는 Ala, Gln 또는 U(X)이며;
aa27은 Met, Val 또는 Leu이며;
aa28은 Asn, Gln 또는 U(X)이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Arg18-Ala19-aa20-Asp21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 1127)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ala 또는 Aib이며;
aa17은 Arg, hArg 또는 Gln이며;
aa20은 U(X)[예를 들어, Lys(X)]이며;
aa23은 Ile 또는 Val이며;
aa24는 Gln 또는 Ala이며;
aa27은 Leu 또는 Val이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Ala18-Ala19-aa20-Glu21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 774)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ser, Ala, Lys 또는 Aib이며;
aa17은 Gln, Glu, Lys 또는 U(X)이며;
aa20은 Lys, Glu 또는 Arg이며;
aa23은 Ile 또는 Val이며;
aa24는 Ala, Gln 또는 U(X)이며;
aa27은 Met, Val 또는 Leu이며;
aa28은 Asn, Gln 또는 U(X)이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Ala18-Ala19-Lys20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-aa27-Asn28-Thr29-NH2(서열 번호 775)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ala 또는 Aib이며;
aa17은 U(X)[예를 들어, Lys(X)]이며;
aa27은 Leu 또는 Val이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Arg18-Ala19-aa20-Asp21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 776)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ser, Ala 또는 Aib이며;
aa17은 Arg, hArg 또는 Gln이며;
aa20은 Lys 또는 U(X)이며;
aa23은 Ile 또는 Val이며;
aa24는 Ala, Gln 또는 U(X)이며;
aa27은 Leu 또는 Val이며;
aa28은 Asn, Gln 또는 U(X)이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Arg18-Ala19-aa20-Asp21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 777)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ser, Ala 또는 Aib이며;
aa17은 Arg, hArg 또는 Gln이며;
aa20은 Lys 또는 U(X)이며;
aa23은 Ile 또는 Val이며;
aa24는 Gln, Ala 또는 U(X)이며;
aa27은 Leu 또는 Val이며;
aa28은 Asn, Gln 또는 U(X)이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16 *-aa17-Ala18-Ala19-aa20 *-Glu21-Phe22-Ile23-Lys(N-오메가-X)24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 778)
상기 식에서,
aa2는 Aib 또는 Gly이며;
aa16 * 및 aa20 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa17은 Arg, hArg 또는 Gln이며;
aa27은 Met, Val, Leu 또는 Nle이며;
aa28은 Asn 또는 Gln이다.
일부 실시양태에서, 계면활성제 X는 1'-알킬 베타-D-글루쿠로닐이다. 특정한 실시양태에서, 알킬 기는 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Ala18-Ala19-Lys20-Glu21-Phe22-Ile23-Ala24-Trp25-Leu26-Leu27-Asn28-Thr29-NH2(서열 번호 779)
상기 식에서,
aa2는 Aib 또는 Gly이며;
aa1aa16은 Glu, Ala 또는 Aib이며;
aa17은 Lys(N-오메가-X)이다.
일부 실시양태에서, 계면활성제 X는 1'-알킬 베타-D-글루쿠로닐이다. 특정한 실시양태에서, 알킬 기는 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16-aa17-Arg18-Ala19-aa20-Asp21-Phe22-aa23-aa24-Trp25-Leu26-aa27-aa28-Thr29-NH2(서열 번호 780)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa16은 Glu, Ala 또는 Aib이며;
aa17은 Arg 또는 hArg이며;
aa20은 Lys(N-오메가-X)이며;
aa23은 Ile 또는 Val이며;
aa24는 Gln 또는 Ala이며;
aa27은 Leu 또는 Val이며;
aa28은 Asn 또는 Gln이다.
일부 실시양태에서, 계면활성제 X는 1'-알킬 베타-D-글루쿠로닐이다. 특정한 실시양태에서, 알킬 기는 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-aa6-Thr7-Ser8-Asp9-aa10-aa11-Z(서열 번호 781)
상기 식에서,
aa2는 Gly, Aib 또는 MePro이며;
aa6은 Phe, 2FPhe, MePhe 또는 2FMePhe이며;
aa10은 Tyr, Nal2, Bip, Bip2Et 또는 Bip2EtMeO이며;
aa11은 Lys(N-오메가-X)이다.
일부 실시양태에서, 계면활성제 X는 1'-알킬 베타-D-글루쿠로닐이다. 특정한 실시양태에서, 알킬 기는 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-aa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16-U(X)17-Ala18-Ala19-Lys20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-aa28-Thr29-NH2(서열 번호 795)
상기 식에서,
aa2는 Gly 또는 Aib이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16 *-Gln17-Ala18-Ala19-aa20 *-Glu21-Phe22-Ile23-Lys(N-오메가-X)24-Trp25-Leu26-Leu27-aa28-Thr29-NH2(서열 번호 796)
상기 식에서,
aa16 * 및 aa20 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa28은 Asn 또는 Gln이며;
계면활성제 X는 1-알킬 베타-D-글루코시드, 1-알킬 베타-D-말토시드, 1-알킬 베타-D-멜리비오시드 등 또는 상응하는 알파 아노머를 포함하며, 여기서 알킬은 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가-X)24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 797)
상기 식에서,
Glu16 * 및 Lys20 *은 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
계면활성제 X는 1-알킬 베타-D-글루코시드, 1-알킬 베타-D-말토시드, 1-알킬 베타-D-멜리비오시드 등 또는 상응하는 알파 아노머를 포함하며, 여기서 알킬은 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-U(X)10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16 *-aa17-Ala18-Ala19-aa20 *-Glu21-Phe22-Ile23-aa24-Trp25-Leu26-Leu27-aa28-Thr29-Z(서열 번호 1025)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H 또는 10 Da 미만의 PEG 함유 기이며;
aa16 * 및 aa20 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa17은 Glu 또는 Gln이며;
aa24는 Ala, Glu 또는 Gln이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16 *-U(X)17-Ala18-Ala19-aa20 *-Glu21-Phe22-Ile23-aa24-Trp25-Leu26-Leu27-aa28-Thr29-Z(서열 번호 1026)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H 또는 10 Da 미만의 PEG 함유 기이며;
aa16 * 및 aa20 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa24는 Ala, Glu 또는 Gln이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-aa10 *-Ser11-Lys12-Tyr13-aa14 *-Asp15-Ser16-aa17-Ala18-Ala19-U(X)20-Glu21-Phe22-Ile23-aa24-Trp25-Leu26-Leu27-aa28-Thr29-Z(서열 번호 1027)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H 또는 10 Da 미만의 PEG 함유 기이며;
aa10 * 및 aa14 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa17은 Glu 또는 Gln이며;
aa24는 Ala, Glu 또는 Gln이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-aa12 *-Tyr13-Gln14-Asp15-aa16 *-aa17-Ala18-Ala19-U(X)20-Glu21-Phe22-Ile23-aa24-Trp25-Leu26-Leu27-aa28-Thr29-Z(서열 번호 1028)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H 또는 10 Da 미만의 PEG 함유 기이며;
aa12 * 및 aa16 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa17은 Glu 또는 Gln이며;
aa24는 Ala, Glu 또는 Gln이며;
aa28은 Asn 또는 Gln이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-aa16 *-Gln17-Ala18-Ala19-aa20 *-Glu21-Phe22-Ile23-U(X)24-Trp25-Leu26-Leu27-aa28-Thr29-Z(서열 번호 1029)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H 또는 10 Da 미만의 PEG 함유 기이며;
aa16 * 및 aa20 *은 독립적으로 Lys 또는 Glu이며, 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
aa28은 Asn 또는 Gln이며;
계면활성제 X는 1-알킬 베타-D-글루코시드, 1-알킬 베타-D-말토시드, 1-알킬 베타-D-멜리비오시드 등 또는 상응하는 알파 아노머를 포함하며, 여기서 알킬은 선형 C8-C20 알킬이다.
다른 실시양태에서, 화학식 I-A, III-A 또는 III-B의 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가-X)24-Trp25-Leu26-Leu27-Gln28-Thr29-Z(서열 번호 1113)
상기 식에서,
Z는 -OH 또는 -NHR3이며;
Glu16 * 및 Lys20 *은 이들의 측쇄를 통하여 고리화되어 락탐을 형성하며;
계면활성제 X는 1-알킬 베타-D-글루코시드, 1-알킬 베타-D-말토시드, 1-알킬 베타-D-멜리비오시드 등 또는 상응하는 알파 아노머를 포함하며, 여기서 알킬은 선형 C8-C20 알킬이다.
일부 실시양태에서, 펩티드 생성물은 하기 구조를 갖는다:
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 601);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 602);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 603);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥타데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 604);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥틸 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 630);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 631);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 632);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 633);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥타데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 634);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 805);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-테트라데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 819);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 820);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-옥타데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 821);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-도데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1114);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-테트라데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1115);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1116);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1117);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1118);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1119);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1120);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1121);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1122);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1123);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1124); 또는
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1125); 또는
이의 약학적으로 허용되는 염, 여기서 Glu16 * 및 Lys20 *은 이들의 측쇄를 통하여 고리화되어 락탐을 형성하는 잔기를 나타낸다.
추가적인 펩티드 생성물은 도 1의 표 1, 도 2의 표 2, 도 3의 표 3 및 도 4의 표 4에 기재되어 있다.
도 5는 N-말단 구역의 결합 부위/GLP-1 수용체의 세포외 도메인의 X선 결정 구조를 도시하며, 임계 소수성 리간드 결합 구역을 나타낸다(리간드 엑센딘-4의 Val19*, Phe22 *, Trp25 * 및 Leu26 * 및, Glu15를 넘어선 엑센딘-4의 서열은 상기 구역과의 양친매성 헬릭스로서 상호작용한다). 펩티드 생성물의 계면활성제 모이어티의 1-알킬 기는 GLP-1 수용체와의 소수성 상호작용에 참여할 수 있다.
일부 실시양태에서, 계면활성제 모이어티는 스페이서를 통하여 펩티드의 링커 아미노산 U에 연결된다. 스페이서는 펩티드 생성물의 수용해도를 증가시킬 수 있으며, 펩티드-계면활성제 연결점의 가요성을 증가시킬 수 있다. 특정한 실시양태에서, 스페이서는 하나 이상의 아미노산을 함유하는 아미노산 스페이서이다. 일부 실시양태에서, 계면활성제 X의 R2의 하나의 존재는 펩티드로의 연결에 사용된 아미노산 스페이서이다. 특정한 실시양태에서, 아미노산 스페이서는 Glym, Glum 또는 Lysm이며, 여기서 m은 1 내지 10의 정수이다. 예를 들면, W1은 -(C=O)-일 수 있으며, R2는 말단 글리신 잔기의 카르복실 기를 통하여 연결되는 Glym 스페이서 또는 말단 글루탐산 잔기의 알파 또는 감마 카르복실 기를 통하여 펩티드의 리신 잔기의 측쇄 아미노 기에 또는 N-말단에 연결되는 Glum 스페이서일 수 있거나 또는 R2는 말단 리신 잔기의 카르복실 기를 통하여 펩티드의 리신 잔기의 측쇄 아미노 기에 또는 N-말단에 연결되는 Lysm 스페이서일 수 있다.
다른 실시양태에서, 스페이서는 아미노산 잔기를 함유하지 않는 친수성 스페이서이다. 예를 들면, 상기 스페이서는 
일 수 있으며, 여기서 n은 1, 2 또는 3이다. 상기 스페이서의 아미노 기는 예를 들면 계면활성제 모이어티의 당류의 C-6 위치에서 카르복실 기에 연결될 수 있으며, 상기 스페이서의 카르복실 기는 예를 들면 펩티드의 아미노산(예를 들어, 리신) 잔기의 측쇄 아미노 기에 또는 N-말단에 연결될 수 있다.
스페이서를 통한 계면활성제 모이어티의 펩티드로의 연결의 3가지 예를 하기에 제시한다. 펩티드는 상부에 있으며, 스페이서는 가운데에 있으며, C12 알킬 기("C12"로 표기함)를 포함하는 계면활성제는 아래에 있다. 좌측의 예에서, 스페이서는 카르복실 기가 펩티드의 리신 잔기의 측쇄 아미노 기를 갖는 아미드 결합을 형성하는 1개의 오르니틴 잔기이다. 가운데의 예에서, 스페이서는 감마 카르복실 기가 펩티드의 리신 잔기의 측쇄 아미노 기를 갖는 아미드 결합을 형성하는 1개의 글루탐산 잔기이다. 우측의 예에서, 스페이서는 1개의 글루탐산 잔기를 포함한다.
펩티드 생성물은 하나 이상의 추가적인 변경을 임의로 가질 수 있다. 상기 변경은 N-말단에서의 아실화(예를 들어, 아세틸화) 및 천연 또는 합성 중합체의 연결(예를 들어, 친수성 합성 중합체, 예컨대 폴리에틸렌 글리콜[PEG], 이는 펩티드 생성물의 수용해도를 증가시킬 수 있음) 또는/및 N-말단, C-말단 또는/및 하나 이상의 측쇄에서지질화(예를 들어, C8-C20 포화 또는 불포화 지방산/2가 산과의 아실화 또는 스테로이드 핵 함유 기, 예컨대 콜레스테롤로의 연결)를 포함하나 이에 제한되지 않는다.
본 개시내용은 본원에 기재된 펩티드 생성물의 유사체 및 변이체를 포함한다. 상기 유사체 및 변이체는 본원에 개시된 특정한 펩티드 생성물의 아미노산 서열의 하나 이상의 위치에서 보존적 치환을 갖는 것을 포함하나 이에 제한되지 않는다. 본원에 기재된 펩티드 생성물에 대한 언급은 이들의 모든 약학적으로 허용되는 염을 포함한다.
펩티드로의 계면활성제 모이어티의 공유 결합은 펩티드 생성물에 이로운 성질의 독특한 조합을 부여한다. 계면활성제 모이어티의 소수성 성질은 소수성 담체 단백질, 예컨대 인간 혈청 알부민(HSA)으로의 펩티드-계면활성제 콘쥬게이트의 결합을 촉진하여 프로테아제 및 다른 유형의 가수분해 효소에 대한 증가된 내성, 감소된 신장 제거율 및 담체 단백질로부터 펩티드 생성물의 느린 방출을 포함한 복수의 기전에 의한 펩티드 생성물의 반감기 및 작용 기간을 증가시킨다. 담체 단백질, 예컨대 HSA(약 67 kDa의 MW)의 소수성 포켓에 대한 펩티드 생성물의 계면활성제 모이어티의 소수성 기의 강하지만 가역적 비공유 결합은 혈액 중에 순환중이며 세포의 표면 상에서 발현되는 프로테아제(예를 들어, DPP-4) 및 다른 유형의 분해 효소로부터의 펩티드 생성물을 차폐시켜서 펩티드 생성물의 면역원성이 더 적게 되며, 펩티드 생성물이 소변으로의 사구체 여과에 의한 신장 제거율을 피하도록 펩티드 생성물의 분자량을 약 60-70 kDa의 여과 역치보다 높게 증가시킨다. 더욱이, HSA로의 펩티드 생성물의 결합은 신생아 Fc 수용체(FcRn)에 의하여 매개된 pH 의존성 HSA 재순환을 통하여 이들의 반감기를 증가시킨다. 일부 실시양태에서, 펩티드 생성물은 적어도 약 3 일, 1 주, 10 일 또는 2 주(예를 들어, 적어도 약 1 주)의 반감기(예를 들어, 순환 반감기 또는/및 제거 반감기)를 갖는다.
게다가, 친수성 당류 기 및 소수성 기를 함유하는 계면활성제 모이어티의 양친매성 성질은 펩티드 생성물의 생체이용률 및 작용 기간을 증가시킨다. 계면활성제 모이어티는 세포 점막 사이의 단단한 접합을 파괴하여 점막 장벽을 가로지른 펩티드 생성물의 투과를 촉진한다. 계면활성제 모이어티는 또한 미셀을 형성할 수 있으며, 이는 막을 통한 펩티드 생성물의 투과를 촉진할 수 있다. 게다가, 미셀의 파괴 과정은 펩티드 생성물의 작용 기간을 연장시킬 수 있다. 계면활성제는 이의 농도가 이의 임계 미셀 농도(CMC)보다 더 클 때 미셀을 형성하며, 동일한 당류 기를 갖는 알킬 글리코시드는 더 낮은 CMC를 가질수록 더 긴 알킬 쇄를 갖는 경향이 있다.
계면활성제 모이어티에 연결되지 않은 펩티드에 비하여 크게 증가된 혈장 및 제거 반감기로 펩티드 생성물 그 자체는 약리학제가 된다. 환언하면, 안정한 계면활성제 모이어티는 펩티드에 생체내 연결된 것을 유지하며, 무상해 펩티드-계면활성제 콘쥬게이트는 근본 유형의 펩티드의 수용체(들)로의 결합에 의하여 생물학적 활성을 나타낼 수 있다. 예를 들면, 본원에 개시된 펩티드 생성물은 GLP-1 수용체(GLP1R) 또는/및 글루카곤 수용체(GCGR)에 결합되어 이를 활성화시켜 생물학적 활성을 나타낼 수 있다. 일부 실시양태에서, 펩티드 생성물은 2중 GLP1R/GCGR 효능제이다. 수용체 결합 또는 활성화의 효력 또는/및 선택율은 계면활성제 성분 또는/및 펩티드 성분을 변경시켜 미세 조정될 수 있다.
약학 조성물
본 개시내용은 또한 본원에 기재된 펩티드 생성물 또는 이의 약학적으로 허용되는 염 및 하나 이상의 약학적으로 허용되는 담체 또는 부형제를 포함하는 약학 조성물을 제공한다. 약학 조성물은 펩티드 생성물 또는 이의 적절한 분획의 치료 유효량을 함유한다. 조성물은 추가적인 치료제를 임의로 함유할 수 있다. 일부 실시양태에서, 펩티드 생성물은 적어도 약 90%, 95% 또는 98% 순수하다.
약학적으로 허용되는 부형제 및 담체는 약학적으로 허용되는 물질, 재료 및 비히클을 포함한다. 부형제의 유형의 비제한적인 예는 액체 및 고체 충전제, 희석제, 결합제, 윤활제, 활택제, 계면활성제, 분석제, 붕해제, 유화제, 습윤제, 현탁제, 농조화제, 용매, 등장화제, 완충제, pH 조절제, 흡수 지연제, 안정화제, 항산화제, 방부제, 항균제, 항세균제, 항진균제, 킬레이트화제, 아쥬번트, 감미제, 풍미제, 착색제, 캡슐화 재료 및 코팅 재료를 포함한다. 약학 제제 중의 상기 부형제의 사용은 당업계에 공지되어 있다. 예를 들면, 통상의 비히클 및 담체는 오일(예를 들어, 식물성 오일, 예컨대 올리브 오일 및 참기름), 수성 용매{예를 들어, 염수, 완충 염수(예를 들어, 인산염 완충 염수[PBS]) 및 등장성 용액(예를 들어, 링거액)} 및 유기 용매(예를 들어, 디메틸 술폭시드 및 알콜[예를 들어, 에탄올, 글리세롤 및 프로필렌 글리콜])을 포함하나 이에 제한되지 않는다. 임의의 통상의 부형제 또는 담체가 펩티드 생성물과 적합성을 갖지 않는 경우를 제외하고, 본 개시내용은 펩티드 생성물을 함유하는 제제 중의 통상의 부형제 및 담체의 사용을 포함한다. 예를 들면 문헌[Remington : The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania) (2005); Handbook of Pharmaceutical Excipients, 5th Ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical Additives, 3rd Ed., Ash and Ash, Eds., Gower Publishing Co. (2007); and Pharmaceutical Pre-formulation and Formulation, Gibson, Ed., CRC Press (Boca Raton, Florida) (2004)]을 참조한다.
적절한 제제는 다양한 요인, 예컨대 선택된 투여 경로에 의존할 수 있다. 펩티드 생성물을 포함하는 약학 조성물의 투여의 잠재적 경로는 경구, 비경구(피내, 피하, 근육내, 혈관내, 정맥내, 동맥내, 복강내, 강내 및 국소 포함) 및 국소(경피, 경점막, 비내[예를 들어, 코 분무 또는 점비액에 의함], 눈[예를 들어, 점안액에 의함], 폐[예를 들어, 경구 또는 코 흡입에 의함], 협측, 설하, 직장[예를 들어, 좌제에 의함] 및 질[예를 들어, 좌제에 의함] 포함)을 포함하나 이에 제한되지 않는다. 특정한 실시양태에서, 펩티드 생성물은 비경구(예를 들어, 피하, 정맥내 또는 근육내) 투여된다. 다른 실시양태에서, 펩티드 생성물은 경구 흡입 또는 코 흡입 또는 취입에 의하여 투여된다.
일부 실시양태에서, 담체는 예컨대 비경구(예를 들어, 피하, 정맥내 또는 근육내) 제제 중의 수계 담체이다. 다른 실시양태에서, 담체는 비수계 담체이다. 특정한 실시양태에서, 비수계 담체는 예컨대 경구 흡입 또는 코 흡입 또는 취입에 의한 투여를 위한 제제 중의 미크론이하 무수 α-락토스 또는/및 다른 부형제를 포함할 수 있는 히드로플루오로알칸(HFA) 또는 HFA 유사 용매이다.
일부 실시양태에서, 펩티드 생성물은 주사에 의하여 비경구(예를 들어, 피하, 정맥내 또는 근육내) 투여된다. 비경구 투여는 위, 위장관(GI) 흡수 및 제1 통과 대사의 강한 산성 환경을 우회한다. 비경구 제제를 생성하는데 사용될 수 있는 부형제 및 담체는 용매(예를 들어, 수성 용매, 예컨대 물, 염수, 생리 염수, 완충 염수[예를 들어, PBS], 평형 염 용액[예를 들어, 링거 BSS] 및 수성 덱스트로스 용액), 등장성/등삼투화제(예를 들어, 염[예를 들어, NaCl, KCl 및 CaCl2] 및 당[예를 들어, 수크로스]), 완충제 및 pH 조절제(예를 들어, 인산이수소나트륨[일염기성 인산나트륨]/인산수소이나트륨[이염기성 인산나트륨], 시트르산/인산나트륨 및 L-히스티딘/L-히스티딘 HCl) 및 유화제(예를 들어, 비이온성 계면활성제, 예컨대 폴리소르베이트[예를 들어, 소르베이트 20 및 80] 및 폴록사머[예를 들어, 폴록사머 188])를 포함하나 이에 제한되지 않는다. 펩티드 제제 및 전달계는 예를 들면 문헌[A. J. Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3rd Ed., CRC Press (Boca Raton, Florida) (2015)]에 논의되어 있다.
부형제는 펩티드 안정성을 증가시키며, 펩티드 용해도를 증가시키며, 펩티드 응집을 억제하거나 또는 용액 점도를 감소시키거나 또는 이들의 임의의 조합 또는 전부인 하나 이상의 물질을 임의로 포함할 수 있다. 상기 물질은 친수성 아미노산(예를 들어, 아르기닌 및 히스티딘), 폴리올(예를 들어, 미오-이노시톨, 만니톨 및 소르비톨), 당류{예를 들어, 글루코스(D-글루코스[덱스트로스] 포함), 락토스, 수크로스 및 트레할로스}, 삼투물질(예를 들어, 트레할로스, 타우린, 아미노산[예를 들어, 글리신, 사르코신, 알라닌, 프롤린, 세린, β-알라닌 및 γ-아미노부티르산] 및 베타인[예를 들어, 트리메틸글리신 및 트리메틸아민 N-옥시드]) 및 비이온성 계면활성제{예를 들어, 알킬 폴리글리코시드, 프로텍(ProTek)® 알킬당류(예를 들어, 장쇄 지방산 또는 상응하는 장쇄 알콜에 커플링된 단당류[예를 들어, 글루코스] 또는 이당류[예를 들어, 말토스 또는 수크로스]) 및 폴리프로필렌 글리콜/폴리에틸렌 글리콜 블록 공중합체(예를 들어, 폴록사머[예를 들어, 플루로닉(Pluronic)™ F-68] 및 게나폴(Genapol)® PF-10 및 이들의 변이체)}를 포함하나 이에 제한되지 않는다. 상기 물질은 펩티드 용해도를 증가시키므로, 이는 제제 중의 펩티드 농도를 증가시키는데 사용될 수 있다. 제제 중의 더 높은 펩티드 농도는 볼루스 투여의 제한된 부피(예를 들어, ≤약 1.5 ㎖)를 갖는 피하 투여에 특히 이롭다. 게다가, 상기 물질은 동결건조된 펩티드의 제조, 보관 및 재구성 중에 펩티드를 안정화시키는데 사용될 수 있다.
비경구(예를 들어, 피하 또는 정맥내) 투여의 경우, 펩티드 치료제로 미리 생성되거나 또는 재구성 후 동결건조된 또는 분말 형태의 펩티드 치료제가 제조되건 간에 수성 제제의 부형제의 예는 하기 표 5에 제시된 것을 포함하나 이에 제한되지 않는다. 염화나트륨(NaCl)이 명백하게 제시되지 않은 표 5의 임의의 제제는 NaCl을 임의로 함유할 수 있다. 예시적인 비경구 제제는 펩티드 생성물, 만니톨, 메티오닌, 티오글리콜산나트륨, 폴리소르베이트 20, pH 조절제(예를 들어, NaOH 또는/및 HCl) 및 탈이온수를 포함한다.
비경구(예를 들어, 피하, 정맥내 또는 근육내) 투여의 경우, 하나 이상의 부형제를 함유하는 수성 용매 중의 펩티드 생성물의 멸균 용액 또는 현탁액은 미리 생성될 수 있으며, 예를 들면 1회용 펜 또는 투약 계수기가 있는 펜의 사전 충전된 주사기 내에 제공될 수 있다. 대안으로, 펩티드 생성물은 동결건조(냉동 건조) 이전에 하나 이상의 부형제를 임의로 함유할 수 있는 수성 용매 중에 용해 또는 현탁될 수 있다. 비경구 투여 직전에, 적절한 용기(예를 들어, 바이알) 중에 보관된 동결건조된 펩티드 생성물은 예를 들면 하나 이상의 부형제를 임의로 함유할 수 있는 멸균수로 재구성할 수 있다.
다른 실시양태에서, 펩티드 생성물은 비내 투여된다. 코점막은 큰 표면적, 다공성 내피, 높은 혈관 상피하 층 및 높은 흡수율을 제공하여 높은 생체이용률을 허용한다. 비내 제제는 부형제, 예컨대 용해도 향상제(예를 들어, 프로필렌 글리콜), 보습제(예를 들어, 만니톨 또는 소르비톨), 완충제 및 물 및 임의로 방부제(예를 들어, 염화벤잘코늄), 점막 점착제(예를 들어, 히드록시에틸셀룰로스) 또는/및 침투 향상제와 함께 펩티드 생성물을 포함할 수 있다. 비내 용액 또는 현탁액 제제는 점적기, 피펫 또는 스프레이를 포함하나 이에 제한되지 않는 임의의 적절한 수단에 의하여, 예를 들면 계측 분무 스프레이 펌프를 사용하여 비강에 투여할 수 있다. 하기 표 6은 코 스프레이 제제의 예시적인 부형제를 제시한다.
추가의 실시양태에서, 펩티드 생성물은 예컨대 경구 흡입 또는 코 흡입에 의하여 폐 투여된다. 폐 투여된 약물은 폐가 체순환으로의 관문이 되기 때문에 폐병 또는/및 전신 질병을 치료할 수 있다. 폐 약물 전달의 잇점은 예를 들면 1) 제1 통과 대사의 방지; 2) 신속 약물 작용; 3) 흡수를 위한 폐포 구역의 큰 표면적, 폐의 높은 투과성(얇은 공기-혈액 장벽) 및 기도의 다량의 혈관구조; 및 4) 큰 폐포 표면적으로 인하여 GI관에 비하여 감소된 세포외 효소 수치를 포함한다. 코 흡입이 폐뿐 아니라 비강 내에서 경점막 체순환으로 약물을 전달할 수 있기는 하나, 코 흡입에 비하여 경구 흡입의 잇점은 약물을 폐로 더 깊은 투과/침착을 포함한다.
경구 또는 코 흡입은 예를 들면 계측된 투약량 흡입기(MDI), 네뷸라이저 또는 건조 분말 흡입기(DPI)에 의하여 달성될 수 있다. 예를 들면, 펩티드 생성물은 경구 또는 코 흡입에 의하여 호흡 기관으로의 에어로졸 투여를 위하여 제제화될 수 있다. 약물은 예를 들면 폐에서의 약물 침착 및 약물 현탁 안정성을 개선시키기 위하여 미분화에 의하여 얻을 수 있는 작은 입자 크기(예를 들어, 약 0.5 미크론 및 약 5 미크론 사이)로 전달된다. 약물은 적절한 추진제, 예컨대 히드로플루오로알칸(HFA, 예를 들어, 1,1,1,2-테트라플루오로에탄[HFA-134a]), 클로로플루오로카본(CFC, 예를 들어, 디클로로디플루오로메탄, 트리클로로플루오로메탄 또는 디클로로테트라플루오로에탄) 또는 적절한 기체(예를 들어, 산소, 압축 공기 또는 이산화탄소)와 함께 가압 팩 내에 제공될 수 있다. 에어로졸 제제 중의 약물은 폐로의 전달을 위하여 추진제 중에서 용해되거나 또는 더 자주 현탁된다. 펩티드 생성물의 계면활성제 모이어티가 계면활성제의 작용을 수행할 수 있기는 하나, 에어로졸은 부형제, 예컨대 계면활성제(폐포 내에서 공기-물 계면에서의 높은 표면 장력을 감소시켜 폐로의 침투를 향상시키며, 약물을 유화, 가용화 또는/및 안정화시킬 수 있으며, 예를 들면 인지질, 예컨대 레시틴이 될 수 있음) 또는/및 안정화제를 함유할 수 있다. 예를 들면, MDI 제제는 펩티드 생성물, 추진제(예를 들어, HFA, 예컨대 1,1,1,2-테트라플루오로에탄) 및 공용매(예를 들어, 알콜, 예컨대 에탄올) 및 임의로 계면활성제(예를 들어, 지방산, 예컨대 올레산)를 포함할 수 있다. MDI 제제는 용해된 기체(예를 들어, CO2)를 임의로 함유할 수 있다. 디바이스 작동 후, 방출된 에어로졸 액적 내의 CO2 기포의 폭발은 액적을 더 작은 액적으로 부수어서 약물의 호흡 가능한 분획을 증가시킨다. 또 다른 예로서, 네뷸라이저 제제는 펩티드 생성물, 킬레이터 또는 방부제(예를 들어, 에데트산이나트륨), 등장화제(예를 들어, NaCl), pH 완충제(예를 들어, 시트르산/시트르산나트륨) 및 물 및 임의로 계면활성제(예를 들어, 트윈(Tween)®, 예컨대 폴리소르베이트 80)를 포함할 수 있다. 약물은 예를 들면 스페이서가 있거나 또는 없는 네뷸라이저 또는 MDI에 의하여 전달될 수 있으며, 전달된 약물 투약량은 계측 챔버(네뷸라이저) 또는 계측 밸브(MDI)에 의하여 제어될 수 있다. 표 6은 예시적인 MDI, 네뷸라이저 및 DPI 제제를 제시한다.
계측된 투약량 흡입기(또한 가압 계측된 투약량 흡입기[pMDI]로 지칭됨)는 가장 널리 사용되는 흡입 디바이스이다. 계측 밸브는 디바이스가 작동될 때마다 정확한 양의 에어로졸(예를 들어, 약 20-100 ㎕)을 전달한다. MDI는 통상적으로 사용자가 숨을 들이마실 때보다 더 빠르게 에어로졸을 생성하며, 이는 입 및 목에서 에어로졸의 대부분의 침착을 초래할 수 있다. 디바이스 작동 및 흡입 사이의 불량한 조정의 문제는 예를 들면 흡기 작동 MDI 또는 조정 디바이스에 의하여 설명될 수 있다. 흡기 작동 MDI(예를 들어, 이지브레쓰(Easibreathe)®)는 디바이스가 사용자의 들숨을 감지하고, 반응에서 약물 투약량을 배출할 때 작동된다. 흡입 유량은 작동기를 통하여 조정되며, 사용자는 흡입 동안 디바이스를 신뢰성 있게 작동시키는 시간을 갖는다. 조정 디바이스에서, 흡입기의 마우스피스 단부에 부착된 튜브인 스페이서(또는 밸브가 있는 홀딩 챔버)는 흡입기에 의하여 분무되는 약물을 수용하는 저장소 또는 챔버로서 작용하며, 에어로졸이 입에 들어가서 더 큰 액적으로부터 추진제의 기화를 허용하는 속도를 감소시킨다. 스페이서는 흡입기의 사용을 단순화시키며, 상기도 대신에 폐에 침착된 약물의 양을 증가시킨다. 스페이서는 방출된 약물 입자가 스페이서의 내부벽에 정전 부착되는 것을 최소로 하기 위하여 대전방지 중합체로 생성될 수 있다.
네뷸라이저는 약 1-5 미크론의 에어로졸 액적을 생성한다. 이들은 폐에 침착된 약물의 양에 크게 영향을 미치는 디바이스 작동 및 흡입 사이의 사용자 조정을 필요로 하지 않는다. MDI 및 DPI에 비하여, 네뷸라이저는 더 긴 투여 시간에도 불구하고, 더 큰 투약량의 약물을 전달할 수 있다. 네뷸라이저의 예는 인간 힘에 의한 네뷸라이저, 제트 네뷸라이저(예를 들어, 에어로이클립스(AeroEclipse)® II BAN[흡기 작동], 콤에어(CompAIR(™ NE-C801[버츄얼 밸브], 파리(PARI) LC® 플러스(Plus)[향상된 호흡] 및 사이드스트림 플러스(SideStream Plus)[향상된 호흡]), 초음파 네뷸라이저 및 진동 메쉬 네뷸라이저(예를 들어, 아키타(Akita)2® 아픽스넵(Apixneb), 계측 챔버가 있는 아이-넵(I-neb) AAD 시스템, 마이크로에어(MicroAir)® NE-U22, 옴론(Omron) U22 및 파리 이플로우(PARI eFlow)® 급속)를 포함하나 이에 제한되지 않는다. 예로서, 펄스 초음파 네뷸라이저는 펄스당 고정된 양의 약물을 에어로졸화할 수 있으며, 사용자가 각각의 펄스에 각각의 호흡을 동기화하도록 하는 광-음향 유발기를 포함할 수 있다.
건조 분말 흡입기(DPI)를 사용한 경구 또는 코 흡입의 경우, 펩티드 생성물은 건조 미분화된 분말의 형태로 제공될 수 있으며, 여기서 약물 입자는 예를 들면 폐에서 분산된 분말의 공기역학 성질 및 약물 침착을 개선시키기 위하여 특정한 작은 크기(예를 들어, 약 0.5 미크론 및 약 5 미크론 사이)를 갖는다. 약 0.5 미크론 및 약 5 미크론 사이의 입자는 말단 세기관지 및 폐포 구역에서의 침강에 의하여 침적된다. 대조적으로, 대부분의 더 큰 입자(> 5 미크론)는 기류가 기도의 다수의 분기로 흐르지 않지만, 그보다는 목의 구인두 구역을 포함한 상기도에서의 충격에 의하여 침착된다. DPI 제제는 약물 입자만을 함유할 수 있거나 또는 적절한 더 큰 베이스/담체, 예컨대 락토스, 전분, 전분 유도체(예를 들어, 히드록시프로필메틸 셀룰로스) 또는 폴리비닐피롤리딘의 분말과 블렌딩될 수 있다. 담체 입자는 흐름을 향상시키며, 응집을 감소시키며, 투약 균일성을 개선시키며, 약물 입자의 분산을 돕는다. DPI 제제는 입자간 결합을 방해하여(유착 방지 작용에 의하여) 제제의 성능을 개선시키는 부형제, 예컨대 스테아르산마그네슘 또는/및 류신을 임의로 함유할 수 있다. 분말 제제는 흡입기 내에 수동으로 로딩되거나 또는 사전 로딩될 수 있는 단위 투약 형태, 예컨대 캡슐(예를 들어, 젤라틴 캡슐) 또는 블리스터 팩 내의 카트리지로 제공될 수 있다. 흡입기의 마우스피스 또는 노즈피스를 입 또는 코에 배치하고, 급격하게 깊게 흡입하여 난기류를 생성하고, 일정 시간(예를 들어, 약 5-10 초) 동안 숨을 참아서 약물 입자가 세기관지 및 폐포 구역에서 침강하도록 하여 약물 입자를 폐로 유인할 수 있다. 사용자는 DPI를 작동시키고, 숨을 들이마시면 디바이스를 통한 기류가 전단응력 및 난기류를 생성하며, 흡입된 공기는 분말층에 투입되며, 정적 분말 블렌드를 유동화시키고, 사용자의 기도에 투입된다. 여기서, 약물 입자는 난기류로 인하여 담체 입자로부터 분리되며, 폐로 깊게 이동하며, 이때 더 큰 담체 입자는 구인두 표면에 충돌하며, 제거된다. 그래서, 사용자의 들이마신 기류는 분말 탈응집 및 공기이온화를 달성하며, 폐에서 약물 침착을 결정한다. (수동 DPI는 약물 입자를 탈응집시키기 위하여 신속한 흡입 기류를 필요로 하는 한편, 신속한 흡입은 MDI 또는 네뷸라이저로는 추천되지 않는데, 이는 상기도에서의 충돌에 의하여 약물 침착을 증가시키는 난기류 및 빠른 속도를 생성하기 때문이다). MDI에 비하여, DPI(호흡 작동식 DPI 포함)는 더 큰 투약량의 약물 및 더 큰 크기의 약물(예를 들어, 거대분자)을 폐로 전달할 수 있다.
락토스(예를 들어, 알파-락토스 일수화물)는 DPI 제제에서 가장 흔히 사용되는 담체이다. DPI 제제용 락토스 일수화물의 등급/유형의 예는 DCL 11, 플로우락(Flowlac)® 100, 인헤일락(Inhalac)® 230, 락토헤일(Lactohale)® 300, 락토프레스(Lactopress)® SD 250(분무 건조된 락토스), 레스피토스(Respitose)® SV003 및 소르볼락(Sorbolac)® 400을 포함하나 이에 제한되지 않는다. DPI 제제는 단일 락토스 등급 또는 상이한 락토스 등급의 조합을 함유할 수 있다. 예를 들면, 락토헤일® 300 또는 소르볼락® 400과 같은 미세한 락토스 등급은 적절한 DPI 담체가 아닐 수 있으며, 흐름을 개선시키기 위하여 DCL 11, 플로우락® 100, 인헤일락® 230 또는 레스피토스® SV003(예를 들어, 약 1:9 비의 미세 락토스 대 거친 락토스)와 같은 거친 락토스 등급과 블렌딩될 필요가 있을 수 있다. 하기 표 7 및 8은 DPI 제제에 사용될 수 있는 락토스의 등급/유형의 비제한적인 예를 제시한다. 담체 입자 크기의 분포는 약물의 미세 입자 분율/투약(FPF 또는 FPD)에 영향을 미치며, 폐로의 약물 전달에는 고 FPF가 요구된다. FPF/FPD는 흡입 공기에서 공기역학 입자 크기 ≤5 미크론으로 DPI 디바이스로부터 호흡 가능한 분율/투약 질량이다. 고 FPF 및 그에 따른 우수한 DPI 성능은 예를 들면 캡슐 외피 또는 DPI 디바이스 내에서 약물의 침착을 방지하며, 약물의 본질적으로 전부를 기도로 전달하기 위하여 대략 1:9 비의 미세한 락토스(예를 들어, 락토헤일® 300) 대 거친 락토스(예를 들어, 레스피토스® SV003) 및 약 20% w/w 오버에이지(overages)를 갖는 DPI 제제로부터 얻을 수 있다.
DPI 제제용 다른 담체는 글루코스, 만니톨(예를 들어, 결정화된 만니톨[펄리톨(Pearlitol) 110 C] 및 분무 건조된 만니톨[펄리톨 100 SD]), 말티톨(예를 들어, 결정화된 말티톨[말티소르브(Maltisorb) P90]), 소르비톨 및 자일리톨을 포함하나 이에 제한되지 않는다.
대부분의 DPI는 에어로졸 생성을 위한 사용자의 흡입에 의존하는 호흡 작동식("수동")이다. 수동 DPI의 예는 에어맥스(Airmax)®, 노볼라이저(Novolizer)® 및 오츠카(Otsuka) DPI(압축 케이크)를 포함하나 이에 제한되지 않는다. 공기 분류기 기술(ACT)은 DPI에 사용되는 효율적인 수동 분말 분산 메카니즘이다. ACT에서, 복수의 공급 채널은 흡입 중에 디바이스 내에서 사이클론을 생성하는 탄젠트 기류를 생성한다. 또한 예를 들면 입자 탈응집을 돕는 에너지를 사용하는 동력 보조("능동") DPI(예를 들면 공기역학, 충돌력 또는 진동에 기초함)가 있다. 예를 들면, 엑수베라(Exubera)® 흡입기의 능동 메카니즘은 스프링 또는 압축 공기 챔버 내에 보관된 역학 에너지를 사용한다. 능동 DPI의 예는 액티스피어(Actispire)®(단일 단위 투약), 아스피레어(Aspirair)®(다중 투약), 엑수베라®(단일 단위 투약), 마이크로도스(MicroDose)®(다중 단위 투약 및 전자 활성화됨), 옴니헤일러(Omnihaler)®(단일 단위 투약), 파이퍼(Pfeiffer) DPI(단일 단위 투약) 및 스피로스(Spiros)®(다중 단위 투약)를 포함하나 이에 제한되지 않는다.
펩티드 생성물은 또한 다른 경로, 예컨대 경구 투여될 수 있다. 경구 제제는 펩티드 생성물 및 당업계에 공지된 통상의 부형제 및 임의로 흡수 향상제, 예컨대 나트륨 N-[8-(2-히드록시벤조일)아미노카프릴레이트](SNAC)를 함유할 수 있다. SNAC는 국소 완충 작용에 의하여 효소 분해로부터 보호하며, GI 흡수를 향상시킨다. 경구 투약 형태(예를 들어, 정제, 캡슐 또는 환제)는 이의 함유물을 위의 강산 및 단백분해 효소로부터 보호하는 장용피를 임의로 가질 수 있다.
일부 실시양태에서, 펩티드 생성물은 지속 방출 조성물로부터 전달된다. 본원에서 사용된 바와 같이, 용어 "지속 방출 조성물"은 지속 방출, 서방 방출, 서방출, 지연 방출, 느린 방출 및 제어 방출 조성물, 시스템 및 디바이스를 포함한다. 일부 실시양태에서, 지속 방출 조성물은 펩티드 생성물을 적어도 약 1 주, 2 주, 3 주, 1 개월, 2 개월, 3 개월 또는 그 이상의 기간에 걸쳐 전달한다.
일부 실시양태에서, 지속 방출 조성물은 생분해성 중합체로 이루어지며, 펩티드 생성물을 혼입한 나노입자 또는 마이크로입자로서 제제화된다. 특정한 실시양태에서, 생분해성 중합체는 락트산 또는/및 글리콜산[예를 들어, L-락트산계 공중합체, 예컨대 폴리(L-락티드-코-글리콜리드) 또는 폴리(L-락트산-코-D,L-2-히드록시옥탄산)]을 포함한다.
추가의 실시양태에서, 지속 방출 조성물은 펩티드 생성물 및 중합체의 혼합물이 대상체에게 근육내 또는 피하 주사될 때 생성되는 데포의 형태로 존재한다. 특정한 실시양태에서, 중합체는 PEG, 폴리락트산(PLA) 또는 폴리글리콜산(PGA) 또는 이들의 공중합체(예를 들어, PLGA 또는 PLA-PEG)이거나 또는 이를 포함한다.
약학 조성물은 모든 활성 및 불활성 성분이 적절한 시스템 중에 조합되며, 투여되는 조성물을 형성하기 위하여 성분을 혼합할 필요가 없는 단일 투약으로서 단위 투약 형태로 제시될 수 있다. 단위 투약 형태는 일반적으로 약물의 치료 유효량을 함유하지만, 복수의 단위 투약 형태의 복용이 치료적 유효량을 달성하도록 이의 적절한 분획을 함유할 수 있다. 단위 투약 형태의 예는 경구 흡수의 경우 정제, 캡슐 또는 환제; 비경구(예를 들어, 정맥내, 피하 또는 근육내) 주사의 경우 1회 사용 펜 또는 투약 계수기가 있는 펜의 사전 충전된 주사기 내의 용액; 및 흡입기에 사전 로딩되거나 또는 수동 로딩된 캡슐, 카트리지 또는 블리스터를 포함한다.
대안으로, 약학 조성물은 활성 성분, 부형제 및 담체(예를 들어, 용매)가 2개 이상의 별도의 용기(예를 들어, 앰풀, 바이알, 튜브, 병 또는 주사기)에 제공되며, 투여되는 조성물을 형성하기 위하여 조합하여야 하는 키트로서 제시될 수 있다. 키트는 조성물(예를 들어, 비경구 주사되는 용액)을 보관, 제조 및 투여하기 위한 설명서를 함유할 수 있다.
키트는 단위 투약 형태로 모든 활성 및 불활성 성분을 또는 2개 이상의 별도의 용기 내에 활성 성분 및 불활성 성분을 함유하며, 본원에 개시된 의학적 병태를 치료하기 위한 약학 조성물을 투여 또는 사용하기 위한 설명서를 함유할 수 있다. 키트는 조성물, 예컨대 인젝션 펜 또는 흡입기를 전달하기 위한 디바이스를 추가로 함유할 수 있다.
일부 실시양태에서, 키트는 펩티드 생성물 또는 이의 약학적으로 허용되는 염 또는 이를 포함하는 약학 조성물 및, 본원에 개시된 의학적 병태, 예컨대 인슐린 내성, 당뇨병, 비만증, 대사 증후군 또는 심혈관 질환 또는 그와 관련된 병태(예를 들어, NASH 또는 PCOS)를 치료하기 위한 펩티드 생성물 또는 조성물의 투여 또는 사용에 대한 설명서를 함유한다. 특정한 실시양태에서, 키트는 펩티드 생성물 또는 조성물을 전달하기 위한 디바이스, 예컨대 인젝션 펜 또는 흡입기를 추가로 함유한다.
펩티드 생성물의 치료적 용도
본 개시내용은 예를 들면 인슐린 내성, 당뇨병, 비만증, 대사 증후군 및 심혈관 질환 및 이와 관련된 병태, 예컨대 NASH 및 PCOS를 치료하기 위한 본원에 기재된 펩티드 생성물의 용도를 추가로 제공한다.
일부 실시양태에서, 펩티드 생성물은 고혈당증, 인슐린 내성, 고인슐린혈증, 당뇨병전기, 당뇨병(1형 및 2형, 임신 및 소아 당뇨병 포함), 당뇨 합병증, 당뇨 신경병증, 당뇨 신장병증, 당뇨 망막병증, 고지질혈증, 고콜레스테롤혈증, 고중성지방혈증, 유리 지방산의 증가된 혈중 농도, 비만증, 대사 증후군, X 증후군, 심혈관 질환(관상 동맥 질환 포함), 죽상경화증, 급성 심혈관 증후군, 허혈(심근 허혈 및 대뇌 허혈/뇌졸중 포함), 허혈-재관류 손상(심근 및 대뇌 IRI 포함), 경색증(심근 및 대뇌 경색증 포함), 협심증, 심부전(예를 들어, 울혈 심부전), 말초 혈관 질환, 혈전증(예를 들어, 심부 정맥 혈전증), 색전증(예를 들어, 폐 색전증), 전신 염증(예를 들어, 증가된 C-반응성 단백질 혈중 수치를 특징으로 하는 것) 및 고혈압을 치료하는데 사용된다. 펩티드 생성물은 혈당 의존성 인슐린 분비의 자극, 인슐린 민감도의 증가, 지방 연소의 자극 및 체중 감소를 포함한 다양한 기전을 통하여 이의 치료 효과를 달성할 수 있다. 펩티드 생성물은 또한 예를 들면 췌장 베타-세포 보호, 심장보호 및 상처 치유를 촉진할 수 있다.
본원에 기재된 펩티드 생성물은 인슐린 내성 또는/및 비만증과 관련된 다른 병태를 치료하는데 사용될 수 있다. 인슐린 내성 또는/및 비만증과 관련된 다른 병태는 관절염(예를 들어, 골관절염), 요통, 호흡 장애(예를 들어, 천식, 비만증 저환기 증후군[픽윅 증후군] 및 폐쇄성 수면 무호흡), 피부병(예를 들어, 당뇨병성 궤양, 흑색 극세포증, 연조직염, 다모증, 간찰진 및 림프부종), 소화기 질환(예를 들어, 담석증[담석], 위식도 역류병[GERD] 및 위마비), 통풍, 고코르티솔증(예를 들어, 쿠싱 증후군), 신장 질환(예를 들어, 만성 신장 질환), 간 질환(예를 들어, 알콜성 및 비알콜성 FLD를 포함한 지방간 질환[FLD]), 신경계 장애(예를 들어, 손목 터널 증후군, 치매[예를 들어, 알츠하이머병 및 혈관 치매], 대퇴 감각이상증, 편두통 및 다발 경화증), 비뇨기과 질환(예를 들어, 발기 부전, 생식선저하증 및 요실금), 다낭성 난소 증후군, 불임증, 월경 장애, 기분 장애(예를 들어, 우울증) 및 암(예를 들어, 자궁내막, 식도, 결장직장, 방광, 신장, 간의 암[예를 들어, 간세포 암종], 췌장 및 피부의 암[예를 들어, 흑색종] 및 백혈병)을 포함하나 이에 제한되지 않는다.
특정한 실시양태에서, 본원에 기재된 펩티드 생성물은 다낭성 난소 증후군(PCOS)을 치료하는데 사용된다. 다른 실시양태에서, 펩티드 생성물은 만성 신장/신 부전(CKF/CRF)으로도 알려진 만성 신장 질환(CKD)을 치료하는데 사용된다. CKD의 가장 흔한 원인은 당뇨병 및 장기간 제어되지 않은 고혈압이다.
추가의 실시양태에서, 본원에 기재된 펩티드 생성물은 지방간 질환(FLD)을 치료하는데 사용된다. 일부 실시양태에서, FLD는 비알콜성 지방간 질환(NAFLD)이다. 특정한 실시양태에서, NAFLD는 비알콜성 지방간염(NASH)이다. 간 지방증으로도 알려진 FLD는 간에서 과도한 지방 축적을 특징으로 한다. FLD는 알콜성 지방간 질환(AFLD) 및 NAFLD를 포함한다. 만성 알콜 중독은 간에서 알콜의 대사 중에 독성 대사산물, 예컨대 알데히드의 생성으로 인하여 지방간을 유발한다. NAFLD는 하기 기재되어 있다. FLD는 당뇨병, 비만증 및 대사 증후군과 관련되어 있다. 지방간은 간경변 또는 간암(예를 들어, 간세포 암종[HCC])으로 진행될 수 있다. 경화 AFLD를 갖는 환자의 약 10% 미만은 HCC로 진행되지만, 간경변 없이 NASH를 갖는 환자의 약 45%까지는 HCC로 진행될 수 있다. HCC는 성인에서 가장 흔한 유형의 원발성 간암이며, 만성 간 염증의 환경에서 발생한다.
NAFLD는 지방, 특히 유리 지방산 및 트리글리세리드가 과도한 알콜 소비, 예컨대 영양분 과부하, 고칼로리 섭취 및 대사성 장애(예를 들어, 이상지질혈증 및 손상된 글루코스 조절)를 제외한 원인으로 인하여 간 세포에서 축적될 때 발생하는 지방간을 특징으로 한다(간 지방증). 간은 간 기능을 방해하지 않으면서 지방을 보유할 수 있으나, 지방간은 지방증이 간의 섬유증과 함께 또는 없이 염증, 간세포 확대 및 세포 손상을 수반하는 병태인 NASH로 진행될 수 있다. 섬유증은 NASH로부터의 사망률의 가장 강력한 예측 변수가 된다. NAFLD는 지방증 단독; 소엽 또는 문맥 염증은 있으나, 확대는 없는 지방증; 확대는 있지만 염증은 없는 지방증; 또는 염증 및 확대가 있는 지방증을 특징으로 할 수 있다.
NASH는 NAFLD의 가장 극단적인 형태이다. NASH는 진행성 질환이며, 환자의 약 20%는 간의 간경변으로 진행되며, 약 10%는 간 질환, 예컨대 간경변 또는 간암(예를 들어, HCC)으로 사망한다. NAFLD는 선진국에서 가장 흔한 간 질환이며, NASH는 2020년까지 미국에서 간 이식의 주요 원인으로서 C형 간염을 대체할 것으로 예상된다. 미국 인구의 약 12-25%는 NAFLD를 가지며, NASH는 미국 인구의 약 2-5%에 영향을 미친다.
NASH를 포함한 NAFLD는 인슐린 내성, 비만증 및 대사 증후군과 관련되어 있다. 예를 들면, 인슐린 내성은 지방간이 간 염증 및 섬유증으로 진행되는데 기여하여 NASH가 된다. 더욱이, 비만증은 NASH를 촉진하여 악화시키며, 체중 감량은 NASH를 완화시킬 수 있다. 그러므로, GLP-1 수용체(GLP1R) 효능제, 글루카곤 수용체(GCGR) 효능제 및 2중 GLP1R/GCGR 효능제를 포함한 본원에 기재된 펩티드 생성물은 NASH를 포함한 NAFLD를 치료하는데 사용될 수 있다.
일부 실시양태에서, 본원에 개시된 인슐린 내성 또는/및 비만증, 예컨대 NAFLD(예를 들어, NASH) 또는 PCOS와 관련된 병태를 치료하는데 사용된 펩티드 생성물은 서열 번호 601, 602, 603, 604, 630, 631, 632, 633, 634, 805, 819, 820, 821, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125의 펩티드 생성물 및 이의 약학적으로 허용되는 염으로부터 선택된다.
펩티드 생성물은 본원에 개시된 병태의 치료를 위한 임의의 적절한 경로에 의하여 투여될 수 있다. 펩티드 생성물의 투여의 잠재적 경로는 경구, 비경구(피내, 피하, 근육내, 혈관내, 정맥내, 동맥내, 복강내, 강내 및 국소 포함) 및 국소(경피, 경점막, 비내[예를 들어, 코 스프레이 또는 점비액에 의하여], 눈[예를 들어, 점안액에 의하여], 폐[예를 들어, 경구 또는 코 흡입에 의하여], 협측, 설하, 직장[예를 들어, 좌제에 의하여] 및 질[예를 들어, 좌제에 의하여] 포함)를 포함하나 이에 제한되지 않는다. 일부 실시양태에서, 펩티드 생성물은 비경구, 예컨대 피하, 정맥내 또는 근육내 투여된다. 다른 실시양태에서, 펩티드 생성물은 경구 흡입 또는 코 흡입 또는 취입에 의하여 투여된다.
본원에 개시된 병태를 치료하기 위한 펩티드 생성물을 사용한 치료 유효량 및 투여의 빈도 및 치료의 길이는 병태의 성질 및 경중도, 화합물의 효력, 투여의 경로, 대상체의 연령, 체중, 일반적인 건강, 성별 및 식이 및 대상체의 치료에 대한 반응을 포함한 각종 요인에 의존할 수 있으며, 치료 중인 주치의에 의하여 결정될 수 있다.
일부 실시양태에서, 펩티드 생성물은 본원에 개시된 병태(예를 들어, 인슐린 내성 또는/및 비만증, 예컨대 NASH 또는 PCOS와 관련된 것)의 치료를 위하여 약 0.1 ㎎ 내지 약 1, 5 또는 10 ㎎ 또는 약 0.1-1 ㎎ 또는 1-10 ㎎의 투약량으로 약 1 주의 기간에 걸쳐 비경구(예를 들어, 피하[sc], 정맥내[iv] 또는 근육내[im]) 투여된다. 추가의 실시양태에서, 펩티드 생성물은 약 0.1-0.5 ㎎, 0.5-1 ㎎, 1-5 ㎎ 또는 5-10 ㎎의 투약량으로 약 1 주의 기간에 걸쳐 비경구(예를 들어, sc, iv 또는 im) 투여된다. 특정한 실시양태에서, 펩티드 생성물은 약 0.1-1 ㎎ 또는 약 0.1-0.5 ㎎ 또는 0.5-1 ㎎의 투약량으로 약 1 주의 기간에 걸쳐 비경구(예를 들어, sc, iv 또는 im) 투여된다.
펩티드 생성물은 본원에 개시된 병태(예를 들어, 인슐린 내성 또는/및 비만증, 예컨대 NASH 또는 PCOS와 관련된 것)의 치료를 위한 임의의 적절한 빈도로 투여될 수 있다. 일부 실시양태에서, 펩티드 생성물은 예를 들면 1일 1회, 2일당 1회, 3일당 1회, 1주당 2회, 1주당 1회 또는 2주당 1회로 sc 또는 iv 투여된다. 특정한 실시양태에서, 펩티드 생성물은 예를 들면 1주당 1회 sc 또는 iv 투여된다.
펩티드 생성물은 환자에게 편리한 하루 중 임의의 시간에 투여될 수 있다. 펩티드 생성물은 실질적으로 음식과 함께(예를 들어, 식사와 함께 또는 식사 전 또는 식사 후 약 1 시간 또는 30 분 이내에) 또는 실질적으로 음식 없이(예를 들어, 식사 전 또는 식사 후 적어도 약 1 또는 2 시간에) 복용될 수 있다.
펩티드 생성물을 사용한 의학적 병태의 치료 길이는 예를 들면 병태의 성질 및 경중도 및 대상체의 치료에 대한 반응에 기초할 수 있으며, 치료 중인 주치의에 의하여 결정될 수 있다. 일부 실시양태에서, 펩티드 생성물은 본원에 개시된 병태를 치료하기 위하여 만성적으로, 예컨대 적어도 약 2 개월, 3 개월, 6 개월, 1 년, 1.5 년, 2 년, 3 년, 5 년, 10 년 또는 그 이상 투여된다. 펩티드 생성물은 또한 병태의 임상 소견이 사라지거나 또는 임상 표적, 예컨대 혈당 수치, 혈압, 지질의 혈중 수치, 체중 또는 신체 질량 지수, 허리 대 엉덩이 비 또는 체지방 비율 또는 이들의 임의의 조합을 달성할 때까지 필요에 따라 복용할 수 있다. 병태의 임상 소견이 다시 나타나거나 또는 임상 표적이 유지되지 않을 경우, 펩티드 생성물의 투여는 재개될 수 있다.
본 개시내용은 본원에 기재된 의학적 병태의 치료를 필요로 하는 대상체에게 본원에 기재된 펩티드 생성물 또는 이의 약학적으로 허용되는 염 또는 이를 포함하는 약학 조성물의 치료 유효량을 투여하는 것을 포함하는, 상기 병태의 치료 방법을 제공한다. 본 개시내용은 약제로서 사용하기 위한 본원에 기재된 펩티드 생성물 또는 이의 약학적으로 허용되는 염 또는 이를 포함하는 조성물을 추가로 제공한다. 게다가, 본 개시내용은 약제의 제조에서 본원에 기재된 펩티드 생성물 또는 이의 약학적으로 허용되는 염의 용도를 제공한다. 펩티드 생성물을 함유하는 약제는 본원에 기재된 임의의 의학적 병태를 치료하는데 사용될 수 있다. 펩티드 생성물은 하나 이상의 추가적인 치료제와 병용하여 임의로 사용될 수 있다.
병용 요법
본원에 기재된 펩티드 생성물은 본원에 개시된 임의의 질병, 예컨대 인슐린 내성, 당뇨병, 비만증, 대사 증후군 또는 심혈관 질환 또는 이와 관련된 임의의 병태, 예컨대 NASH 또는 PCOS를 치료하기 위하여 하나 이상의 추가적인 치료제와 병용하여 임의로 사용될 수 있다. 일부 실시양태에서, 하나 이상의 추가적인 치료제는 당뇨병 치료제, 비만증 치료제(지질 강하제 및 친포만감제(pro-satiety agent) 포함), 항아테롬경화제, 소염제, 항산화제, 항섬유화제, 혈압강하제 및 이들의 조합으로부터 선택된다.
당뇨병 치료제는 하기를 포함하나 이에 제한되지 않는다:
비구아니드(예를 들어, 부포르민 및 메트포르민)를 포함한 AMP-활성화된 단백질 키나제(AMPK) 효능제;
티아졸리딘디온(예를 들어, 발라글리타존, 시글리타존, 다르글리타존, 엔글리타존, 로베글리타존, 네토글리타존, 피오글리타존, 리보글리타존, 로시글리타존 및 트로글리타존) 및 사로글리타자르(2중 PPAR-α/γ 효능제)를 포함한 퍼옥시좀 증식체 활성화 수용체 감마(PPAR-γ) 효능제;
엑센딘-4, 알비글루티드, 둘라글루티드, 엑세나티드, 리라글루티드, 릭시세나티드, 세마글루티드, 타스포글루티드, CNTO736, CNTO3649, HM11260C(LAPS-엑센딘), NN9926(OG9S7GT), TT401 및 ZY0G1을 포함한 글루카곤 유사 펩티드-1(GLP-1) 수용체 효능제;
알로글립틴, 아나글립틴, 두토글립틴, 에보글립틴, 게미글립틴, 고소글립틴, 리나글립틴, 오마리글립틴, 삭사글립틴, 셉타글립틴, 시타글립틴, 테넬리글립틴, 트렐라글립틴 및 빌다글립틴을 포함한 디펩티딜 펩티다제 4(DPP-4) 억제제;
카나글리플로진(또한 SGLT1을 억제함), 다파글리플로진, 엠파글리플로진, 에르투글리플로진, 이프라글리플로진, 루세오글리플로진, 레모글리플로진 에타보네이트, 소타글리플로진(또한 SGLT1을 억제함) 및 토포글리플로진을 포함한 나트륨-글루코스 수송 단백질 2(SGLT2) 억제제;
메글리티니드(예를 들어, 미티글리니드, 나테글리니드 및 레파글리니드) 및 술포닐우레아{제1 세대(예를 들어, 아세토헥사미드, 카르부타미드, 클로르프로파미드, 글리시클라미드[톨헥사미드], 메타헥사미드, 톨라자미드 및 톨부타미드) 및 제2 세대(예를 들어, 글리벤클라미드[글리부리드], 글리보르누리드, 글리클라지드, 글리메피리드, 글리피지드, 글리퀴돈, 글리속세피드 및 글리클로피라미드) 포함}를 포함한 췌장 베타 세포에 대한 ATP 의존성 K+(KATP) 채널의 차단제;
신속 작용 인슐린(예를 들어, 인슐린 아스파르트, 인슐린 글룰리신 및 인슐린 리스프로), 중간 작용 인슐린(예를 들어, NPH 인슐린) 및 장기간 작용 인슐린(예를 들어, 인슐린 데글루덱, 인슐린 데테미르 및 인슐린 글라르진)을 포함한 인슐린 및 이들의 유사체; 및
이들의 유사체, 유도체 및 염.
특정한 실시양태에서, 당뇨병 치료제는 비구아니드(예를 들어, 메트포르민), 티아졸리딘디온(예를 들어, 피오글리타존 또는 로시글리타존) 또는 SGLT2 억제제(예를 들어, 엠파글리플로진 또는 토포글리플로진) 또는 이들의 임의의 조합이거나 또는 이를 포함한다.
비만증 치료제는 하기를 포함하나 이에 제한되지 않는다:
암페타민, 덱삼페타민, 암페프라몬, 클로벤조렉스, 마진돌, 펜테르민(토피라메이트와 함께 또는 없이) 및 로르카세린을 포함한 식욕 억제제(식욕억제);
아밀린, 칼시토닌, 콜레시스토키닌(CCK), GLP-1, 렙틴, 옥신토모듈린, 췌장 폴리펩티드(PP), 펩티드 YY(PYY) 및 뉴로펩티드 Y(NPY)의 섬모 신경영양 인자(예를 들어, 악소킨) 및 더 긴 시간 작용하는 유사체를 포함한 친포만감제;
카울레르페닌, 세틸리스타트, 에벨락톤 A 및 B, 에스테라스틴, 립스타틴, 오를리스타트, 페르시퀴닌, 판클리신 A-E, 발리락톤 및 비브라락톤을 포함한 리파제 억제제;
항고지질혈증제; 및
이들의 유사체, 유도체 및 염.
항고지질혈증제는 하기를 포함하나 이에 제한되지 않는다:
스타틴{예를 들어, 아토르바스타틴, 세리바스타틴, 플루바스타틴, 메바스타틴, 모나콜린(예를 들어, 모나콜린 K[로바스타틴]), 피타바스타틴, 프라바스타틴, 로수바스타틴 및 심바스타틴} 및 플라바논(예를 들어, 나린게닌)을 포함한 HMG-CoA 리덕타제 억제제;
라파퀴스타트, 자라고즈산 및 RPR-107393을 포함한 스쿠알렌 신타제 억제제;
안토시아닌, 베나치올리드, 클로로아세틸화 비오틴, 시클로딤, 디클로폽, 할록시폽, 소라펜(예를 들어, 소라펜 A1α), 5-(테트라데실옥시)-2-푸란카르복실산(TOFA), CP-640186, GS-0976, NDI-010976; 7-(4-프로필옥시-페닐에티닐)-3,3-디메틸-3,4 디히드로-2H-벤조[b][1,4]디옥세핀; N-에틸-N'-(3-{[4-(3,3-디메틸-1-옥소-2-옥사-7-아자스피로[4.5]데크-7-일)피페리딘-1-일]-카르보닐}-1-벤조티엔-2-일)우레아; 5-(3-아세트아미도부트-1-이닐)-2-(4-프로필옥시펜옥시)티아졸; 및 1-(3-{[4-(3,3-디메틸-1-옥소-2-옥사-7-아자스피로[4.5]데크-7-일)피페리딘-1-일]-카르보닐}-5-(피리딘-2-일)-2-티에닐)-3-에틸우레아를 포함한 아세틸-CoA 카르복실라제(ACC) 억제제;
피브레이트(예를 들어, 베자피브레이트, 시프로피브레이트, 클리노피브레이트, 클로피브르산, 클로피브레이트, 알루미늄 클로피브레이트[알피브레이트], 클로피브리드, 에토피브레이트, 페노피브르산, 페노피브레이트, 겜피브로질, 로니피브레이트 및 심피브레이트), 이소플라본(예를 들어, 다이드제인 및 게니스테인) 및 퍼플루오로알카노산(예를 들어, 퍼플루오로옥탄산 및 퍼플루오로노난산)을 포함한 PPAR-α 효능제;
엘라피브라노(2중 PPAR-α/δ 효능제), GFT505(2중 PPAR-α/δ 효능제), GW0742, GW501516(2중 PPAR-β/δ 효능제), 소델글리타자르(GW677954), MBX-8025 및 이소플라본(예를 들어, 다이드제인 및 게니스테인)을 포함한 PPAR-δ 효능제;
티아졸리딘디온(상동), 사로글리타자르(2중 PPAR-α/γ 효능제), 4-옥소-2-티옥소티아졸린(예를 들어, 로다닌), 베르베린, 호노키올, 퍼플루오로노난산, 시클로펜테논 프로스타글란딘(예를 들어, 시클로펜테논 15-데옥시-Δ-프로스타글란딘 J2[15d-PGJ2]) 및 이소플라본(예를 들어, 다이드제인 및 게니스테인)을 포함한 PPAR-γ 효능제;
내인성 리간드(예를 들어, 옥시스테롤, 예컨대 22(R)-히드록시콜레스테롤, 24(S)-히드록시콜레스테롤, 27-히드록시콜레스테롤 및 콜레스테노산) 및 합성 효능제(예를 들어, 아세틸-포도카르프 이량체, 히포콜아미드, N,N-디메틸-3β-히드록시-콜렌아미드 [DMHCA], GW3965 및 T0901317)를 포함한 간 X 수용체(LXR) 효능제;
내인성 리간드(예를 들어, 9-시스-레티노산) 및 합성 효능제(예를 들어, 벡사로텐, AGN 191659, AGN 191701, AGN 192849, BMS649, LG100268, LG100754 및 LGD346)를 포함한 레티노이드 X 수용체(RXR) 효능제;
아바시미브, 펙티미브, 펠리토린, 테르펜돌 C 및 플라바논(예를 들어, 나린게닌)을 포함한 아실-CoA 콜레스테롤 아실트랜스퍼라제(ACAT, aka ACAT1[SOAT1] 및 ACAT2[SOAT2]를 포함한 스테롤 O-아실트랜스퍼라제[SOAT])의 억제제;
아람콜, CAY-10566, CVT-11127, SAR-224, SAR-707, XEN-103; 3-(2-히드록시에톡시)-4-메톡시-N-[5-(3-트리플루오로메틸벤질)티아졸-2-일]벤즈아미드 및 4-에틸아미노-3-(2-히드록시에톡시)-N-[5-(3-트리플루오로메틸벤질)티아졸-2-일]벤즈아미드; 1'-{6-[5-(피리딘-3-일메틸)-1,3,4-옥사디아졸-2-일]피리다진-3-일}-5-(트리플루오로메틸)-3,4-디히드로스피로[크로멘-2,4'-피페리딘]; 5-플루오로-1'-{6-[5-(피리딘-3-일메틸)-1,3,4-옥사디아졸-2-일]피리다진-3-일}-3,4-디히드로스피로[크로멘-2,4'-피페리딘]; 6-[5-(시클로프로필메틸)-4,5-디히드로-1'H,3H-스피로[1,5-벤족사제핀-2,4'-피페리딘]-1'-일]-N-(2-히드록시-2-피리딘-3-일에틸)피리다진-3-카르복스아미드; 6-[4-(2-메틸벤조일)피페리딘-1-일]피리다진-3-카르복실산(2-히드록시-2-피리딘-3-일에틸)아미드; 4-(2-클로로펜옥시)-N-[3-(메틸 카르바모일)페닐]피페리딘-1-카르복스아미드, 콘쥬게이트된 리놀레산의 시스-9,트랜스-11 이성질체 및 트랜스-10,시스-12 이성질체, WO 2009/129625 A1에 개시된 치환된 헤테로방향족 화합물, SCD-1에 대한 mRNA를 표적화하는 안티센스 폴리뉴클레오티드 및 펩티드-핵산(PNA) 및 SCD-1-표적화 siRNA를 포함한 스테아로일-CoA 데사튜라제-1(SCD-1, aka 스테아로일-CoA 델타-9 데사튜라제) 활성 또는 발현의 억제제;
아나세트라핍, 달세트라핍, 에바세트라핍, 토르세트라핍 및 AMG 899(TA-8995)를 포함한 콜레스테릴에스테르 전이 단백질(CETP) 억제제;
임플리타피드, 로미타피드, 디를로타피드, 미트라타피드, CP-346086, JTT-130, SLx-4090, MTTP에 대한 mRNA를 표적화하는 안티센스 폴리뉴클레오티드 및 PNA, MTTP-표적화 마이크로RNA(예를 들어, miRNA-30c) 및 MTTP-표적화 siRNA를 포함한 미소체 트리글리세리드 전이 단백질(MTTP) 활성 또는 발현의 억제제;
GLP-1 수용체 효능제(상동);
BMS-986036(페길화된 FGF21)을 포함한 섬유모세포 성장 인자 21(FGF21) 및 이의 유사체 및 유도체;
베르베린(PCSK9 수치를 감소시킴), 아넥신 A2(PCSK9 활성을 억제함), 항-PCSK9 항체(예를 들어, 알리로쿠맙, 보코시주맙, 에볼로쿠맙, LGT-209, LY3015014 및 RG7652), PCSK9에 결합하는 LDL 수용체의 표피 성장 인자-A(EGF-A) 도메인을 모사하는 펩티드, PCSK9-결합 아드넥틴(예를 들어, BMS-962476), PCSK9에 대한 mRNA를 표적화하는 안티센스 폴리뉴클레오티드 및 PNA 및, PCSK9-표적화 siRNA(예를 들어, 인클리시란[ALN-PCS] 및 ALN-PCS02)를 포함한 전단백질 전환효소 섭틸리신/켁신 9형(PCSK9) 활성 또는 발현의 억제제;
apoA-I 모사체(예를 들어, 2F, 3F, 3F-1, 3F-2, 3F-14, 4F, 4F-P-4F, 4F-IHS-4F, 4F2, 5F, 6F, 7F, 18F, 5A, 5A-C1, 5A-CH1, 5A-CH2, 5A-H1, 18A, 37pA [18A-P-18A], ELK[네임], ELK-1A, ELK-1F, ELK-1K1A1E, ELK-1L1K, ELK-1W, ELK-2A, ELK-2A2K2E, ELK-2E2K, ELK-2F, ELK-3E3EK, ELK-3E3K3A, ELK-3E3LK, ELK-PA, ELK-P2A, ELKA[네임], ELKA-CH2, ATI-5261, CS-6253, ETC-642, FAMP[네임], FREL[네임] 및 KRES[네임]) 및 apoE 모사체(예를 들어, Ac-hE18A-NH2[AEM-28], Ac-[R]hE18A-NH2, AEM-28-14, EpK, hEp, mR18L, COG-112, COG-133 및 COG-1410)를 포함한 아포지질단백질 모사체 펩티드;
도코사헥사엔산(DHA), 도코사펜타엔산(DPA), 에이코사펜타엔산(EPA), α-리놀렌산(ALA), 어유(예를 들면 DHA 및 EPA를 함유함) 및 이들의 에스테르(예를 들어, 글리세릴 및 에틸 에스테르)를 포함한 오메가-3 지방산;
이들의 유사체, 유도체 및 염.
특정한 실시양태에서, 비만증 치료제는 리파제 억제제(예를 들어, 오를리스타트) 또는/및 항고지질혈증제(예를 들어, 스타틴, 예컨대 아토르바스타틴 또는/및 피브레이트, 예컨대 패노피브레이트)이거나 또는 이를 포함한다.
혈압강하제는 하기를 포함하나 이에 제한되지 않는다:
레닌 억제제(예를 들어, 알리스키렌), 안지오텐신-전환 효소(ACE) 억제제(예를 들어, 베나제프릴, 캅토프릴, 에날라프릴, 포시노프릴, 리시노프릴, 모엑시프릴, 페린도프릴, 퀴나프릴, 라미프릴 및 트란돌라프릴), 안지오텐신 II 수용체 1형(AT1) 길항제(예를 들어, 아질사르탄, 칸데사르탄, 에프로사르탄, 피마사르탄, 이르베사르탄, 로사르탄, 올메사르탄 메독소밀, 올메사르탄, 텔미사르탄 및 발사르탄) 및 알도스테론 수용체 길항제(예를 들어, 에플레레논 및 스피로노락톤)를 포함한 레닌-앤지오텐신-알도스테론 계통(RAAS)의 길항제;
고리작용 이뇨제(예를 들어, 부메타니드, 에타크린산, 푸로세미드 및 토르세미드), 티아지드 이뇨제(예를 들어, 벤드로플로메티아지드, 클로로티아지드, 히드로클로로티아지드, 에피티지드, 메티클로티아지드 및 폴리티아지드), 티아지드 유사 이뇨제(예를 들어, 클로르탈리돈, 인다파미드 및 메톨라존), 시클레타닌(초기 원위 요세관 이뇨제), 칼륨 보존성 이뇨제(예를 들어, 아밀로리드, 에플레레논, 스피로노락톤 및 트리암테렌) 및 테오브로민을 포함한 이뇨제;
디히드로피리딘(예를 들어, 암로디핀, 레밤로디핀, 실니디핀, 클레비디핀, 펠로디핀, 이스라디핀, 레르카니디핀, 니카르디핀, 니페디핀, 니모디핀, 니솔디핀 및 니트렌디핀) 및 비-디히드로피리딘(예를 들어, 딜티아젬 및 베라파밀)을 포함한 칼슘 채널 차단제;
클로니딘, 구아나벤즈, 구안파신, 메틸도파 및 목소니딘을 포함한 α2-아드레노수용체 효능제;
독사조신, 인도라민, 니세르골린, 펜옥시벤즈아민, 펜톨아민, 프라조신, 테라조신 및 톨라졸린을 포함한 α1-아드레노수용체 길항제(알파 차단제);
아테놀롤, 베탁솔롤, 비소프롤롤, 카르테올롤, 카르베디롤, 라베탈롤, 메토프롤롤, 나돌롤, 네비볼롤, 옥스프레놀롤, 펜부톨롤, 핀돌롤, 프로프라놀롤 및 티몰롤을 포함한 β-아드레노수용체(β1 또는/및 β2) 길항제(베타 차단제);
부신돌롤, 카르베딜롤 및 라베탈롤을 포함한 혼합 알파/베타 차단제;
선택성 ETA 수용체 길항제(예를 들어, 암브리센탄, 아트라센탄, 엔도넨탄, 시탁센탄, 지보텐탄 및 BQ-123) 및 2중 ETA/ETB 길항제(예를 들어, 보센탄, 마시텐탄 및 테조센탄)을 포함한 엔도텔린 수용체 길항제;
히드랄라진, 미녹시딜, 테오브로민, 나트륨 니트로프루시드, 유기 니트레이트(예를 들어, 체내에서 산화질소로 전환되는 이소소르비드 모노니트레이트, 이소소르비드 디니트레이트 및 니트로글리세린), 내피 산화질소 신타제(eNOS) 자극제(예를 들어, 시클레타닌), 가용성 구아닐레이트 시클라제의 활성화제(예를 들어, 시나시구아트 및 리오시구아트), 포스포디에스테라제 5형(PDE5) 억제제(예를 들어, 아바나필, 벤즈아미드나필, 다산타필, 디나필, 로데나필, 미로데나필, 실데나필, 타달라필, 우데나필, 바르데나필, 디피리다몰, 파파베린, 프로펜토필린, 자프리나스트 및 T-1032), 프로스타글란딘 E1(알프로스타딜) 및 이의 유사체(예를 들어, 리마프로스트 및 미소프로스톨), 프로스타사이클린 및 이의 유사체(예를 들어, 아타프로스트, 베라프로스트[예를 들어, 에수베라프로스트], 5,6,7-트리노르-4,8-인터-m-페닐렌-9-플루오로-PGI2, 카르바사이클린, 이소카르바사이클린, 클린프로스트, 시프로스텐, 엡탈로프로스트, 시카프로스트, 일로프로스트, 피밀프로스트, SM-10906(데스-메틸 피밀프로스트), 낙사프로스텐, 타프로스텐, 트레프로스티닐, CS-570, OP-2507 및 TY-11223), 비-프로스타노이드 프로스타사이클린 수용체 효능제(예를 들어, 1-프탈라지놀, 랄리네팩, 셀렉시팩, ACT-333679[MRE-269, 셀렉시팩의 활성 대사산물] 및 TRA-418), 포스포리파제 C(PLC) 억제제 및 단백질 키나제 C(PKC) 억제제(예를 들어, BIM-1, BIM-2, BIM-3, BIM-8, 켈레리트린, 시클레타닌, 고시폴, 미야베놀 C, 미리시트린, 루복시스타우린 및 베르바코시드를 포함한 다른 혈관확장제;
마그네슘 및 황산마그네슘을 포함한 미네랄; 및
이들의 유사체, 유도체 및 염.
특정한 실시양태에서, 혈압강하제는 티아지드 또는 티아지드 유사 이뇨제(예를 들어, 히드로클로로티아지드 또는 클로르탈리돈), 칼슘 채널 차단제(예를 들어, 암로디핀 또는 니펜디핀), ACE 억제제(예를 들어, 베나제프릴, 캅토프릴 또는 페린도프릴) 또는 안지오텐신 II 수용체 길항제(예를 들어, 올메사르탄 메녹소밀, 올메사르탄, 텔미사르탄 또는 발사르탄) 또는 이들의 임의의 조합이거나 또는 이를 포함한다.
일부 실시양태에서, 본원에 기재된 펩티드 생성물은 NAFLD, 예컨대 NASH를 치료하기 위하여 하나 이상의 추가적인 치료제와 병용할 수 있다. 일부 실시양태에서, 하나 이상의 추가적인 치료제는 당뇨병 치료제, 비만증 치료제, 소염제, 항섬유화제, 항산화제, 혈압강하제 및 이들의 조합으로부터 선택된다.
NAFLD(예를 들어, NASH)를 치료하는데 사용될 수 있는 치료제는 하기를 포함하나 이에 제한되지 않는다:
PPAR-δ 효능제(예를 들어, MBX-8025, 엘라피브라노[2중 PPAR-α/δ 효능제] 및 GW501516[2중 PPAR-β/δ 효능제]) 및 PPAR-γ 효능제(예를 들어, 티아졸리딘디온, 예컨대 피오글리타존 및 사로글리타자르[2중 PPAR-α/γ 효능제]) - PPAR-δ 및 -γ 효능작용을 포함한 PPAR 효능제는 인슐린 민감도를 증가시키며, PPAR-α 효능작용은 간 지방증을 감소시키며, PPAR-δ 효능작용은 대식세포 및 쿱퍼(Kupffer) 세포의 활성화를 억제하며;
파르네소이드 X 수용체(FXR) 효능제, 예컨대 오베티콜산 및 GS-9674-FXR 효능제는 간 글루코신합성, 지방형성, 지방증 및 섬유증을 감소시키며;
섬유모세포 성장 인자 19(FGF19) 및 이의 유사체 및 유도체, 예컨대 NGM-282 - FGF19 유사체는 간 글루코신합성 및 지방증을 감소시키며;
섬유모세포 성장 인자 21(FGF21) 및 이의 유사체 및 유도체, 예컨대 BMS-986036(페길화된 FGF21) - FGF21 유사체는 간 지방증, 세포 손상 및 섬유증을 감소시키며;
스타틴(예를 들어, 로수바스타틴)을 포함한 HMG-CoA 리덕타제 억제제 - 스타틴은 지방간염 및 섬유증을 감소시키며;
ACC 억제제, 예컨대 NDI-010976(간 표적화된) 및 GS-0976 - ACC 억제제는 새로이 지방형성 및 간 지방증을 감소시키며;
SCD-1 억제제, 예컨대 아람콜 - SCD-1 억제제는 간 지방증을 감소시키며, 인슐린 민감도를 증가시키며;
SGLT2 억제제, 예컨대 카나글리플로진, 이프라글리플로진 및 루세오글리플로진 - SGLT2 억제제는 체중, 간 ALT 수치 및 섬유증을 감소시키며;
CCR2 또는/및 CCR5의 길항제, 예컨대 세니크리비록 - CCR2(CCL2[MCP1]에 결합됨) 및 CCR5(CCL5[RANTES]에 결합됨)의 길항제는 염증 세포(예를 들어, 대식세포)의 활성화 및 간으로의 이동을 억제하며, 간 섬유증을 감소시키며;
아폽토시스 신호 조절 키나제 1(ASK1) 억제제(예를 들어, 셀론세르팁) 및 카스파제 억제제(예를 들어, 엠리카산[팬-카스파제 억제제])를 포함한 아폽토시스 억제제 - 아폽토시스 억제제는 간 지방증 및 섬유증을 감소시키며;
리실 옥시다제 유사 2(LOXL2) 억제제, 예컨대 심투주맙 - LOXL2는 콜라겐 형성에서 핵심 기질 효소이며, 간에서 주로 발현되며;
갈렉틴-3 억제제, 예컨대 GR-MD-02 및 TD139 - 갈렉틴-3은 간 섬유증의 발생에 대하여 매우 중요하며;
비타민 E(예를 들어, α-토코페롤) 및 반응성 산소 종(ROS)의 스캐빈저 및 자유 라디칼(예를 들어, 시스테아민, 글루타티온, 멜라토닌 및 펜톡시필린[또한 TNF-α 및 포스포디에스테라제의 억제에 의한 항염증제])을 포함한 항산화제 - 비타민 E는 간 지방증, 간세포 확대 및 소엽 염증을 감소시키며;
이들의 유사체, 유도체 및 염.
일부 실시양태에서, 본원에 기재된 펩티드 생성물은 NAFLD(예를 들어, NASH)를 치료하기 위하여 PPAR 효능제(예를 들어, PPAR-δ 효능제, 예컨대 엘라피브라노 또는/및 PPAR-γ 효능제, 예컨대 피오글리타존), HMG-CoA 리덕타제 억제제(예를 들어, 스타틴, 예컨대 로수바스타틴), FXR 효능제(예를 들어, 오베티콜산) 또는 항산화제(예를 들어, 비타민 E) 또는 이들의 임의의 조합과 병용된다. 특정한 실시양태에서, NAFLD(예를 들어, NASH)의 치료를 위한 하나 이상의 추가적인 치료제는 비타민 E 또는/및 피오글리타존이거나 또는 이를 포함한다.
펩티드 생성물의 제조
WO 2015/184177 A1은 펩티드 생성물의 합성을 기재한다. 하기 실시예 또한 대표적인 펩티드 생성물의 합성을 기재한다.
실시예
하기 실시예는 단지 본 개시내용을 예시하고자 한다. 다른 프로세스, 검정, 실험, 프로토콜, 절차, 방법론, 시약 및 조건은 대안으로 적절하게 사용될 수 있다.
실시예
1. N-α-
Fmoc
, N-ε-(1-
옥틸
β-D-
글루쿠로니드
-6-일)-L-리신과 같은 시약
오븐 건조시킨 250 ㎖ 삼각 플라스크에 1-옥틸 β-D-글루쿠론산(3.06 g, 10 mmol, 카르보신쓰 리미티드(Carbosynth Ltd.)), 50 ㎖ 무수 DMF 및 무수 1-히드록시벤조트리아졸(1.62 g, 12 mmol)을 넣었다. 50 ㎖의 DMF 중의 N,N'-디시클로헥실카르보디이미드(2.48 g, 12 mmol)의 냉각된(4℃) 용액을 교반하면서 첨가하고, 반응을 5 분 동안 진행되도록 하였다. N,N'-디시클로헥실우레아의 상당한 백색 침전물을 프릿 처리된 유리 깔때기 상에서 여과하고, 여과액을 25 ㎖ 무수 DMF 중의 N-α-Fmoc-L-리신(3.68 g, 10 mmol)의 용액에 첨가하였다. 반응을 25 분 동안 실온으로 가온시키면서 또는 닌히드린 색상이 매우 옅어질 때까지 진행되도록 하였다. 반응 혼합물을 여과하고, 스트리핑하여 건조시키고, MeOH에 용해시켜 MeOH/Et2O로부터 결정화시키고, Et2O로 흐림점까지 서서히 희석한 후, 냉장시켰다. EtOAc로부터 EtOAc/EtOH/AcOH까지의 용매 구배를 사용하여 실리카 겔 크로마토그래피에 의하여 추가로 정제를 실시할 수 있다.
N-α-Boc-L-리신을 사용한 유사한 반응은 N-말단 혼입 및 유리 N-말단으로의 분열에 적절한 N-α-Boc,N-ε-(1-옥틸 β-D-글루쿠로니드-6-일)-L-리신을 산출한다. N-α-Ac-L-리신을 사용한 유사한 반응은 펩티드의 N-말단에서 블로킹된 N-말단으로 혼입시키기에 적절한 N-α-Ac,N-ε-(1-옥틸 β-D-글루쿠로니드-6-일)-L-리신을 산출한다. 적절한 양의 N-α-Fmoc-L-오르니틴을 사용한 유사한 반응은 N-α-Fmoc,N-δ-(1-옥틸 β-D-글루쿠로니드-6-일)-L-오르니틴을 산출한다. 다른 N-모노-보호된 디아미노산을 사용한 유사한 반응은 상응하는 시약을 공급한다. 대안으로, 커플링 도중에 및 1-옥틸 β-D-글루쿠론산의 사전활성화 없이 일시적인 Me3Si 에스테르 보호기의 사용은 시약의 형성으로의 용이한 경로를 제공한다. 일시적인 Me3Si 에스테르는 Fmoc-Lys-OH와 디클로로메탄(CH2Cl2) 중의 등몰량의 N,O-비스(트리메틸실릴)아세트아미드의 반응에 의하여 생성된다. 유기층은 상기와 같은 1-알킬 글루코로니드와의 커플링에 대하여 준비된 CH2Cl2 중의 용액으로서 원하는 시약을 함유한다. 여과된 반응 혼합물을 수성 NaHSO4로 세정하여 Me3Si 에스테르를 가수분해시킨 후, MgSO4 상에서 건조시킨 후, 용매를 제거하였다.
유사하게, 퍼아세틸 또는 퍼벤조일 1-옥틸 β-D-글루쿠론산을 사용한 것을 제외하고, 시약(예를 들어, Ac2O를 사용한 처리에 의하여 형성된 2,3,4-트리스아세틸 1-옥틸 β-D-글루쿠론산 등)의 Ac- 또는 Bz-보호된 형태를 얻는다. 상기 시약은 수지로부터의 산 분열 중에 안정성을 증가시켰으며, 탈보호 중의 불안정성이 검출될 때 사용한다. 상기 생성물의 최종 탈보호는 상기 기재된 바와 같이 MeOH/NH3, MeOH/NaOMe 또는 MeOH/NH2NH2의 사용에 의하여 분열 후 염기-촉매화된 트랜스에스테르화에 의하여 실시된다.
실시예
2. 합성
펩티드
일반적으로, 펩티드 합성 방법은 보호된 아미노산을 성장하는 펩티드 쇄로 순차적으로 첨가하는 것을 포함한다. 통상적으로 제1의 아미노산의 아미노 또는 카르복실 기 및 임의의 반응성 측쇄 기를 보호한다. 그 후, 상기 보호된 아미노산을 불활성 고체 지지체에 연결시키거나 또는 용액 중에 사용하며, 또한 적절하게 보호된 서열에서 그 다음 아미노산은 아미드 결합의 형성으로 처리될 수 있는 조건 하에서 첨가한다. 원하는 아미노산 모두를 적절한 서열에 연결시킨 후, 보호 기 및 임의의 고체 지지체를 제거하여 미정제 펩티드를 얻는다. 펩티드를 탈염시키고, 크로마토그래피에 의하여 정제한다.
약 50개보다 적은 아미노산을 갖는 펩티드의 제조 방법의 일례는 고체상 펩티드 합성을 포함한다. 그러한 방법에서, α-아미노(Nα) 기 및 임의의 반응성 측쇄 작용기는 산- 또는 염기-민감성 기에 의하여 보호된다. 보호기는 잔존하는 펩티드 쇄에 영향을 미치지 않으면서 쉽게 제거 가능하면서 펩티드 결합 형성의 조건에 안정하여야 한다. 적절한 α-아미노 보호기는 t-부틸옥시카르보닐(Boc), 벤질옥시카르보닐(Cbz), o-클로로벤질옥시카르보닐, 비페닐이소프로필옥시카르보닐, t-아밀옥시카르보닐(Amoc), 이소보르닐옥시카르보닐, α,α-디메틸-3,5-디메톡시벤질옥시-카르보닐, o-니트로페닐술페닐, 2-시아노-t-부톡시카르보닐, 9-플루오레닐-메톡시카르보닐(Fmoc) 등, 바람직하게는 Boc 또는 Fmoc을 포함하나 이에 제한되지 않는다. 적절한 측쇄 보호기는 아세틸, 벤질(Bzl 또는 Bn), 벤질옥시메틸(Bom), Boc, t-부틸, o-브로모벤질옥시카르보닐, t-부틸, t-부틸디메틸실릴, 2-클로로벤질(Cl-z), 2,6-디클로로벤질, 시클로헥실, 시클로펜틸, 이소프로필, 피발릴, 테트라히드로피란-2-일, 토실(Tos), 2,2,4,6,7-펜타메틸디히드로벤조푸란-5-술포닐(Pbf), 트리메틸실릴 및 트리틸을 포함하나 이에 제한되지 않는다. 화합물의 합성을 위한 바람직한 Nα-보호기는 Fmoc이다. 바람직한 측쇄 보호기는 Glu, Tyr, Thr, Asp 및 Ser의 경우 -O-t-부틸; Lys 및 Trp 측쇄의 경우 Boc; Arg의 경우 Pbf; 및 Asn, Gln 및 His의 경우 Trt를 포함한다. Lys 잔기의 선택적 변경의 경우, Fmoc 또는 t-부틸계 보호기를 분열시키는 시약에 의하여서는 제거되지 않는 보호기를 사용한 직교 보호가 바람직하다. Lys 측쇄의 변형에 바람직한 예는 피페리딘이 아닌 히드라진에 의하여 제거된 것 - 예를 들면 1-(4,4-디메틸-2,6-디옥소시클로헥스-1-일리덴)-3-메틸부틸(ivDde), 1-(4,4-디메틸-2,6-디옥소시클로헥스-1-일리덴)에틸(Dde) 및 알릴옥시카르보닐(Alloc)을 포함하나 이에 제한되지 않는다.
Glu(O-알릴) 및 Fmoc-Lys(Alloc)을 혼입 및 사용하여 일시적인 보호를 제공한 후, 차후의 제거 및 작용화된 계면활성제와의 반응을 위하여 Lys(Dde) 보호기를 보유하면서 락탐 형성을 위하여 탈보호시키기 때문에 측쇄 락탐 형성이 요구되는 경우 Fmoc-Lys(ivDde) 또는 Fmoc-Lys(Dde) 보호기 반응이 바람직하다. 산성 및 염기성 잔기(예를 들어, Glu 및 Lys) 사이의 측쇄 락탐은 당업계의 표준 프로토콜을 사용한 N,N'-디이소프로필카르보디이미드(DIC)/1-히드록시벤조트리아졸(HOBt) 또는 2-(1H-벤조트리아졸-1-일)-1,1,3,3-테트라메틸아미늄 헥사플루오로포스페이트(HBTU)/ N,N-디이소프로필에틸아민(DIEA)을 사용한 카르복실 측쇄 작용기의 활성화에 의하여 알릴계 보호기의 제거 후 실시된다.
고체상 합성에서, C-말단 아미노산은 우선 적절한 수지 지지체에 연결된다. 적절한 수지 지지체는 사용된 매체 중에 불용성인 것뿐 아니라 단계적 축합 및 탈보호 반응의 시약 및 반응 조건에 대하여 불활성인 물질이다. 시판 중인 수지의 예는 반응성 기, 예를 들면 클로로메틸화된 코-폴리-(스티렌-디비닐벤젠), 히드록시메틸화된 코-폴리-(스티렌-디비닐벤젠) 등으로 변형된 스티렌/디비닐벤젠 수지를 포함한다. 벤질화된, 히드록시메틸화된 페닐아세트아미도메틸(PAM) 수지 및 히드록시메틸펜옥시아세틸아미도메틸(HMPA)은 펩티드 C-말단 산의 제조에 바람직하다. 화합물의 C-말단이 아미드인 경우, 바람직한 수지는 p-메틸벤즈히드릴아미노-코-폴리(스티렌-디비닐-벤젠) 수지 및 2,4-디메톡시벤즈히드릴아미노계 수지("링크(Rink) 아미드") 등이다. 더 큰 펩티드의 합성에 바람직한 지지체는 다른 중합체 매트릭스, 예컨대 링크 아미드-PEG 및 PAL-PEG-PS 수지(어플라이드 바이오시스템즈(Applied Biosystems)) 및, Fmoc 프로토콜을 사용한 펩티드 아미드 합성에 대하여 설계된 유사한 수지 상에 그래프팅된 PEG 서열을 함유하는 시판 중인 수지이다. 그래서, 특정한 경우에, PEG 쇄로의 아미드 연결을 갖는 것이 바람직할 수 있다. 상기 경우에, N-Fmoc-아미노-PEG-카르복실산을 상기 아미드-형성 수지(예를 들어, 링크 아미드 수지 등)에 연결하는 것이 편리하다. 쇄의 제1의 아미노산은 PEG 쇄의 아미노 작용기로의 N-Fmoc-아미노산으로서 커플링될 수 있다. 최종 탈보호는 원하는 펩티드-NH-PEG-코-NH2 생성물을 산출한다.
PAM 또는 HMPA 수지로의 연결은 에탄올, 아세토니트릴, N,N-디메틸포름아미드(DMF) 등 중의 이들의 암모늄, 세슘, 트리에틸암모늄, 1,5-디아자비시클로-[5.4.0]운데크-5-엔, 테트라메틸암모늄 또는 유사 염, 바람직하게는 DMF 중의 세슘 염으로서 Nα-보호된 아미노산, 예컨대 Boc-아미노산을 수지와 고온, 예컨대 약 40℃ 및 약 60℃ 사이, 바람직하게는 약 50℃에서 약 12 내지 72 시간, 바람직하게는 약 48 시간 동안 반응시켜 달성될 수 있다. 이는 궁극적으로 산 분열 후 펩티드 산 생성물 또는 아미노분해후 아미드를 산출한다.
Nα-Boc-아미노산은 예를 들면 DIC/HOBt-매개된 커플링에 의하여 약 2 내지 24 시간, 바람직하게는 약 2 시간 동안 약 10℃ 및 약 50℃ 사이의 온도, 바람직하게는 약 25℃에서 용매, 예컨대 CH2Cl2 또는 DMF, 바람직하게는 CH2Cl2 중에서 벤즈히드릴아민 수지에 연결될 수 있다.
Boc계 프로토콜의 경우, 보호된 아미노산의 연속하는 커플링은 당업계에 공지된 방법에 의하여, 통상적으로 자동화된 펩티드 합성기로 실시될 수 있다. 트리에틸아민, DIEA, N-메틸모르폴린(NMM), 콜리딘 또는 유사 염기를 사용한 중화 후, 각각의 보호된 아미노산은 대략 약 1.5 내지 2.5배의 몰 과잉으로 투입되며, 커플링은 불활성 비수성 극성 용매, 예컨대 CH2Cl2, DMF, N-메틸피롤리돈(NMP), N,N-디메틸아세트아미드(DMA) 또는 이들의 혼합물 중에서, 바람직하게는 디클로로메탄 중에서 상온에서 실시한다. Fmoc계 프로토콜의 경우, 탈보호에 산을 사용하지 않지만, 염기, 바람직하게는 DIEA 또는 NMM을 일반적으로 커플링 혼합물에 혼입한다. 커플링은 통상적으로 DMF, NMP, DMA 또는 혼합 용매, 바람직하게는 DMF 중에서 실시한다. 대표적인 커플링제는 N,N'-디시클로헥실카르보디이미드(DCC), N,N'-디이소프로필-카르보디이미드(DIC) 및 다른 카르보디이미드 단독으로 또는 HOBt, O-아실 우레아, 벤조트리아졸-1-일-옥시트리스(피롤리디노)포스포늄 헥사플루오로포스페이트(PyBop), N-히드록시숙신이미드, 다른 N-히드록시이미드 또는 옥심의 존재하에서의 것이다. 대안으로, 보호된 아미노산 활성 에스테르(예를 들어, p-니트로페닐, 펜타플루오로페닐 등) 또는 대칭 무수물을 사용할 수 있다. 바람직한 커플링제는 아미늄/우로늄 유형, 예컨대 HBTU, O-(7-아자벤조트리아졸-1-일)-1,1,3,3-테트라메틸우로늄 헥사플루오로포스페이트(HATU), 2-(6-클로로-1H-벤조트리아졸-1-일)-1,1,3,3-테트라메틸아미늄 헥사플루오로포스페이트(HCTU) 등이다.
Fmoc-PAL-PEG-PS 수지로의 바람직한 연결 방법은 DMF 중의 20% 피페리딘을 사용한 수지 링커의 탈보호에 이어서 DMF 중의 HBTU:디-이소프로필에틸아민(DIEA)(1:2)을 사용하여 마이크로파 보조된 펩티드 합성기로 5 분, 75℃ 최대 커플링 사이클로 N-α-Fmoc 보호된 아미노산, 약 5배 몰 과잉의 N-α-Fmoc-아미노산의 반응에 의하여 달성될 수 있다.
본 개시내용의 펩티드는 C-말단에서 PEG 기(dPEG)를 함유할 수 있다. 상기 PEG 기는 아미노 말단 및 카르복실 말단을 갖는 폴리에틸렌 글리콜의 단쇄일 수 있다. 그래서, 이는 본질적으로 비천연 아미노산이며, 합성을 위한 다른 아미노산과 유사하게 처리한다. 예를 들면, Fmoc-아미도옥시-dPEG4-산은 퀀타 바이오디자인(Quanta Biodesign)으로부터 시판 중이며(#10213), 합성의 제1의 단계에서 상기 기재된 N-Fmoc 또는 N-Boc 아미노산에 사용된 바와 유사한 방식으로 링크 또는 HMPA 수지에 연결된다. 표준 강산 조건을 사용한 탈보호는 상응하는 산 또는 아미드 C-말단을 갖는 상응하는 짧은 dPEG C-말단 변형된 펩티드를 제공한다.
마이크로파 보조 펩티드 합성기에서의 Fmoc계 프로토콜의 경우, N-α-Fmoc 아미노산 보호기는 0.1 M 1-히드록시벤조트리아졸(HOBt)을 함유하는 DMF 중의 20% 피페리딘을 사용하여 30 초에 이어서 3 분 동안 75℃로 설정된 최대 온도로 2중 탈보호 프로토콜로 제거된다. HOBt를 탈보호 용액에 첨가하여 아스파르티미드 형성을 감소시킨다. 그 다음 아미노산의 커플링은 HBTU:DIEA(1:2)를 사용하여 5 분, 75℃ 최대 2중 커플링 사이클로 5배 몰 과잉을 사용한다.
고체상 합성의 종료시 완전 보호된 펩티드를 수지로부터 제거한다. 수지 지지체로의 연결이 벤질 에스테르 유형을 갖는 경우, 분열은 알킬아미드 C-말단을 갖는 펩티드의 경우 알킬아민 또는 플루오로알킬아민을 사용한 아미노분해에 의하여 또는 예를 들면 비치환된 아미드 C-말단을 갖는 펩티드의 경우 암모니아/메탄올 또는 암모니아/에탄올을 사용하여 약 -10℃ 및 약 50℃ 사이의 온도에서, 바람직하게는 약 25℃에서, 약 12 내지 24 시간, 바람직하게는 약 18 시간 동안 가암모니아 분해에 의하여 수행될 수 있다. 히드록시 C-말단을 갖는 펩티드는 HF 또는 다른 강 산성 탈보호 요법에 의하여 또는 비누화에 의하여 분열될 수 있다. 대안으로, 펩티드는 예를 들면 메탄올을 사용한 트랜스에스테르화에 이어서 아미노분해 또는 비누화에 의하여 수지로부터 제거될 수 있다. 보호된 펩티드는 실리카 겔 또는 역상 HPLC에 의하여 정제될 수 있다.
측쇄 보호 기는 아미노분해 생성물을 아니솔 또는 다른 카르보늄 이온 스캐빈저의 존재하에서 예를 들면 무수 액체 HF로 처리하고, HF/피리딘 착체로 처리, 트리스(트리플루오로아세틸)붕소 및 트리플루오로아세트산으로 처리에 의하여, 수소 및 탄소상 팔라듐 또는 폴리비닐피롤리돈을 사용한 환원에 의하여 또는 액체 암모니아 중의 나트륨, 바람직하게는 액체 HF 및 아니솔을 사용하여 약 -10℃ 및 10℃ 사이의 온도에서, 바람직하게는 약 0℃에서 약 15 분 내지 2 시간, 바람직하게는 약 1.5 시간 동안 환원에 의하여 펩티드로부터 제거될 수 있다.
벤즈히드릴아민형 수지 상의 펩티드의 경우, 수지 분열 및 탈보호 단계는 상기 기재된 바와 같이 액체 HF 및 아니솔을 사용하거나 또는 바람직하게는 더 온화한 분열 칵테일의 사용에 의하여 단일 단계로 합쳐질 수 있다. 예를 들면, PAL-PEG-PS 수지의 경우, 바람직한 방법은 마이크로파 보조된 펩티드 합성기에서 당업계에 공지된 온화한 분열 칵테일 중 하나, 예컨대 TFA/물/트리-이소-프로필실란/3,6-디옥사-1,8-옥탄디티올(DODT)(92.5/2.5/2.5/2.5)을 사용하여 18 분 동안 매번 38℃에서 2중 탈보호 프로토콜의 사용이다. 알킬 글리코시드 함유 물질의 분열은 9/1 내지 19/1 범위 내의 TFA/물 비를 사용한 프로토콜을 사용하여 알킬 글리코시드 연결의 생존을 나타낸다. 통상의 칵테일은 94% TFA:2% EDT; 2% H2O; 2% TIS이다. 통상적으로 완전 탈보호된 생성물은 침전되고, 저온(-70℃ 내지 4℃) Et2O로 세정하고, 탈이온수 중에서 세정하고, 동결건조시켰다.
펩티드 용액을 탈염(예를 들어, 바이오래드(BioRad) AG-3® 음이온 교환 수지 사용)시킬 수 있으며, 펩티드를 하기 유형 중 임의의 또는 전부를 사용하여 크로마토그래피 단계의 시퀀스에 의하여 정제한다: 아세테이트 형태로 약염기성 수지 상의 이온 교환; 비유도체화된 코-폴리(스티렌-디비닐벤젠), 예컨대 앰버라이트(Amberlite)® XAD 상의 소수성 흡착 크로마토그래피; 실리카 겔 흡착 크로마토그래피; 카르복시메틸셀룰로스 상의 이온 교환 크로마토그래피; 예를 들면 세파덱스(Sephadex)® G-25 상의 분배 크로마토그래피; 역류 분포; 초임계 유체 크로마토그래피; 및 HPLC, 특히 옥틸- 또는 옥타데실실릴실리카(ODS) 결합된 상 컬럼 팩킹 상의 역상 HPLC.
본원에는 적절한 수지 지지체 상의 보호된 아미노산을 순차적 축합시키고, 보호기 및 수지 지지체를 제거하고, 생성물을 정제하여 공유 변형된 펩티드를 제공하는 것을 포함하는, 본원에 기재된 공유 변형된 펩티드 및 이의 약학적으로 허용되는 염의 제조 방법이 제공된다. 그러한 방법은 당업계에 공지된 펩티드 합성을 위한 임의의 프로토콜, 예컨대 마이크로파 보조된 고체 상 합성을 사용할 수 있다. 일부 실시양태에서, 펩티드는 알킬 글리코시드에 연결된다.
실시예
3.
우론산을
생성하는 산화 방법
20 ㎖의 아세토니트릴 및 20 ㎖의 탈이온(DI)수 중의 1-도데실 β-D-글루코피라노시드(2.0 g, 5.74 mmol, 카르보신쓰)의 용액에 (디아세톡시요오도)벤젠(4.4 g, 13.7 mmol, 플루카(Fluka)) 및 TEMPO(0.180 g, 1.15 mmol)를 첨가하였다. 생성된 혼합물을 실온에서 20 시간 동안 교반하였다. 반응에 이어서 질량 분석(예를 들어, LCQ ESI)을 실시하고, 완료시 반응 혼합물을 물로 희석하고, 무수 상태로 동결건조시켜 1.52 g(73% 미정제 수율)의 미정제 생성물인 1-도데실 β-D-글루쿠론산을 백색 분말로서 얻고, 이를 추가로 정제하지 않고 고체 상 합성에 직접 사용하였다. 더 긴 알킬 기의 경우, 아세토니트릴 대신에 1,4-디옥산을 사용하였으며, 온도를 30℃ 정도로 높게 승온시켰다. 유사한 방식으로, 본원에 기재된 생성물 및 시약을 생성하는데 사용된 원하는 알킬 당류 우론산을 생성한다.
예를 들면 상응하는 1-옥틸, 1-데실, 1-운데실, 1-테트라데실, 1-헥사데실 및 1-옥타데실 글리코시드(아나트레이스(Anatrace), 미국 오하이오주 모미 소재)를 사용한 것을 제외하고 유사한 방식으로, 본원에 기재된 생성물 및 시약을 생성하는데 사용되는 원하는 1-알킬 당류 우론산을 생성하였다. 예를 들면 상응하는 1-옥틸, 1-데실, 1-운데실, 1-테트라데실, 1-헥사데실 및 1-옥타데실 β-D-멜리비오시드 또는 β-D-말토시드(아나트레이스)를 사용한 것을 제외하고 유사한 방식으로 본원에 기재된 생성물 및 시약을 생성하는데 사용되는 원하는 1-알킬 이당류 우론산을 생성하였다.
실시예
4. C-말단 아미드를 갖는 펩티드 생성물(EU-A387)의 제조
Fmoc-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Bip-Ser-Lys-Tyr-Leu-Glu-Ser-Lys(Alloc)-링크 아미드 수지(서열 번호 782)의 샘플은 실시예 1에 기재된 바와 같은 Nα-Fmoc-보호된 아미노산의 순차 첨가에 의하여 생성하고, Lys-N-엡실론 위치에서 DMF/CH2Cl2(1:1) 중의 Pd(PPh3)4(0.5 eq.) 및 DMBA(20 eq.)를 사용한 인큐베이션에 의하여 밤새 암실에서 실온에서 탈보호시켰다. DMF/CH2Cl2에 의하여 세정한 후, Lys 측쇄를 DMF/CH2Cl2 중의 1'-도데실 β-D-글루쿠론산으로 DIC/HOBt를 사용하여 아실화시켰다. 커플링의 완료는 닌히드린에 의하여 체크하였으며, 생성물을 CH2Cl2로 대규모로 세정하였다.
생성물 수지를 최종 탈보호시키고, 분열 칵테일(94% TFA, 2% EDT, 2% H2O, 2% TIS)로 240 분의 기간 동안 실온에서 처리하여 수지로부터 분열시켰다. 혼합물을 Et2O로 처리하여 생성물을 침전시키고, Et2O로 대규모로 세정하여 진공 하에서 건조시킨 후 미정제 표제 펩티드 생성물을 얻었다.
정제는 2개의 배취로 역상(C18) HPLC에 의하여 실시하였다. 미정제 펩티드를 4.1×25 ㎝ HPLC 컬럼 상에서 15 ㎖/min의 유속으로(15% 유기 변형제, 아세트산 완충제) 로딩하고, 15-45% 완충제 B로부터의 구배로 60 분 이내에 50℃에서 용출시켰다. 생성물 분획을 동결건조시켜 분석 HPLC(18.6 min; 0.1% TFA 중의 30-60% CH3CN)/질량 분석(M+1 피크 = 2382.14)에 의하여 98%의 순도를 갖는 표제 펩티드 생성물을 얻었다. 유사한 방식으로, 본 개시내용의 다른 펩티드 생성물을 생성하였으며, 이의 특징은 하기에 제시한다.
표제 화합물의 상응하는 1-메틸 및 1-옥틸 유사체는 시약 1'-메틸 β-D-글루쿠론산 및 1'-옥틸 β-D-글루쿠론산(카르보신쓰)을 사용한 것을 제외하고 유사한 방식으로 생성한다. 상응하는 1-데실, 1-도데실, 1-테트라데실, 1-헥사데실, 1-옥타데실, 1-에이코실 및 고급 유사체는 상기 기재된 바와 같이 생성된 상응하는 단당류 및 이당류 우론산을 사용하여 생성한다. 대안으로, 1-알킬 글루쿠로닐 또는 다른 우론 아실화 유사체는 탈보호 또는 부분 탈보호된 펩티드의 초기 정제에 이어서 원하는 우론산의 아실화에 의하여 생성할 수 있다.
실시예
5. C-말단 산을 갖는 펩티드 생성물의 제조
Boc-His(Trt)-Aib-Gln(Trt)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Ser(tBu)-Lys(Boc)-Tyr(tBu)-Leu-Asp(OtBu)-Glu(O-알릴)-Gln(Trt)-Ala-Ala-Lys(Alloc)-Glu(O-tBu)-Phe-Ile-Lys(Dde)-Trp(Boc)-Leu-Leu-Gln(Trt)-Thr(tBu)-HMPA(서열 번호 783) 수지(Fmoc-Thr(tBu)-HMPA) 수지로부터 출발함, 치환 0.45 mmol/g)의 샘플은 실시예 1에 기재된 바와 같은 Nα-Fmoc-보호된 아미노산의 순차적 첨가에 의하여 생성하였다. Glu 및 Lys 잔기의 알릴-보호된 측쇄는 인큐베이션에 의하여 DMF/CH2Cl2(1:1) 중의 Pd(PPh3)4(0.5 eq.) 및 DMBA(20 eq.)를 사용하여 밤새 암실에서 실온에서 탈보호시켰다. 담황색 수지를 얻을 때까지 수지를 DMF 중의 0.5% DIEA(2회), DMF 중의 0.5% 나트륨 디에틸디티오카르바메이트(2회) 및 DMF/CH2Cl2로 세정하였다. 측쇄 락탐은 Glu 및 Lys 잔기를 DMF 중의 DIC/HOBT(5 eq.)로 커플링시켜 형성하였다. 반응은 닌히드린을 사용하여 완료되었는지를 체크하였으며, 필요할 경우 재커플링시켰다. DMF/CH2Cl2를 사용한 세정 후, Lys 측쇄를 인큐베이션에 의하여 DMF 중의 5% 히드라진 수화물(10 eq.)로 2회, 각각의 경우에 15 분 동안 탈보호시켰다. DMF/CH2Cl2로 세정한 후, 탈보호된 Lys 잔기의 측쇄 아미노 기를 DIC/HOBt를 사용하여 DMF/CH2Cl2 중의 1'-테트라데실 β-D-멜리비오우론산과 반응시켰다. 커플링의 완료는 닌히드린에 의하여 체크하였으며, 생성물을 CH2Cl2로 대규모로 세정하였다, 닌히드린에 의하여 완료되지 않은 임의의 커플링은 다시 실시하였다. 일반적으로, 10-12 g의 펩티드 생성물 수지는 2 mmole 합성으로부터 얻었다.
생성물 수지를 최종 탈보호시키고, 분열 칵테일(94% TFA, 2% EDT, 2% H2O, 2% TIS)로 240 분의 기간 동안 실온에서 처리하여 수지로부터 분열시켰다. 혼합물을 Et2O로 처리하여 생성물을 침전시키고, Et2O로 대규모로 세정하여 미정제 표제 펩티드 생성물을 진공 하에서 건조시킨 후 얻었다. 일반적으로, 5-8 g의 미정제 펩티드 생성물을 얻었다.
정제는 2개의 배취로 역상(C18) HPLC에 의하여 실시하였다. 미정제 펩티드(1-1.5 g)를 4.1×25 ㎝ HPLC 컬럼 상에서 15 ㎖/min의 유속으로(15% 유기 변형제, 0.1% TFA 완충제) 로딩시키고, 35-55% 완충제 B로부터의 구배로 70 분 이내에 실온에서 용출시켰다. 덜 순수한 분획의 재정제는 >70%의 순도를 갖는 분획에 실시하였다. 생성물 분획을 동결건조시켜 분석 HPLC(10.3 min, 0.1% TFA 중의 45-75% CH3CN)/질량 분석(1317.67, +3 하전됨; 1976.13, +2 하전됨; 분자량 3950.44)에 의하여 98.7%의 순도를 갖는 EU-A1077을 얻었다. 유사한 방식으로, 본 개시내용의 다른 펩티드 생성물을 생성하였으며, 이의 특징은 하기에 제시한다.
표제 화합물의 상응하는 1-메틸 및 1-옥틸 유사체는 시약 1'-메틸 β-D-글루쿠론산 및 1'-옥틸 β-D-글루쿠론산(카르보신쓰)을 사용한 것을 제외하고, 유사한 방식으로 생성하였다. 상응하는 1-옥틸, 1-데실, 1-운데실, 1-테트라데실, 1-헥사데실 및 1-옥타데실 β-D-글루코우론산(상기 기재된 바와 같이 생성함)을 사용한 것을 제외하고 유사한 방식으로 본 개시내용의 펩티드 생성물을 생성하였다. 상응하는 1-옥틸, 1-데실, 1-운데실, 1-테트라데실, 1-헥사데실 및 1-옥타데실 β-D-멜리비오우론산 또는 β-D-말토우론산(상기 기재된 바와 같이 생성함)을 사용한 것을 제외하고 유사한 방식으로 본 개시내용의 펩티드 생성물을 생성하였다. 대안으로, 1-알킬 글루쿠로닐 또는 다른 우론 아실화 유사체는 탈보호된 또는 부분 탈보호된 펩티드의 초기 정제에 이어서 원하는 우론산 시약의 아실화에 의하여 생성할 수 있다. 대안으로, HMPA 수지-결합된 중간체의 가암모니아분해는 상응하는 C-말단 아미드를 산출한다.
분석 및 특징화는 HPLC/질량 분석에 의하여 양성 이온 모드로 하기 표에 제시된 용출 구배를 사용하여 실시하였다.
0.1% TFA 중의 HPLC 구배:
[a] 30 분에 걸쳐 35 내지 65% CH3CN
[b] 20 분에 걸쳐 30 내지 60% CH3CN
[c] 20 분에 걸쳐 35 내지 65% CH3CN
[d] 20 분에 걸쳐 25 내지 55% CH3CN
[e] 20 분에 걸쳐 40 내지 70% CH3CN
[f] 20 분에 걸쳐 45 내지 75% CH3CN
HPLC는 페노메넥스 루나(Phenomenex Luna) C18 5 미크론 250×4.6 ㎜ 분석 컬럼 상에서 실시하였다.
하기 표는 상기 기재된 바와 같이 합성 및 분석한 다른 화합물을 제시한다:
0.1% TFA 중의 HPLC 구배:
[a] 30 분에 걸쳐 35 내지 65% CH3CN
[b] 20 분에 걸쳐 30 내지 60% CH3CN
[c] 20 분에 걸쳐 35 내지 65% CH3CN
[d] 20 분에 걸쳐 25 내지 55% CH3CN
[e] 20 분에 걸쳐 40 내지 70% CH3CN
[f] 20 분에 걸쳐 45 내지 75% CH3CN
[g] 20 분에 걸쳐 50 내지 80% CH3CN
[h] 20 분에 걸쳐 10 내지 40% CH3CN
[i] 20 분에 걸쳐 30 내지 90% CH3CN
[j] 20 분에 걸쳐 10 내지 90% CH3CN
[k] 20 분에 걸쳐 30 내지 95% CH3CN
[l] 30 분에 걸쳐 30 내지 60% CH3CN
[m] 20 분에 걸쳐 20 내지 100% CH3CN
[n] 20 분에 걸쳐 20 내지 80% CH3CN
[o] 20 분에 걸쳐 30 내지 50% CH3CN
HPLC는 페노메넥스 루나 C18 5 미크론 250×4.6 ㎜ 분석 컬럼 상에서 실시하였다.
실시예
6. 인간 혈장 중에서 펩티드 생성물의
시험관내
안정성
1 ㎎/㎖ 스톡 용액은 DMSO/CH3CN(1/1) 중에서 생성하였다. 50% CH3CN 중의 표준 작업 용액은 스톡 용액으로 생성하였다. 작업 용액의 농도는 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000 및 20,000 ng/㎖이었다. 10 ㎕의 작업 용액을 90 ㎕ 블랭크 플라즈마에 스파크 처리하고, 혼합물을 와류 처리하였다. 300 ㎕의 내부 표준 용액(베라파밀, 100% CH3CN 중의 20 ng/㎖)을 첨가하고, 혼합물을 와류 처리하고, 원심분리하였다. 상청액을 HPLC 컬럼에 로딩시키기 위하여 HPLC 투입판에 옮겼다. 표준 샘플은 2, 5, 10, 20, 50, 100, 200, 500, 1,000 및 2,000 ng/㎖이었다. QC 샘플은 5(LQC), 50(MQC) 및 500(HQC) ng/㎖이었다. 혈장 안정성 실험의 경우, EU-A993, EU-A1023 및 인간 GLP-1(7-36)(바켐(Bachem))의 샘플은 인간 혈장 중에서(약 6-20 ng/㎖ 또는 정량화 한계보다 높은 유사한 농도) 생성하였으며, 시점 t = 0, 0.5, 1, 2, 4 및 8 시간에서 인큐베이션 중에 30℃에서 샘플링하였다. 샘플을 상기 기재된 바와 같이 내부 표준 용액(100% CH3CN)으로 처리하여 펩티드를 침전시키고, 질량 분석에 의한 정량화를 위하여 HPLC 컬럼에 로딩하기 위하여 상청액을 투입판에 로딩하였다.
사용한 기기는 API-4000 질량 분석기, ESI 양성, MRM 스캔이고; ACE C8 컬럼(2.1×50 ㎜, 5 ㎛)을 갖는 시마즈(Shimadzu) HPLC/CTC 오토샘플러, 이동상 A: 물 중의 0.1% 포름산 및 5 mM NH4OAc, 이동상 B: CH3CN 중의 0.1% 포름산, 10 ㎕의 샘플을 투입하였다.
화합물 신호(양) 대 시간의 플롯은 4 시간 이내에 본질적으로 GLP-1(7-36)의 완전한 분열을 나타냈으나, 적어도 8 시간의 기간에 걸쳐 인간 혈장 중의 무상해 펩티드 생성물의 양의 검출 가능한 변화는 없었다(도 8). 펩티드 생성물 둘 다는 시험관내 검정에서 단백질분해로부터의 보호 및 긴 혈장 반감기를 나타냈다.
실시예
7. GLP-1 및 글루카곤 수용체에서 펩티드 생성물의 활성의 세포 검정
화합물을 약 1 ㎎의 양으로 정확하게 계량하고, 표준 세포 검정(세렙 쏘시에떼 아노님(Cerep SA))으로 검정하였다. 판독치는 효능제 또는 길항제 모드로 테스트 화합물로 처치한 세포에서 생성된 cAMP의 양이었다. 사용한 검정은 글루카곤(인간, CHO 세포로 클로닝함) 및 GLP-1(쥐과 세포주) 세포 검정에서 cAMP 수치의 자극이었다. 검정은 문헌[Chicchi et al., J. Biol . Chem ., 272:7765-7769 (1997)] 및 [Runge et al., Br. J. Pharmacol ., 138:787-794 (2003)]에 기재되어 있다.
EU-A391의 경우, GCGR 세포 반응은 변경되지 않았으며, GLP1R 세포 반응은 420 nM의 EC50으로 급격하게 상승하였다.
추가의 일련의 세포 검정은 표준 세포 검정(디스커버x(DiscoveRx), 리드헌터(LeadHunter) 검정)으로 cAMP 자극 또는 아레스틴 활성화의 판독을 사용하여 실시하였다. 화합물을 약 1 ㎎의 양으로 정확하게 계량하고, 희석 및 검정을 위하여 디스커버x에 수송하였다. 세포 검정은 CHO 세포로 클로닝한 인간 글루카곤 수용체 및 CHO 세포로 클로닝된 인간 GLP-1 수용체를 사용하였다.
실시예
8. db/db 마우스에서 펩티드 생성물의
글루코스
저하 활성
본 실험을 위하여 db/db B6BKS (D) Leprdb/J(균주 000697) 마우스 암컷 60 마리는 도착시 약 8-9 주령이었다(잭슨 래버러토리(Jackson Laboratory), 미국 메인주 바 하버 소재). 마우스를 체중에 의하여 무작위로 나누고, 각각 마우스 암컷 8마리의 처치군 2개에게 테스트 화합물 EU-A994, EU-A995 또는 EU-A1026을 100 또는 300 nmole/㎏의 투약 수준으로 투여하였다. 마우스 암컷 8 마리의 군 1개는 비히클 대조군으로 하며, 비히클, 염수 중의 0.2% BSA, pH 7.4를 투여하였다. 마우스 8 마리의 추가의 군 1개에게는 양성 대조군 화합물인 리라글루티드를 50 nmole/㎏의 투약 수준으로 투여하였다. 테스트 화합물, 비히클 및 양성 대조군 화합물을 1 일차에 약 0, 7 및 24 시간에서 6 ㎖/㎏의 투약 부피로 피하 주사하였다.
임상 관찰은 접수시, 무작위 분배전 및 1일차 내지 5일차에 매일 실시하였다. 체중은 접수시, 무작위 분배전 및 1일차 내지 5일차에 매일 측정 및 기록하였다. 음식 소비는 1일차 내지 5일차에 매일 측정 및 기록하였다. 글루코스 분석을 위한 혈액 샘플은 실험전(-3일차) 및 1일차에 1차 투약 후 0, 1, 2, 4, 8, 10, 24, 48, 72 및 96 시간에 채혈하였다. 실험 종료시, 모든 동물을 안락사시키고, 시체는 추가로 평가하지 않고 폐기하였다.
2일차 3일차에 리라글루티드 및 고 투약량 EU-A994 및 고 투약량 EU-A1026 및 3 일차 및 4일차에 저 투약량 EU-A1026에서 비히클에 비하여 상당한 체중 변화가 보고되었다. 음식 소비에 관하여서는 리라글루티드 처치된 동물은 1일차 및 2일차에 비히클과 상당한 차이가 있었으며, 1일차에 고 투약량 EU-A994, 1일차 및 2일차에 저 투약량 EU-A995, 1일차에 고 투약량 EU-A994 및 2일차에 저 투약량 및 고 투약량 EU-A102는 리라글루티드와는 상당한 차이가 있었다. 10 시간에서의 리라글루티드 및 10 및 24 시간에서의 고 투약량 EU-A994에 대한 글루코스 수치는 비히클과는 상당한 차이가 있었다. 유사한 방식으로, 다른 펩티드 생성물을 혈당, 체중 및 음식 소비에 대한 이의 효과에 대하여 테스트하였다.
도 9는 t = 0 및 7 시간에서 피하 주사한 EU-A992(250 nmol/㎏), EU-A1167(250 nmol/㎏) 및 EU-A1168(250 nmol/㎏)이 당뇨병 db/db 마우스 모델에서 약 72 시간 동안 마우스의 증가된 혈당 수치를 정상 범위로 감소시켰다는 것을 도시한다.
실시예
9.
DIO
마우스에서 펩티드 생성물의 활성
식이 유발된 비만(DIO) C57BL/6J 마우스 수컷(잭스 랩스(JAX Labs)) 50마리를 6 주령으로 입수하였다. 마우스는 식별을 위하여 귀에 표시해 두고, HEPA-여과된 공기로 양으로 환기되는 폴리카르보네이트 케이지에 케이지당 마우스 5 마리의 밀도로 각각 수용하였다. 동물 룸은 전체를 제어된 12 시간 명/암 주기로 인공 형광 조명으로 밝혔다. 동물 룸에서의 정상 온도 및 상대 습도 범위는 각각 22±4℃ 및 50±15%이었다. 2.8-3.1의 pH로 산성화된 여과된 수도물 및고지방 식이(리서치 다이어트(Research Diets) D12492, 60 kcal %)를 자유로이 제공하였다.
2 주 적응 후, 마우스 50마리를 하기 군으로 무작위로 나누고(n = 10): 군 1: 비히클로 처치; 군 2: 저 투약량 EU-A994; 군 3: 고 투약량 EU-A594; 군 4: 저 투약량 EU-A1024; 및 군 5: 고 투약량 EU-A1024. 마우스에게 1일차(0 및 7 시간에서), 3, 6, 9, 12, 15, 18, 21 및 24 일차에 피하 투약하였다. 체중 및 케이지측 관찰은 매일 기록하였다. 음식 및 물 섭취는 매주 기록하였다. 마우스는 1일차(투약전) 및 26일차에 전신 지방량 및 제지방량에 대하여 NMR 측정을 실시하였다. 26일차에 마우스는 경구 글루코스 내성 테스트를 위하여 밤새 금식하였다. 그 다음 날, 1차 혈액 샘플을 꼬리 닉(nick)을 통하여 채혈하였다(t = 0). 그 후, 마우스에게 1.0 g/㎏ 글루코스의 볼루스를 투여하였다. 혈액 샘플은 글루코스 투약 후 꼬리 닉을 통하여 0, 15, 30, 60, 90 및 120 분에 얻었으며, 혈장 글루코스는 혈당 측정기를 사용하여 즉시 측정하였다.
마우스를 28일차에 희생시켰다. 말단 혈액을 혈청/혈장으로 처리하였으며, 분액을 글루코스, 인슐린 및 지질 프로파일의 분석을 위하여 보냈다. 체 조성은 NMR에 의하여 측정하였다. EU-A1024는 경구 글루코스 내성 테스트(OGTT)에서 글루코스 운동을 감소시키며, 기초 인슐린 분비를 감소시키지만, 글루코스 의존성 인슐린 분비를 증가시키며, 체중 증가가 감소되었으며(도 10), 지방량은 감소시키며, 제지방량에 대하여서는 효과가 적었다(도 11).
실시예
10. NASH의 마우스 모델에서
SP
-1373의 효과
생검 증명된 DIO-NASH 마우스 모델에서, SP-1373, 펩티드-계면활성제 콘쥬게이트 및 2중 GLP-1 수용체/글루카곤 수용체 효능제는 세마글루티드(GLP-1 효능제) 및 엘라피브라노(PPAR-α/δ 효능제)에 비하여 간 조직병리학 및 대사 변수에서 우수한 결과 측정을 입증하였다. C57BL/6JRj 마우스 수컷(약 20 g, 도착시 5 주령, 실험 시작시 37 주령)에게 40% 지방(18% 트랜스-지방), 2% 콜레스테롤 및 40% 탄수화물(20% 프룩토스)을 포함하는 AMLN 식이를 실험 시작 전 32 주 동안 및 실험 기간 동안 먹여서 비알콜성 지방간염(NASH)을 유발하였다.
실험에 참여하는 모든 마우스는 -3주차에 생검전 간에 기초하여 계층화하였다. 섬유증 스코어 ≥1 및 지방증 스코어 ≥2의 마우스만이 실험에 포함시켰다. 계층화된 마우스를 -3주차에 간 콜라겐 1형 알파 1(col1α1) 정량화에 기초하여 처치군으로 무작위로 나누었다. NASH 실험의 군은 1) 1일 1회(QD) 12 주 동안 피하(SC) 투여한 비히클(0.05% 트윈 80, 50 mM Na2HPO4, pH 8)(n = 12); 2) QD 12 주 동안 SC 투여한 저 투약량(5 nmole/㎏)의 SP-1373(n = 11); 3) QD 12 주 동안 SC 투여한 고 투약량(10 nmole/㎏)의 SP-1373(n = 11); 4) QD 12 주 동안 경구 투여한 78 μmole/㎏의 엘라피브라노(PO)(n = 12); 및 5) QD 12 주 동안 SC 투여한 10 nmole/㎏의 세마글루티드(n = 12)이었다.
체중은 전체 실험 기간 동안 매일 측정하였다. 음식 섭취는 처음 14 일 동안 매일 측정한 후, 실험 종료시까지 매주 측정하였다. EchoMRI 전신 스캔은 11주차에 수행하였다. 실험에서 알라닌 트랜스아미나제(ALT), 아스파르테이트 트랜스아미나제(AST), γ-글루타밀트랜스퍼라제(GGT), 트리글리세리드(TG) 및 총 콜레스테롤(TC)의 혈장 수치, TG, TC, col1α1 및 갈렉틴-3의 간 수치, 간에서의 각종 mRNA의 발현 레벨 및 간 중량을 측정하고, 간 생검/부검을 실시하여 간의 지방증, 염증, 확대 및 섬유증을 평가하였다.
혈액 및 혈장 검정의 경우, 혈액 샘플을 헤파린 처리된 시험관에 수집하고, 혈장을 분리시키고, 분석할 때까지 -80℃에서 보관하였다. ALT, AST, GGT, TG 및 TC 수치는 시판 키트(로슈 다이애고노스틱스(Roche Diagnostics), 독일 소재) 및 코바스(Cobas)™ C-501 자동분석기를 사용하여 제조업자의 지시사항에 따라 측정하였다.
간 조직 검정의 경우, 간에서의 트리글리세리드 및 콜레스테롤 함량은 트리글리세리드 및 콜레스테롤 시약(Cat. No. 22-045-795 및 Cat. No. 22-045-780, 각각 로슈 다이애고노스틱스, 독일 소재) 및 코바스™ C-501 자동분석기를 사용하여 측정하였다. 균질화된 간 조직을 80-100℃로 2회 가열하고, 마이크로원심분리기로 원심분리하고, 생성된 상청액 중의 트리글리세리드 및 콜레스테롤 함량을 측정하였다.
마우스의 체조성은 EchoMRI 3-1 체조성 분석기(EchoMRI, 미국)에 의하여 평가하였다. 마취하지 않은 마우스를 MRI 스캐너의 내부의 플라스틱 시험관에 약 80 초 동안 두었다. 체조성은 지방 조직량, 무지방 조직량(제지방 조직량) 및 물로서 표현하였다.
간 생검의 경우, 마우스를 이소플루란(2-3%)의 흡입에 의하여 마취하였다. 작은 복부 절개를 중심선에 만들고, 간의 좌측 측엽을 노출시켰다. 간 조직의 원뿔형 웨지(약 50 ㎎)를 측엽의 원위 부분으로부터 절개하고, 조직학을 위하여 10% 중성 완충 포르말린(4% 포름알데히드) 중에 고정시켰다. 간의 절단면을 바이폴라 응고(ERBE VIO 100 외과용전기 유닛)를 사용하여 순간 전기응고시켰다. 예비생검 후, 간을 복강에 넣고, 복벽을 봉합하고, 피부를 스테이플로 닫았다. 수술후 회복의 경우, 마우스에게 카르프로펜(5 ㎎/㎏)을 수술 당일에 및 수술후 1일차 및 2일차에 피하 투여하였다.
조직학적 염색의 경우, 간단히 파라핀 매립된 구획을 갖는 슬라이드를 크실렌 중에서 탈파라핀화시킨 후, 일련의 등급의 에탄올 중에 재수화시켰다. 헤마톡실린 및 에오신(H&E) 염색의 경우, 슬라이드를 메이어 헤마톡실린(다코(Dako)) 중에서 인큐베이션하고, 수도물로 세정하고, 에오신 Y 용액(시그마-알드리치(Sigma-Aldrich)) 중에서 염색하고, 수화시키고, 퍼텍스(Pertex)로 장착한 후, 스캐닝하기 전에 마르게 두었다. 피크로시리우스 레드(PSR) 염색의 경우, 슬라이드를 바이게르트(Weigert) 철 헤마톡실린(시그마-알드리치) 중에서 인큐베이션하고, 수도물로 세정하고, 피크로시리우스 레드(시그마-알드리치)로 염색한 후, 산성화된 물로 2회 세정하였다. 과잉의 물은 슬라이드를 흔들어서 제거하고, 슬라이드를 99% 에탄올의 3회 교환으로 탈수시키고, 크실렌으로 청소하고, 퍼텍스로 장착한 후, 스캐닝하기 전에 마르게 두었다.
콜라겐 1형 알파 1(col1α1) 및 갈렉틴-3(GAL3) 면역조직화학적(IHC) 염색의 경우, 내인성 퍼옥시다제 활성의 항원 회복 및 차단 후, 슬라이드를 1차 항원(col1α1의 경우 서던 바이오테크(Southern Biotech)로부터의 Cat. No. 1310-01 또는 갈렉틴-3의 경우 바이오레전드(Biolegend)로부터의 Cat. No. 125402)과 함께 인큐베이션하였다. 항-col1α1 1차 항원은 중합체 호스래디시 퍼옥시다제(HRP)-링커 항체 콘쥬게이트를 사용하여 검출하였으며, 항-GAL3 1차 항체는 링커 2차 항체를 사용하여 검출한 후, 중합체 HRP-링커 항체 콘쥬게이트를 사용하여 증폭시켰다. 그 다음, 1차 항원을 3,3'-디아미노벤지딘(DAB)을 색소원으로 하여 가시화하였다. 마지막으로, 구획을 헤마톡실린으로 대조염색하고, 커버슬립으로 덮었다.
간의 지방증, 염증, 확대 및 섬유증을 평가하기 위하여, 간 샘플을 포르말린 중에 고정시키고, 파라핀 중에 매립시키고, 구획을 헤마톡실린 및 에오신 또는 피크로시리우스 레드로 염색하였다. 샘플을 하기 표 9에 요약한 바와 같이 지방증, 염증, 확대 및 섬유증에 대하여 스코어를 매겼다.
SP-1373(고 투약량)은 비만인 마우스의 체중을 낮은 정상 범위로 크게 감소시켰으며, 세마글루티드 및 엘라피브라노는 더 적은 체중 감소를 유발하였다(도 12a 및 12b[고 투약량 SP-1373은 62일차에 비히클 군에 의도치 않게 투여되었다]). SP-1373은 전신 지방 조직량에서 뚜렷한 감소를 야기하였으며(도 13a 및 13b), 전신 제지방 조직량에 대하여서는 최소의 효과를 나타냈다. 총 콜레스테롤(TC, 도 14b), 알라닌 트랜스아미나제(ALT, 도 15a) 및 아스파르테이트 트랜스아미나제(AST, 도 15b)의 혈장 수치는 또한 SP-1373-처치된 동물에서 크게 감소되었다. 혈장 ALT 및 AST 수치 및 AST/ALT 비는 간 건강에 대한 임계 바이오마커이다. SP-1373의 이로운 효과는 2중 GLP-1 수용체/글루카곤 수용체 효능작용의 잇점을 입증한다. GLP-1 수용체 효능작용은 인슐린 생성 및 혈당 의존성 인슐린 분비를 자극하며, 혈당 수치를 낮추며, 식욕을 억제하며, 체중 감량을 야기하였다. 글루카곤 수용체 효능작용은 항고지질혈증 및 포만 효과를 가지며, 지방 연소 및 에너지 소비를 자극하며, 체중을 감소시킨다.
SP-1373은 세마글루티드보다 더 많은 간 중량의 큰 감소를 야기하는 반면, 엘라피브라노는 실제로 간 중량을 증가시켰다(도 16). 헤마톡실린 및 에오신 염색을 사용한 간의 조직학은 간지방증에서의 중간의 감소를 나타낸 세마글루티드 처치된 동물(도 17e)과는 대조적으로 고 투약량 SP-1373으로 처치된 동물에서 간 지방증의 거의 완전한 부재를 밝혀냈다(도 17c[커다란 백색 타원형 구조체는 정맥임]). 도 18a 및 18b는 조직학적 정량적 평가에 의하여 측정시 동물의 상이한 군에서 % 환부 면적 및 총 간 지질 함량에 관하여 생검후 간 지방증을 나타냈으며, 고 투약량 SP-1373으로 처치한 동물에서 간 지방증의 거의 완전한 부재를 확인하였다. SP-1373은 세마글루티드보다 더 많이 간 트리글리세리드(TG) 및 총 콜레스테롤(TC) 수치를 크게 감소시킨 반면, 엘라피브라노는 간 TG 및 TC 수치에 효과가 거의 또는 전혀 없었다(도 19a 및 19b). SP-1373은 또한 세마글루티드보다 더 많이 항-col1α1 항체로 염색한 총 간 콜라겐 1형 알파 1(간 섬유증의 측정치)을 크게 감소시키며, 엘라피브라노는 보통의 효과를 가졌다(도 20). 마찬가지로, SP-1373은 세마글루티드보다 더 많이 항-GAL3 항체(간 염증 및 섬유증에 대한 바이오마커)로 염색한 총 간 갈렉틴-3을 크게 감소시킨 반면, 엘라피브라노는 본질적으로 효과가 없었다(도 21).
고 투약량 SP-1373은 처치된 동물 모두에서 간 지방증을 크게 감소시키거나 또는 제거하였다(도 22c). 도 22a-22e에서, 각각의 동물의 경우 실험전으로부터 실험후 생검에서의 변화는 선으로 나타내며, 간 지방증은 지방증을 갖는 표면적에 관하여 0-3으로 스코어를 매겼다. 처치된 동물 대부분은 간 염증이 덜한 것으로 나타났다(도 23a-23e). 도 23a-23e에서, 각각의 동물의 경우 실험전으로부터 실험후 생검에서의 변화는 선으로 나타내며, 간 염증은 경중도에서 0-3으로 스코어를 매겼다. 초기에 간세포 확대를 나타낸 동물 거의 전부는 SP-1373, 엘라피브라노 또는 세마글루티드로 처치 후 확대를 나타내지 않았다(도 24a-24e). 도 24a-24e에서, 각각의 동물의 경우 실험전으로부터 실험후 생검에서의 변화는 선으로 나타내며, 간세포 확대는 0-2의 경중도로 스코어를 매겼다. 간 지방증, 염증 및 확대 스코어는 하기 표 9에서 설명한다.
NASH 활성의 임상 측정인 NAS(비알콜성 지방간 질환[NAFLD] 활성 스코어) 스코어는 대부분의 처치된 동물에서 개선되었으며, 고 투약량 SP-1373에 의하여 최대로 감소되었다(도 25a-25e). 도 25a-25e에서, 각각의 동물의 경우 실험전으로부터 실험후 생검에서의 변화는 선으로 나타냈다. NAS 스코어는 간 지방증(0-3), 염증(0-3) 및 확대(0-2)에 대한 스코어의 합이며, 최대 스코어는 8이다. 5 이상의 NAS 스코어를 갖는 인간은 NASH를 갖는 것으로 진단하며, 3 이하의 NAS 스코어를 갖는 인간은 NASH를 갖지 않는 것으로 진단한다. NASH의 마우스 모델로 번역되는 경우, 고 투약량 SP-1373은 처치된 동물 모두에서 NASH를 역전시켰다(도 25c).
SP-1373 및 엘라피브라노는 대부분의 동물에서 간 섬유증을 감소시켰다(도 26b-26d). 간 섬유증은 1형 및 3형 콜라겐을 염색시키는 피크로시리우스 레드를 사용하여 평가하였다. 도 26a-26e에서, 각각의 동물의 경우 실험전으로부터 실험후 생검에서의 변화는 선으로 나타내며, 간 섬유증은 하기 표 9에 설명한 바와 같이 0-4로 스코어를 매겼다.
SP-1373은 섬유증에 관련된 mRNA 인코딩 단백질{예를 들어, 콜라겐 1형 알파 1(col1α1), 전환 성장 인자-β1(TGFβ1) 및 갈렉틴-3(GAL3, aka MAC2)}, 염증{예를 들어, 인터류킨-1α(IL-1α), IL-1β, 종양 괴사 인자-α(TNF-α), GAL3, CD14, 톨 유사 수용체 4(TLR4), p38 미토겐 활성화된 단백질(MAP) 키나제 11 및 NF-κB}, 단핵구 동원{예를 들어, 케모킨(C-C 모티브) 리간드 5(CCL5, aka RANTES), 단핵구 화학유인 단백질 1(MCP1, aka CCL2), 케모킨(C-C 모티브) 수용체 1(CCR1) 및 CCR2} 및 예를 들면 대식세포{예를 들어, GAL3, EGF 유사 모듈 함유 뮤신 유사 호르몬 수용체 유사 1(EMR1, aka F4/80), CD14, CD68 및 CD86}로의 단핵구 분화를 포함한 간에서 NASH 관련 mRNA의 발현을 감소시킨다(도 27a-27f 및 도 28a-28f). 섬유증과 관련하여 보다 구체적으로, SP-1373은 섬유증 섬유 형성에 관련된 mRNA 인코딩 단백질의 간 발현(도 29a-29i) 및 간 성상 세포(간 섬유증과 관련된 주요 세포 유형)의 활성화 및 근섬유모세포 증식(도 30a-30f)을 감소시킨다. 더욱이, SP-1373은 세포예정사의 염증성이 큰 형태인 파이롭토시스에 관여하는 mRNA 인코딩 단백질의 간 발현을 감소시킨다(도 31a-31f). 본 단락에서 언급된 도면의 경우, 특정 mRNA의 발현 수준은 유전자에 따른 복수 테스트에 대한 보정후의 비히클에 비하여 평균+SEM 및 *P<0.05, **P<0.01 및 ***P<0.001이다. SP-1373은 또한 지질 합성(예를 들어, 지방산 신타제[FAS], 스테아로일-CoA 데사튜라제-1[SCD1] 및 3-히드록시-3-메틸글루타릴-CoA 신타제 1[HMGCS1]) 및 지질 흡수(예를 들어, CD36)에 관여하는 mRNA 인코딩 단백질의 간 발현을 감소시킨다. 게다가, SP-1373은 파르네소이드 X 수용체(FXR) mRNA의 간 발현을 증가시킨다. 게다가, SP-1373은 예를 들면 인슐린 신호 및 글루코스 항상성에 관여하는 유전자 인코딩 단백질의 발현을 변경시켰다.
요컨대, SP-1373은 간 지방증을 역전시키며, 간 염증 및 섬유증을 감소시키며, NAS 스코어를 크게 개선시키면서 또한 NASH의 널리 인지된 번역 마우스 모델에서의 대사 및 당조절 결핍을 설명한다. SP-1373은 GLP-1 및 글루카곤 수용체에서 강력한 균형 잡힌 완전 효능제이며, 항당뇨병 및 항비만증 효과를 갖는다. GLP-1 효능제 세마글루티드에 비하여, SP-1373은 더 강한 항고혈당성 효과를 가지며, 체중, 지방 조직량 및 식품 섭취를 더 큰 정도로 감소시키며, 작용 기간이 더 길다. DIO-NASH 마우스 모델에서, 세마글루티드 또는 엘라피브라노(2중 PPAR-α/δ 효능제)를 사용한 처치에 비하여 SP-1373을 사용한 처치는 체중, 혈장 총 콜레스테롤(TC) 및 알라닌 트랜스아미나제(ALT) 수치, NAS 스코어, 간지방증, 간 트리글리세리드(TG) 및 TC 수치, 간 체중, 간 콜라겐 I형 알파 1 함량(간 섬유증의 측정치) 및 간 갈렉틴-3 함량(간 염증 및 섬유증의 측정치)에서의 더 큰 감소를 초래하였다. 그러므로, SP-1373은 예를 들면 인슐린 내성, 당뇨병(1형 및 2형 포함), 고지질혈증, 비만증, 대사 증후군 및 심혈관 질환 및 이와 관련된 병태, 예컨대 NAFLD(NASH 포함)를 치료하는 데 유용하다.
본 개시내용의 다양한 실시양태를 기재하였으나, 그러한 실시양태는 단지 예시 및 예로서 제공된다. 이의 각종 수정예 및 변경예는 당업계의 기술자에게 자명할 것이며, 본 개시내용에 포함된다. 본 개시내용의 실시양태에 대한 각종 대안은 본 개시내용을 실시하는데 사용될 수 있으며, 본 개시내용에 포함되는 것으로 이해한다.
SEQUENCE LISTING
<110> SPITFIRE PHARMA, INC.
<120> IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER
DISORDERS
<130> 53459-702.601
<140> PCT/US2019/012194
<141> 2019-01-03
<150> 62/613,396
<151> 2018-01-03
<160> 1137
<170> PatentIn version 3.5
<210> 1
<211> 30
<212> PRT
<213> Homo sapiens
<400> 1
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
20 25 30
<210> 2
<211> 29
<212> PRT
<213> Homo sapiens
<400> 2
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr
20 25
<210> 3
<211> 37
<212> PRT
<213> Homo sapiens
<400> 3
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn
20 25 30
Arg Asn Asn Ile Ala
35
<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 4
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 5
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 6
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 7
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 7
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 8
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 8
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 9
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 9
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 10
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 10
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 11
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 11
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 12
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 13
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 13
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 14
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 14
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 15
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 15
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 16
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 16
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 17
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 17
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 18
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 19
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 19
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 20
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 20
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 21
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 21
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 22
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 23
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 23
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 24
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 24
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 25
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 25
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 26
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 26
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 27
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 27
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 28
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 28
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 29
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 29
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 30
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 30
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 31
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 31
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 32
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 32
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 33
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 33
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 34
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 34
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 35
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 35
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 36
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 36
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 37
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 37
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 38
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 38
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 39
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 39
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 40
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 40
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly
1 5 10 15
Arg Xaa
<210> 41
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 41
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 42
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 43
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 43
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa
1 5 10
<210> 44
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 44
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 45
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 45
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 46
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 46
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 47
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 47
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 48
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 48
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 49
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 49
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 50
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 50
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 51
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 51
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 52
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 52
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 53
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 53
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 54
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 54
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 55
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 55
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 56
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 56
His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 57
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 57
His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 58
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 58
His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 59
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 59
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 60
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 60
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 61
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 61
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 62
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 62
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 63
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 63
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 64
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 64
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 65
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 65
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 66
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 66
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 67
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 67
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa
1 5 10 15
<210> 68
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 68
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 69
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 69
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 70
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 70
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 71
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 71
His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 72
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 72
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 73
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 73
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 74
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 74
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 75
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 75
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 76
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 76
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 77
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 77
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 78
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 78
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 79
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 79
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 80
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2,6F-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip2Et4MeO
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 80
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 81
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 81
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa
<210> 82
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 82
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa
<210> 83
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 83
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa
<210> 84
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 84
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 85
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 85
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 86
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 86
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 87
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 87
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 88
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 88
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 89
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 89
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa
<210> 90
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 90
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 91
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 91
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 92
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 92
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 93
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 93
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Xaa Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 94
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 94
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Xaa
1 5 10 15
Xaa
<210> 95
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 95
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 96
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 96
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 97
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (12)..(12)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 97
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Xaa
1 5 10
<210> 98
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (12)..(12)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 98
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa Xaa
1 5 10
<210> 99
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 99
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 100
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 100
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 101
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 101
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 102
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 102
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 103
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 103
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 104
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 104
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa Xaa
<210> 105
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 105
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa Xaa
<210> 106
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 106
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa Xaa
<210> 107
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Nal(2)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 107
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa Lys Tyr Leu Glu Arg
1 5 10 15
Xaa Xaa
<210> 108
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 108
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 109
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 109
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 110
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 110
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 111
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 111
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa
1 5 10
<210> 112
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term NHEt"
<400> 112
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa
1 5 10
<210> 113
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 113
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa
1 5 10 15
<210> 114
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Aib
<220>
<221> source
<223> /note="C-term NHEt"
<400> 114
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa
1 5 10 15
<210> 115
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Aib
<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 115
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa
1 5 10 15
<210> 116
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 116
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 117
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 117
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 118
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 118
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 119
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 119
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 120
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 120
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 121
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 121
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 122
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 122
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 123
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 123
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 124
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 124
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 125
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 125
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 126
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 126
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 127
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 127
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 128
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 128
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 129
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 129
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 130
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 130
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 131
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 131
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 132
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 132
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 133
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 133
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 134
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 134
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 135
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 135
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 136
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 136
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 137
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 137
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 138
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 138
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 139
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 139
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 140
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 140
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 141
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 141
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 142
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 142
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 143
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 143
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 144
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 144
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 145
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 145
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 146
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 146
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 147
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 147
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 148
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 148
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 149
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 149
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 150
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 150
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 151
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 151
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 152
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 152
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 153
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 153
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 154
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 154
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 155
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 155
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 156
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 156
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 157
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 157
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 158
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 158
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 159
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 159
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Gln Xaa Phe Xaa
20
<210> 160
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 160
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 161
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 161
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 162
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 162
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 163
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 163
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 164
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 164
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 165
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Me-Phe
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 165
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 166
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 166
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 167
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 167
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 168
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 168
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 169
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 169
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 170
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 170
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 171
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 171
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Ala Lys Xaa Phe Xaa
20
<210> 172
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 172
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Xaa Phe Xaa
20
<210> 173
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 173
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Xaa Phe Xaa
20
<210> 174
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 174
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Ala Ala Lys Xaa Phe Xaa
20
<210> 175
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 175
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Ala Ala Lys Xaa Phe Xaa
20
<210> 176
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 176
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Ala Ala Lys Xaa Phe Xaa
20
<210> 177
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 177
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Ala Ala Lys Xaa Phe Xaa
20
<210> 178
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 178
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Xaa Phe Xaa
20
<210> 179
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 179
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Arg Tyr Leu Asp Glu
1 5 10 15
Arg Ala Ala Lys Xaa Phe Xaa
20
<210> 180
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 180
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 181
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 181
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 182
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 182
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 183
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 183
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 184
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 184
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 185
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 185
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 186
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 186
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 187
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C1)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 187
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 188
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 188
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 189
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 189
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa
<210> 190
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 190
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa
<210> 191
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 191
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa
<210> 192
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 192
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 193
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 193
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 194
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 194
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 195
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac5c
<220>
<221> source
<223> /note="C-term amide"
<400> 195
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 196
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 196
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa
<210> 197
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 197
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa
<210> 198
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 198
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg
1 5 10 15
Xaa Xaa
<210> 199
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 199
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 200
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 200
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 201
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 201
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 202
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 202
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 203
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 203
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 204
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 204
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 205
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 205
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg
1 5 10 15
Xaa Xaa
<210> 206
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 206
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg
1 5 10 15
Xaa Xaa
<210> 207
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 207
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg
1 5 10 15
Xaa Xaa
<210> 208
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(19)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 208
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Arg Xaa Xaa
<210> 209
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(19)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 209
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Arg Xaa Xaa
<210> 210
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(19)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 210
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Arg Xaa Xaa
<210> 211
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 211
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 212
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 212
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 213
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 213
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 214
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 214
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 215
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 215
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 216
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 216
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 217
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 217
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Xaa Xaa
<210> 218
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> hArg
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 218
His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Xaa Xaa
<210> 219
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (22)..(22)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 219
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Gln Xaa Xaa
20
<210> 220
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 220
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Xaa Xaa
20
<210> 221
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 221
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Xaa Xaa
20
<210> 222
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 222
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 223
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 223
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa
<210> 224
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 224
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 225
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 225
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 226
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 226
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Gln Xaa
20
<210> 227
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 227
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Xaa
20
<210> 228
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 228
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Xaa
<210> 229
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 229
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa
<210> 230
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 230
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa
<210> 231
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 231
His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
<210> 232
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 232
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Xaa Xaa
20
<210> 233
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 233
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Xaa Xaa
20
<210> 234
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 234
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Xaa Xaa
<210> 235
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 235
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Xaa Xaa
<210> 236
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 236
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa
1 5 10 15
Xaa
<210> 237
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 237
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Xaa
1 5 10 15
<210> 238
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 238
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 239
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Ac4c
<220>
<221> source
<223> /note="C-term amide"
<400> 239
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa
<210> 240
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 240
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Xaa
<210> 241
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 241
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Arg
<210> 242
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 242
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa
<210> 243
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 243
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 244
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 244
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa
<210> 245
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Ac4c
<220>
<221> source
<223> /note="C-term amide"
<400> 245
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa
<210> 246
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 246
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Arg Xaa
<210> 247
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (18)..(18)
<223> hArg
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 247
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 248
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 248
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 249
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Ac4c
<220>
<221> source
<223> /note="C-term amide"
<400> 249
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 250
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 250
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa
<210> 251
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 251
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 252
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 252
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 253
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 253
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 254
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 254
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa
<210> 255
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 255
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Xaa Xaa
<210> 256
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 256
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Ala Lys
20
<210> 257
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 257
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Ala Lys
20
<210> 258
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 258
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Ala Lys
20
<210> 259
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 259
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Ala Lys
20
<210> 260
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 260
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Ala Lys
20
<210> 261
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 261
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 262
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 262
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 263
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 263
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 264
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 264
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 265
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 265
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 266
<400> 266
000
<210> 267
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 267
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 268
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 268
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 269
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 269
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 270
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 270
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 271
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 271
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 272
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 272
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 273
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 273
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 274
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 274
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 275
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 275
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 276
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 276
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 277
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C22)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 277
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 278
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 278
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 279
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 279
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 280
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 280
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 281
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 281
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 282
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 282
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa
<210> 283
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 283
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Xaa
<210> 284
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 284
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Xaa
<210> 285
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 285
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Xaa
<210> 286
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 286
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Xaa
<210> 287
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 287
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Xaa Xaa
<210> 288
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 288
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 289
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 289
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 290
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 290
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 291
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 291
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 292
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 292
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 293
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 293
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 294
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 294
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 295
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 295
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 296
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 296
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 297
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 297
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 298
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 298
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 299
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 299
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 300
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 300
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 301
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 301
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 302
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 302
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 303
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 303
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 304
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 304
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 305
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 305
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 306
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 306
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 307
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 307
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 308
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 308
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 309
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 309
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 310
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 310
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 311
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 311
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 312
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 312
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 313
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 313
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 314
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 314
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 315
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 315
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 316
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 316
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 317
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 317
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 318
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 318
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 319
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 319
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 320
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 320
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 321
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 321
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 322
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 322
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa Xaa
20
<210> 323
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 323
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 324
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 324
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 325
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 325
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 326
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 326
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 327
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 327
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 328
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 328
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 329
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 329
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 330
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 330
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 331
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 331
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 332
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 332
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 333
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 333
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 334
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 334
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 335
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 335
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 336
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 336
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 337
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 337
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 338
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac3c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 338
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa Xaa
<210> 339
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 339
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Xaa
<210> 340
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 340
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Xaa Xaa
<210> 341
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 341
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa
<210> 342
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 342
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 343
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 343
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa
<210> 344
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> MOD_RES
<222> (19)..(19)
<223> Aib
<220>
<221> source
<223> /note="C-term amide"
<400> 344
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Xaa Xaa
<210> 345
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 345
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 346
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 346
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 347
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 347
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 348
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 348
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Xaa
<210> 349
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 349
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Arg Xaa
<210> 350
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Ac4c
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> hArg
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 350
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Xaa
1 5 10 15
Xaa Xaa
<210> 351
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (13)..(17)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (13)..(13)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 351
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Glu Leu Asp Ser
1 5 10 15
Lys Xaa
<210> 352
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 352
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Lys
20
<210> 353
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 353
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Arg Lys
20
<210> 354
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 354
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Arg Lys
20
<210> 355
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 355
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Arg Lys
20
<210> 356
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 356
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Arg Lys
20
<210> 357
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 357
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Arg Lys
20
<210> 358
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 358
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Gln Lys
20
<210> 359
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C14)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 359
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Gln Lys
20
<210> 360
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C16)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 360
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Gln Lys
20
<210> 361
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C18)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 361
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Gln Lys
20
<210> 362
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C20)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 362
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Ala Gln Lys
20
<210> 363
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (17)..(21)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (17)..(17)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Lys(C12)
<220>
<221> SITE
<222> (21)..(21)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 363
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Glu Xaa Val Arg Lys
20
<210> 364
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 364
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 365
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 365
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 366
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 366
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 367
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 367
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 368
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 368
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Xaa
1 5 10
<210> 369
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 369
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 370
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 370
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 371
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 371
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Xaa
1 5 10
<210> 372
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 372
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 373
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 373
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 374
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 374
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa
1 5 10
<210> 375
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 375
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 376
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 376
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 377
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(16)
<220>
<221> source
<223> /note="C-term amide"
<400> 377
His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa
1 5 10
<210> 378
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 378
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 379
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 379
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 380
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 380
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 381
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 381
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 382
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 382
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 383
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 383
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 384
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 384
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 385
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 385
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 386
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 386
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 387
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 387
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 388
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> source
<223> /note="C-term amide"
<400> 388
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Lys Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 389
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 389
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 390
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 390
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 391
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 391
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 392
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> source
<223> /note="C-term amide"
<400> 392
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 393
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 393
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 394
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 394
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 395
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 395
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 396
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 396
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 397
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 397
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 398
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 398
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 399
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 399
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 400
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 400
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 401
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 401
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 402
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 402
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 403
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 403
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 404
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 404
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 405
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 405
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 406
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 406
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 407
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 407
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 408
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 408
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 409
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 409
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 410
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 410
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 411
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 411
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 412
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 412
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 413
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 413
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 414
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 414
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 415
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 415
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 416
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 416
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 417
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 417
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 418
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 418
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 419
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 419
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 420
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 420
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 421
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 421
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 422
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 422
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 423
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 423
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 424
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 424
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 425
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 425
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 426
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 426
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 427
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 427
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 428
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 428
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 429
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 429
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 430
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 430
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 431
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 431
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 432
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 432
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 433
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 433
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 434
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 434
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 435
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 435
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 436
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 436
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 437
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 437
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 438
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 438
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 439
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 439
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 440
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 440
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 441
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 441
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 442
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 442
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 443
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 443
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 444
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 444
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 445
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 445
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 446
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 446
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 447
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 447
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 448
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 448
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 449
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 449
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 450
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 450
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 451
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 451
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 452
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 452
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 453
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 453
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 454
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 454
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 455
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 455
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 456
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 456
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 457
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 457
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 458
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 458
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 459
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 459
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 460
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 460
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 461
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 461
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 462
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 462
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 463
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 463
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 464
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 464
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 465
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 465
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 466
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 466
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 467
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 467
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 468
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 468
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 469
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 469
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 470
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 470
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 471
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 471
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 472
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 472
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 473
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 473
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 474
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 474
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 475
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 475
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 476
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 476
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 477
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 477
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 478
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 478
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 479
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 479
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 480
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 480
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 481
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 481
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 482
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 482
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 483
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 483
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 484
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 484
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 485
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 485
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 486
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 486
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 487
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 487
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 488
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 488
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 489
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 489
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 490
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 490
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 491
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 491
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 492
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 492
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 493
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 493
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 494
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 494
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 495
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 495
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 496
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 496
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 497
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 497
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 498
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 498
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 499
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 499
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 500
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(12)
<220>
<221> source
<223> /note="C-term amide"
<400> 500
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 501
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 501
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 502
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 502
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 503
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 503
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 504
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 504
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 505
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 505
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 506
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 506
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 507
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 507
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 508
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 508
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 509
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 509
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 510
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 510
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 511
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 511
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 512
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 512
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 513
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 513
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 514
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 514
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 515
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 515
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 516
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 516
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 517
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 517
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 518
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 518
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 519
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 519
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 520
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 520
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 521
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 521
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 522
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 522
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 523
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 523
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 524
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 524
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 525
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 525
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 526
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 526
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 527
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 527
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 528
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 528
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 529
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 529
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 530
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 530
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 531
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 531
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 532
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 532
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 533
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 533
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 534
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 534
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 535
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 535
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 536
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 536
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 537
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 537
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 538
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 538
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 539
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 539
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr
20 25
<210> 540
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 540
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 541
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 541
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 542
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 542
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 543
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 543
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 544
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 544
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 545
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 545
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 546
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 546
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 547
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 547
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 548
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 548
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 549
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 549
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 550
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 550
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 551
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 551
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr
20 25
<210> 552
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 552
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 553
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 553
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 554
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 554
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 555
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 555
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 556
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 556
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 557
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 557
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 558
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 558
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 559
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 559
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 560
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 560
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 561
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 561
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 562
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 562
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 563
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 563
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 564
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 564
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 565
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 565
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 566
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 566
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 567
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 567
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 568
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 568
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 569
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 569
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 570
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 570
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 571
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 571
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 572
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 572
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 573
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 573
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 574
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 574
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 575
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 575
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 576
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 576
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 577
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 577
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 578
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 578
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 579
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 579
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 580
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 580
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 581
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aib
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 581
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 582
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 582
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 583
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 583
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 584
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 584
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 585
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 585
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 586
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 586
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 587
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 587
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 588
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 588
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 589
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 589
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 590
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 590
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 591
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 591
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 592
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 592
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 593
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 593
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr
20 25
<210> 594
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 594
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 595
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 595
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 596
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 596
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 597
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 597
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 598
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 598
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 599
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 599
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr
20 25
<210> 600
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 600
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 601
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 601
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 602
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 602
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 603
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 603
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 604
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 604
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 605
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 605
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 606
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M8)
<220>
<221> source
<223> /note="C-term amide"
<400> 606
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 607
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M12)
<220>
<221> source
<223> /note="C-term amide"
<400> 607
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 608
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M14)
<220>
<221> source
<223> /note="C-term amide"
<400> 608
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 609
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M16)
<220>
<221> source
<223> /note="C-term amide"
<400> 609
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 610
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M18)
<220>
<221> source
<223> /note="C-term amide"
<400> 610
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 611
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M20)
<220>
<221> source
<223> /note="C-term amide"
<400> 611
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 612
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M8)
<220>
<221> source
<223> /note="C-term amide"
<400> 612
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 613
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M12)
<220>
<221> source
<223> /note="C-term amide"
<400> 613
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 614
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M14)
<220>
<221> source
<223> /note="C-term amide"
<400> 614
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 615
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M16)
<220>
<221> source
<223> /note="C-term amide"
<400> 615
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 616
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M18)
<220>
<221> source
<223> /note="C-term amide"
<400> 616
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 617
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(M20)
<220>
<221> source
<223> /note="C-term amide"
<400> 617
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 618
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M8)
<220>
<221> source
<223> /note="C-term amide"
<400> 618
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 619
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M12)
<220>
<221> source
<223> /note="C-term amide"
<400> 619
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 620
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M14)
<220>
<221> source
<223> /note="C-term amide"
<400> 620
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 621
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M16)
<220>
<221> source
<223> /note="C-term amide"
<400> 621
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 622
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M18)
<220>
<221> source
<223> /note="C-term amide"
<400> 622
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 623
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M20)
<220>
<221> source
<223> /note="C-term amide"
<400> 623
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 624
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M8)
<220>
<221> source
<223> /note="C-term amide"
<400> 624
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 625
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M12)
<220>
<221> source
<223> /note="C-term amide"
<400> 625
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 626
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M14)
<220>
<221> source
<223> /note="C-term amide"
<400> 626
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 627
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M16)
<220>
<221> source
<223> /note="C-term amide"
<400> 627
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 628
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M18)
<220>
<221> source
<223> /note="C-term amide"
<400> 628
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 629
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(M20)
<220>
<221> source
<223> /note="C-term amide"
<400> 629
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 630
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term amide"
<400> 630
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 631
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 631
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 632
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 632
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 633
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 633
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 634
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 634
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 635
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me20)
<220>
<221> source
<223> /note="C-term amide"
<400> 635
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 636
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term amide"
<400> 636
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 637
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 637
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 638
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 638
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 639
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 639
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 640
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 640
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 641
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me20)
<220>
<221> source
<223> /note="C-term amide"
<400> 641
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 642
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term amide"
<400> 642
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 643
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 643
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 644
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 644
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 645
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 645
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 646
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 646
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 647
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me20)
<220>
<221> source
<223> /note="C-term amide"
<400> 647
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 648
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term amide"
<400> 648
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 649
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 649
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 650
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 650
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 651
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 651
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 652
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 652
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 653
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me20)
<220>
<221> source
<223> /note="C-term amide"
<400> 653
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr
20 25
<210> 654
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 654
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 655
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 655
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 656
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 656
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 657
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 657
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 658
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 658
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 659
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 659
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 660
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 660
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 661
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 661
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 662
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 662
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 663
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 663
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 664
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 664
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 665
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 665
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 666
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 666
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 667
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 667
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 668
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 668
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 669
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 669
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 670
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 670
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 671
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 671
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 672
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 672
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 673
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 673
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 674
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 674
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 675
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 675
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 676
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 676
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 677
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 677
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 678
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 678
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 679
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 679
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 680
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 680
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 681
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 681
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 682
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 682
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 683
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 683
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 684
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 684
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 685
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 685
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 686
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 686
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 687
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 687
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 688
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 688
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 689
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 689
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 690
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 690
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 691
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 691
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 692
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 692
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 693
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 693
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 694
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 694
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 695
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 695
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 696
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 696
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 697
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 697
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 698
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 698
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 699
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 699
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 700
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 700
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 701
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 701
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 702
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 702
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 703
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 703
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 704
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 704
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 705
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 705
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 706
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 706
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 707
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 707
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 708
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 708
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 709
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 709
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 710
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 710
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 711
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 711
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 712
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 712
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 713
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 713
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 714
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 714
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 715
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 715
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 716
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 716
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 717
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 717
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 718
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 718
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 719
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 719
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 720
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 720
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 721
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 721
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 722
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 722
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 723
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 723
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 724
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 724
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 725
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> EtBip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 725
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 726
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 726
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 727
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 727
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 728
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 728
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 729
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 729
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 730
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 730
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 731
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 731
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 732
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 732
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 733
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 733
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 734
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 734
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 735
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 735
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 736
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 736
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 737
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 737
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 738
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 738
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 739
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 739
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 740
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 740
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 741
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 741
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 742
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 742
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 743
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 743
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 744
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 744
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 745
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 745
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 746
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 746
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 747
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 747
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 748
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 748
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 749
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> MeLys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 749
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 750
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 750
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 751
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 751
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 752
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 752
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 753
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 753
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 754
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 754
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 755
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 755
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 756
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 756
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 757
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 757
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 758
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 758
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 759
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 759
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 760
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 760
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 761
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Alpha-MePro
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 761
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 762
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 762
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 763
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 763
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 764
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 764
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 765
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 765
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 766
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 766
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 767
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 767
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 768
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me8
<220>
<221> source
<223> /note="C-term amide"
<400> 768
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 769
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me12
<220>
<221> source
<223> /note="C-term amide"
<400> 769
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 770
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me14
<220>
<221> source
<223> /note="C-term amide"
<400> 770
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 771
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me16
<220>
<221> source
<223> /note="C-term amide"
<400> 771
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 772
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me18
<220>
<221> source
<223> /note="C-term amide"
<400> 772
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 773
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys Me20
<220>
<221> source
<223> /note="C-term amide"
<400> 773
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 774
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ser" or "Ala" or "Lys" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Glu" or "Lys" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu" or "Arg"
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Gln" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val" or "Leu"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 774
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Met Asn Thr
20 25
<210> 775
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ala" or "Aib"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> U(X); wherein 'U' is a natural or unnatural amino
acid comprising a functional group
covalently attached to the surfactant X
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 775
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Asn Thr
20 25
<210> 776
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ser" or "Ala" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg" or "Gln"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ala" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 776
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Lys Asp Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 777
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ser" or "Ala" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg" or "Gln"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ala" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 777
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Lys Asp Phe Ile Gln Trp Leu Leu Asn Thr
20 25
<210> 778
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Gly"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg" or "Gln"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega-X)
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val" or "Leu" or "Nle"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 778
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Arg Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr
20 25
<210> 779
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Gly"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ala" or "Aib"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega-X)
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 779
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 780
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ala" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(N-omega-X)
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ala"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 780
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Ile Gln Trp Leu Leu Asn Thr
20 25
<210> 781
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib" or "MePro"
<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="2FPhe" or "MePhe" or "2FMePhe"
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Nal2" or "Bip" or "Bip2Et" or "Bip2EtMeO"
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(N-omega-X)
<220>
<221> source
<223> /note="C-term -OH or -NH-R3"
<220>
<221> SITE
<222> (1)..(11)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 781
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Xaa
1 5 10
<210> 782
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> source
<222> /note="N-term Fmoc"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Alloc)
<400> 782
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser
1 5 10 15
Xaa
<210> 783
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> source
<222> /note="N-term Boc"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> His(Trt)
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (3)..(3)
<223> Gln(Trt)
<220>
<221> MOD_RES
<222> (5)..(5)
<223> Thr(tBu)
<220>
<221> MOD_RES
<222> (7)..(7)
<223> Thr(tBu)
<220>
<221> MOD_RES
<222> (8)..(8)
<223> Ser(tBu)
<220>
<221> MOD_RES
<222> (9)..(9)
<223> Asp(OtBu)
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Tyr(tBu)
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Ser(tBu)
<220>
<221> MOD_RES
<222> (12)..(12)
<223> Lys(Boc)
<220>
<221> MOD_RES
<222> (13)..(13)
<223> Tyr(tBu)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Asp(OtBu)
<220>
<221> MOD_RES
<222> (16)..(16)
<223> Glu(O-Allyl)
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Gln(Trt)
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Alloc)
<220>
<221> MOD_RES
<222> (21)..(21)
<223> Glu(O-tBu)
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Dde)
<220>
<221> MOD_RES
<222> (25)..(25)
<223> Trp(Boc)
<220>
<221> MOD_RES
<222> (28)..(28)
<223> Gln(Trt)
<220>
<221> MOD_RES
<222> (29)..(29)
<223> Thr(tBu)
<220>
<221> source
<223> /note="C-term HMPA"
<400> 783
Xaa Xaa Xaa Gly Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
1 5 10 15
Xaa Ala Ala Xaa Xaa Phe Ile Xaa Xaa Leu Leu Xaa Xaa
20 25
<210> 784
<400> 784
000
<210> 785
<400> 785
000
<210> 786
<400> 786
000
<210> 787
<400> 787
000
<210> 788
<400> 788
000
<210> 789
<400> 789
000
<210> 790
<400> 790
000
<210> 791
<400> 791
000
<210> 792
<400> 792
000
<210> 793
<400> 793
000
<210> 794
<400> 794
000
<210> 795
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 795
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Asn Thr
20 25
<210> 796
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega-X)
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 796
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 797
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega-X)
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 797
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 798
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C9)
<220>
<221> source
<223> /note="C-term amide"
<400> 798
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 799
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C10)
<220>
<221> source
<223> /note="C-term amide"
<400> 799
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 800
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(C11)
<220>
<221> source
<223> /note="C-term amide"
<400> 800
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 801
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me8)
<220>
<221> source
<223> /note="C-term amide"
<400> 801
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 802
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 802
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 803
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 803
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 804
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 804
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 805
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 805
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 806
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(alpha-Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 806
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 807
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term OH"
<400> 807
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 808
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term OH"
<400> 808
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 809
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term OH"
<400> 809
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 810
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term OH"
<400> 810
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 811
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term OH"
<400> 811
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 812
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term OH"
<400> 812
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 813
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term OH"
<400> 813
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 814
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term OH"
<400> 814
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 815
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term OH"
<400> 815
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 816
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term OH"
<400> 816
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 817
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 817
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 818
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 818
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 819
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 819
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 820
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 820
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 821
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 821
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 822
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term OH"
<400> 822
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 823
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 823
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 824
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term OH"
<400> 824
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 825
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me10)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 825
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 826
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me12)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 826
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 827
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me14)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 827
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 828
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me16)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 828
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 829
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me18)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 829
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 830
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me12)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 830
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 831
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Lys(Me12)
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term OH"
<400> 831
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 832
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 832
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 833
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 833
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 834
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 834
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 835
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 835
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 836
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 836
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 837
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 837
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 838
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 838
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 839
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 839
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 840
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 840
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 841
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 841
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 842
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me10)
<220>
<221> source
<223> /note="C-term OH"
<400> 842
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 843
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me12)
<220>
<221> source
<223> /note="C-term OH"
<400> 843
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 844
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me14)
<220>
<221> source
<223> /note="C-term OH"
<400> 844
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 845
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me16)
<220>
<221> source
<223> /note="C-term OH"
<400> 845
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 846
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Me18)
<220>
<221> source
<223> /note="C-term OH"
<400> 846
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 847
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me10)
<220>
<221> source
<223> /note="C-term OH"
<400> 847
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 848
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me12)
<220>
<221> source
<223> /note="C-term OH"
<400> 848
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 849
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me14)
<220>
<221> source
<223> /note="C-term OH"
<400> 849
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 850
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me16)
<220>
<221> source
<223> /note="C-term OH"
<400> 850
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 851
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Me18)
<220>
<221> source
<223> /note="C-term OH"
<400> 851
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 852
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me12)
<220>
<221> source
<223> /note="C-term OH"
<400> 852
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 853
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me10)
<220>
<221> source
<223> /note="C-term OH"
<400> 853
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 854
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me14)
<220>
<221> source
<223> /note="C-term OH"
<400> 854
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 855
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me16)
<220>
<221> source
<223> /note="C-term OH"
<400> 855
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 856
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me18)
<220>
<221> source
<223> /note="C-term OH"
<400> 856
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 857
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 857
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 858
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 858
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 859
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 859
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 860
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 860
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 861
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 861
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 862
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 862
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 863
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 863
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 864
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 864
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 865
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 865
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 866
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 866
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 867
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 867
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 868
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 868
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 869
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 869
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 870
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 870
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 871
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 871
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 872
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 872
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 873
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 873
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 874
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term PEGa"
<400> 874
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 875
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 875
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 876
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 876
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 877
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 877
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 878
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 878
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 879
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 879
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 880
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 880
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 881
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 881
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 882
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 882
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 883
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 883
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 884
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 884
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 885
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 885
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 886
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term PEGb"
<400> 886
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 887
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 887
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 888
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 888
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 889
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 889
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 890
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 890
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 891
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 891
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 892
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 892
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 893
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 893
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 894
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 894
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 895
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 895
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 896
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 896
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 897
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 897
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 898
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term PEGc"
<400> 898
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 899
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 899
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 900
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 900
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 901
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 901
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 902
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 902
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 903
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 903
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 904
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 904
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 905
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me8)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 905
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 906
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 906
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 907
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 907
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 908
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 908
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 909
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 909
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 910
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term PEGd"
<400> 910
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 911
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term OH"
<400> 911
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 912
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term OH"
<400> 912
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 913
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term OH"
<400> 913
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 914
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term OH"
<400> 914
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 915
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term OH"
<400> 915
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 916
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term OH"
<400> 916
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 917
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z8)
<220>
<221> source
<223> /note="C-term OH"
<400> 917
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 918
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term OH"
<400> 918
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 919
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term OH"
<400> 919
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 920
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term OH"
<400> 920
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 921
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term OH"
<400> 921
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 922
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term OH"
<400> 922
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 923
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z8)
<220>
<221> source
<223> /note="C-term OH"
<400> 923
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 924
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z10)
<220>
<221> source
<223> /note="C-term OH"
<400> 924
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 925
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z12)
<220>
<221> source
<223> /note="C-term OH"
<400> 925
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 926
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z14)
<220>
<221> source
<223> /note="C-term OH"
<400> 926
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 927
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z16)
<220>
<221> source
<223> /note="C-term OH"
<400> 927
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 928
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z18)
<220>
<221> source
<223> /note="C-term OH"
<400> 928
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 929
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z8)
<220>
<221> source
<223> /note="C-term OH"
<400> 929
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 930
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z10)
<220>
<221> source
<223> /note="C-term OH"
<400> 930
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 931
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z12)
<220>
<221> source
<223> /note="C-term OH"
<400> 931
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 932
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z14)
<220>
<221> source
<223> /note="C-term OH"
<400> 932
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 933
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z16)
<220>
<221> source
<223> /note="C-term OH"
<400> 933
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 934
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z18)
<220>
<221> source
<223> /note="C-term OH"
<400> 934
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 935
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z8)
<220>
<221> source
<223> /note="C-term OH"
<400> 935
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 936
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z10)
<220>
<221> source
<223> /note="C-term OH"
<400> 936
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 937
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z12)
<220>
<221> source
<223> /note="C-term OH"
<400> 937
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 938
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z14)
<220>
<221> source
<223> /note="C-term OH"
<400> 938
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 939
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z16)
<220>
<221> source
<223> /note="C-term OH"
<400> 939
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 940
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z18)
<220>
<221> source
<223> /note="C-term OH"
<400> 940
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 941
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z8)
<220>
<221> source
<223> /note="C-term amide"
<400> 941
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 942
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 942
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 943
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 943
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 944
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 944
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 945
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 945
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 946
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS1(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 946
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 947
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z8)
<220>
<221> source
<223> /note="C-term amide"
<400> 947
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 948
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 948
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 949
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 949
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 950
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 950
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 951
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 951
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 952
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS2(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 952
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 953
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z8)
<220>
<221> source
<223> /note="C-term amide"
<400> 953
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 954
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 954
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 955
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 955
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 956
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 956
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 957
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 957
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 958
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> LysS3(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 958
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 959
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 959
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 960
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 960
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 961
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 961
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 962
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 962
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 963
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 963
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 964
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 964
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 965
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 965
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 966
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 966
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 967
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 967
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 968
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 968
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 969
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 969
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 970
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 970
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 971
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 971
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 972
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 972
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 973
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 973
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 974
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 974
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 975
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 975
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 976
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 976
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 977
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 977
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 978
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 978
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 979
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 979
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 980
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 980
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 981
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 981
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 982
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 982
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 983
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 983
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 984
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 984
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 985
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 985
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 986
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 986
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 987
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 987
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 988
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 988
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 989
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 989
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 990
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 990
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 991
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 991
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 992
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 992
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 993
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 993
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 994
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 994
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 995
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 995
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 996
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 996
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 997
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 997
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 998
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 998
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 999
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 999
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1000
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1000
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1001
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1001
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1002
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 1002
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1003
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1003
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1004
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1004
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1005
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1005
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1006
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1006
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1007
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me10)
<220>
<221> source
<223> /note="C-term amide"
<400> 1007
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1008
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1008
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1009
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1009
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1010
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1010
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1011
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1011
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1012
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1012
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1013
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1013
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1014
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z10)
<220>
<221> source
<223> /note="C-term amide"
<400> 1014
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1015
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1015
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1016
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1016
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1017
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1017
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1018
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS1(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1018
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1019
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1019
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1020
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1020
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1021
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS2(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1021
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1022
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1022
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1023
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1023
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1024
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (12)..(12)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> LysS3(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1024
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1025
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Gln"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "Gln"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1025
His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Lys
1 5 10 15
Glu Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1026
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "Gln"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1026
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1027
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Glu"
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Gln"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "Gln"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1027
His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1028
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclic"
<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Glu"
<220>
<221> SITE
<222> (12)..(16)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Gln"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "Gln"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1028
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Gln Asp Lys
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1029
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu"
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclized through side chain to form a lactam linkage"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1029
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr
20 25
<210> 1030
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1030
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1031
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1031
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1032
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1032
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1033
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1033
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1034
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1034
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1035
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1035
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1036
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1036
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1037
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1037
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1038
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1038
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1039
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1039
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1040
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1040
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1041
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1041
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1042
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1042
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1043
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1043
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1044
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1044
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1045
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1045
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1046
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1046
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1047
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1047
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1048
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1048
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1049
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1049
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1050
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1050
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1051
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1051
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1052
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1052
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1053
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1053
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1054
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1054
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1055
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1055
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1056
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1056
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1057
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1057
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1058
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1058
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1059
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1059
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1060
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS1(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1060
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1061
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1061
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1062
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1062
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1063
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1063
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1064
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1064
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1065
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1065
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1066
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1066
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1067
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS2(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1067
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1068
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z10)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1068
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1069
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z12)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1069
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1070
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1070
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1071
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1071
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1072
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1072
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1073
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1073
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1074
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> LysS3(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1074
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1075
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1075
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1076
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1076
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1077
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Me18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1077
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1078
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z14)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1078
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1079
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z16)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1079
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1080
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z18)
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1080
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1081
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1081
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1082
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1082
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1083
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1083
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1084
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1084
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1085
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1085
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1086
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1086
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1087
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1087
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1088
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1088
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1089
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1089
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1090
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1090
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1091
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1091
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1092
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1092
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr
20 25
<210> 1093
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1093
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1094
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1094
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1095
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Me18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1095
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1096
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1096
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1097
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1097
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1098
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys(Z18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1098
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1099
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z12)
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1099
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1100
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z14)
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1100
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1101
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z16)
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1101
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1102
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z14CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1102
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1103
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z16CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1103
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1104
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(Z18CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1104
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1105
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z14CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1105
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1106
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z16CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1106
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1107
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (10)..(14)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (10)..(10)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (14)..(14)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(Z18CO2)
<220>
<221> source
<223> /note="C-term amide"
<400> 1107
His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser
1 5 10 15
Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1108
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> pGlu
<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="N(R3)His" or "N(R4)His"
<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="D-Ser" or "Ala" or "Gly" or "Pro" or "MePro" or
"Aib" or "Ac4c" or "Ac5c"
<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Cit"
<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="D-Ala"
<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ser"
<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Trp" or "2FPhe" or "MePhe" or "2FMePhe" or "Nal2"
<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Ser"
<220>
<221> VARIANT
<222> (9)..(9)
<223> /replace="Asp"
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (11)..(11)
<223> /replace="Leu" or "Met" or "Nal2" or "Bip" or "Bip2EtMeO" or
"Glu" or "Lys" or "U; wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X"
<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Asn" or "Bip" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Glu" or "Ser" or "Arg" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Gln" or "Cit" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (15)..(15)
<223> /replace="Met" or "Nle" or "Glu" or "Lys" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Ac5c" or "Lys"
or "Arg" or "U; wherein 'U' is any natural
or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (18)..(18)
<223> /replace="hArg" or "Gln" or "Glu" or "Cit" or "Aib" or "Ac4c"
or "Ac5c" or "Lys" or "U; wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (19)..(19)
<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or "Ac5c" or "U;
wherein 'U' is any natural or unnatural amino acid comprising
a functional group used for covalent attachment to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Val" or "Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (21)..(21)
<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib" or "Ac4c"
or "Ac5c" or "U; wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (22)..(22)
<223> /replace="Glu" or "Leu" or "Aib" or "Ac4c" or "Ac5c" or "U;
wherein 'U' is any natural or unnatural amino acid comprising
a functional group used for covalent attachment to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Trp" or "Nal2" or "Aib" or "Ac4c" or "Ac5c" or "U;
wherein 'U' is any natural or unnatural amino acid comprising
a functional group used for covalent attachment to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (25)..(25)
<223> /replace="Ala" or "Glu" or "Cit" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="Nal2" or "U; wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="U; wherein 'U' is any natural or unnatural amino acid
comprising a functional group used for covalent attachment to
the surfactant X" or " "
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Val" or "Leu" or "Nle" or "Lys" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (29)..(29)
<223> /replace="Lys" or "Glu" or "Gln" or "Cit" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (30)..(30)
<223> /replace="Gly" or "Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (31)..(31)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "Arg" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (32)..(32)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (33)..(33)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (34)..(34)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (35)..(35)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (36)..(36)
<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (37)..(37)
<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or "U; wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> MOD_RES
<222> (38)..(38)
<223> U; wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X
<220>
<221> VARIANT
<222> (38)..(38)
<223> /replace=" "
<220>
<221> source
<223> /note="C-term OH, N-R4-His or -NH-R3"
<220>
<221> SITE
<222> (1)..(38)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 1108
Xaa His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp
1 5 10 15
Ser Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr Lys Arg
20 25 30
Asn Arg Asn Asn Ala Xaa
35
<210> 1109
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> pGlu
<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="N(R3)His" or "N(Ac)His"
<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Ala" or "Gly" or "MePro" or "Aib" or
"Ac4c" or "Ac5c"
<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Cit"
<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="D-Ala"
<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ser"
<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Trp" or "2FPhe" or "MePhe" or "2FMePhe" or
"Nal2"
<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Ser"
<220>
<221> VARIANT
<222> (9)..(9)
<223> /replace="Asp"
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (11)..(11)
<223> /replace="Leu" or "Met" or "Nal2" or "Bip" or
"Bip2EtMeO" or "U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently attached
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Asn" or "Bip" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional group
covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Glu" or "Ser" or "Arg" or "U(X); wherein 'U' is
a natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Gln" or "Cit" or "U(X); wherein 'U' is
a natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (15)..(15)
<223> /replace="Met" or "Nle" or "Glu" or "Lys" or
"U(X); wherein 'U' is a natural or unnatural amino acid
comprising a functional group covalently attached to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Glu" or "U(X); wherein 'U' is a natural
or unnatural amino acid comprising a functional group
covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Ac5c"
or "Lys" or "Arg" or "U(X); wherein 'U' is a natural or
unnatural amino acid comprising a functional group covalently
attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (18)..(18)
<223> /replace="hArg" or "Gln" or "Glu" or "Lys" or "Cit"
or "Aib" or "Ac4c" or "Ac5c" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (19)..(19)
<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or
"Ac5c" or "U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently
attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Val" or "Aib" or "Ac4c" or
"Ac5c" or "U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently
attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (21)..(21)
<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib"
or "Ac4c" or "Ac5c" or "U(X); wherein 'U' is a natural
or unnatural amino acid comprising a functional group
covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (22)..(22)
<223> /replace="Glu" or "Leu" or "Aib" or "Ac4c" or "Ac5c"
or "U(X); wherein 'U' is a natural or unnatural amino acid
comprising a functional group covalently attached to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Trp" or "Nal2" or "Aib" or "Ac4c" or
"Ac5c" or "U(X); wherein 'U' is a natural or unnatural
amino acid comprising a functional group covalently
attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or
"U(X); wherein 'U' is a natural or unnatural amino
acid comprising a functional group covalently attached
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (25)..(25)
<223> /replace="Gln" or "Glu" or "Cit" or "U(X); wherein 'U' is
a natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="Nal2" or "U(X); wherein 'U' is a
natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="U(X); wherein 'U' is a natural or
unnatural amino acid comprising a functional group
covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Val" or "Leu" or "Nle" or "Lys" or
"U(X); wherein 'U' is a natural or unnatural amino
acid comprising a functional group covalently attached
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (29)..(29)
<223> /replace="Lys" or "Glu" or "Gln" or "U(X); wherein 'U' is
a natural or unnatural amino acid comprising a functional
group covalently attached to the surfactant X" or " "
<220>
<221> VARIANT
<222> (30)..(30)
<223> /replace="Gly" or "Aib" or "Ac4c" or "Ac5c" or "U(X);
wherein 'U' is a natural or unnatural amino acid comprising
a functional group covalently attached to the surfactant X"
or " "
<220>
<221> source
<223> /note="C-term -OH or -NH-R3"
<220>
<221> SITE
<222> (1)..(30)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 1109
Xaa His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp
1 5 10 15
Ser Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr
20 25 30
<210> 1110
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Glu" or "Lys" or "U(X); wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Glu"
<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Glu" or "Lys"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Lys"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Glu" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Lys" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term -OH or -NH-R3"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 1110
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Glu Glu Phe Ile Gln Trp Leu Leu Glu Thr
20 25
<210> 1111
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="MePro" or "Aib"
<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Cit"
<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="2FPhe" or "MePhe" or "2FMePhe" or "Nal2"
<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Nal2" or "Bip" or "Bip2EtMeO" or "Glu" or "Lys"
or "U(X); wherein 'U' is any natural or unnatural amino
acid comprising a functional group used for covalent
attachment to the surfactant X"
<220>
<221> VARIANT
<222> (11)..(11)
<223> /replace="Asn" or "Bip" or "U(X); wherein 'U' is any natural
or unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Glu" or "Ser" or "U(X); wherein 'U' is any natural
or unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Gln" or "Cit" or "U(X); wherein 'U' is any natural
or unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Nle" or "Glu" or "Lys" or "U(X); wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (15)..(15)
<223> /replace="Glu" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Lys" or "Arg" or
"U(X); wherein 'U' is any natural or unnatural amino acid
comprising a functional group used for covalent attachment
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg" or "Gln" or "Glu" or "Lys" or "Cit" or "Aib"
or "U(X); wherein 'U' is any natural or unnatural amino acid
comprising a functional group used for covalent attachment
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (18)..(18)
<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or "Ac5c" or "U(X);
wherein 'U' is any natural or unnatural amino acid comprising
a functional group used for covalent attachment to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (19)..(19)
<223> /replace="Aib" or "U(X); wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib" or "U(X);
wherein 'U' is any natural or unnatural amino acid comprising
a functional group used for covalent attachment to the
surfactant X" or " "
<220>
<221> VARIANT
<222> (21)..(21)
<223> /replace="Glu" or "Leu" or "Aib" or "U(X); wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (22)..(22)
<223> /replace="U(X); wherein 'U' is any natural or unnatural amino
acid comprising a functional group used for covalent attachment
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Ile" or "Aib" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used for
covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Glu" or "Gln" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used for
covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (25)..(25)
<223> /replace="U(X); wherein 'U' is any natural or unnatural amino
acid comprising a functional group used for covalent attachment
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="U(X); wherein 'U' is any natural or unnatural amino
acid comprising a functional group used for covalent attachment
to the surfactant X" or " "
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val" or "Leu" or "Nle" or "Lys" or "U(X); wherein 'U'
is any natural or unnatural amino acid comprising a functional
group used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Glu" or "Gln" or "Cit" or "U(X); wherein 'U' is any
natural or unnatural amino acid comprising a functional group
used for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (29)..(29)
<223> /replace="Thr" or "Aib" or "U(X); wherein 'U' is any natural
or unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X" or " "
<220>
<221> VARIANT
<222> (30)..(30)
<223> /replace="Arg" or "U(X); wherein 'U' is any natural or unnatural
amino acid comprising a functional group used for covalent
attachment to the surfactant X" or " "
<220>
<221> source
<223> /note="C-term OH or -NH-R3"
<220>
<221> SITE
<222> (1)..(30)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<220>
<221> source
<223> /note="See specification as filed for detailed description of
substitutions and preferred embodiments"
<400> 1111
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15
Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr Arg
20 25 30
<210> 1112
<400> 1112
000
<210> 1113
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega-X)
<220>
<221> source
<223> /note="C-term -OH or -NHR3"
<400> 1113
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1114
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-dodecyl alpha-D-melibiouronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-dodecyl beta-D-glucouronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1114
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1115
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-tetradecyl alpha-D-melibiouronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-tetradecyl beta-D-glucouronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1115
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1116
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-hexadecyl alpha-D-melibiouronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-hexadecyl beta-D-glucouronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1116
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1117
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-(13-carboxyl-tridecyloxy) beta-D-glucuronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1117
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1118
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-(15-carboxyl-pentadecyloxy) beta-D-glucuronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1118
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1119
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl))
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> source
<223> /note="C-term amide"
<400> 1119
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr
20 25
<210> 1120
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-(13-carboxyl-tridecyloxy) beta-D-glucuronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1120
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1121
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-(15-carboxyl-pentadecyloxy) beta-D-glucuronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1121
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1122
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl))
<220>
<221> source
<223> /note="C-term amide"
<400> 1122
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1123
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl])
<220>
<221> source
<223> /note="C-term amide"
<400> 1123
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1124
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega[1-(15-carboxyl-pentadecyloxy) beta-D-melibiouronyl])
<220>
<221> source
<223> /note="C-term amide"
<400> 1124
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1125
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> SITE
<222> (16)..(20)
<223> /note="Cyclic"
<220>
<221> SITE
<222> (16)..(16)
<223> /note="Glu cyclized through side chain to form a lactam linkage"
<220>
<221> SITE
<222> (20)..(20)
<223> /note="Lys cyclized through side chain to form a lactam linkage"
<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys(N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-melibiouronyl])
<220>
<221> source
<223> /note="C-term amide"
<400> 1125
His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr
20 25
<210> 1126
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ser" or "Ala" or "Lys" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Lys" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Glu" or "Arg"
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Gln" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val" or "Leu"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln" or "U(X); wherein 'U' is any natural or
unnatural amino acid comprising a functional group used
for covalent attachment to the surfactant X"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1126
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Met Asn Thr
20 25
<210> 1127
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Aib"
<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Ala" or "Aib"
<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="hArg" or "Gln"
<220>
<221> MOD_RES
<222> (20)..(20)
<223> U(X); wherein 'U' is any natural or unnatural
amino acid comprising a functional group used
for covalent attachment to the surfactant X
<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Ala"
<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Val"
<220>
<221> VARIANT
<222> (28)..(28)
<223> /replace="Gln"
<220>
<221> source
<223> /note="C-term amide"
<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no
preference with respect to those in the annotations
for variant positions"
<400> 1127
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15
Arg Arg Ala Xaa Asp Phe Ile Gln Trp Leu Leu Asn Thr
20 25
<210> 1128
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 1128
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1129
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 1129
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1130
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1130
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1131
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1131
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1132
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C16)
<220>
<221> source
<223> /note="C-term amide"
<400> 1132
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1133
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C18)
<220>
<221> source
<223> /note="C-term amide"
<400> 1133
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1134
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Alpha-MeFF
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Bip
<220>
<221> MOD_RES
<222> (11)..(11)
<223> Lys(C20)
<220>
<221> source
<223> /note="C-term amide"
<400> 1134
His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa
1 5 10
<210> 1135
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C8)
<220>
<221> source
<223> /note="C-term amide"
<400> 1135
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1136
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C12)
<220>
<221> source
<223> /note="C-term amide"
<400> 1136
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
<210> 1137
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (17)..(17)
<223> Lys(C14)
<220>
<221> source
<223> /note="C-term amide"
<400> 1137
His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala
1 5 10 15
Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr
20 25
Claims (23)
- 다낭성 난소 증후군, 신장 질환 또는 간 질환의 치료에 사용하기 위한 펩티드 생성물 또는 이의 약학적으로 허용되는 염으로서, 상기 펩티드 생성물은 하기 화학식 I-A를 가지며, 펩티드에 공유 결합된 계면활성제 X를 포함하고, 상기 펩티드는 링커 아미노산 U 및 하나 이상의 다른 아미노산을 포함하는 것인 펩티드 생성물 또는 이의 약학적으로 허용되는 염:
상기 식에서, 계면활성제 X는 하기 화학식 I의 모이어티이며:
상기 식에서,
R1a는 각각의 경우에 독립적으로 결합, H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬(-알킬아릴) 기, 비치환된 또는 치환된 알킬옥시아릴 기, 또는 스테로이드 핵 함유 기이며;
R1b, R1c 및 R1d는 각각의 경우에 독립적으로 결합, H, 보호기, 당류, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬 기, 비치환된 또는 치환된 알킬옥시아릴 기, 또는 스테로이드 핵 함유 기이며;
R2는 각각의 경우에 독립적으로 결합, U에의 결합, H, 비치환된 또는 치환된 C1-C30 알킬 기, 비치환된 또는 치환된 아랄킬 기, 비치환된 또는 치환된 알킬옥시아릴 기, 스테로이드 핵 함유 기, -NH-, -S-, -O-NH-, 스페이서, -트리아졸로-, -NH(C=O)-CH2- 또는 -(CH2)m-말레이미드-이며;
W1은 각각의 경우에 독립적으로 -CH2-, -CH2-O-, -CH2-S-, -CH2-NH-, -(C=O)-, -(C=O)-NH-, -(C=S)- 또는 -(C=S)-NH-이며;
W2는 각각의 경우에 독립적으로 -O-, -S-, -NH- 또는 -CH2-이며;
R1a, R1b, R1c, R1d 또는 R2 중 하나 이상의 존재는 비치환된 또는 치환된 C1-C30 알킬, 아랄킬, 알킬옥시아릴 또는 스테로이드 핵 함유 기이며;
m은 1 내지 10의 정수이며;
n은 1, 2 또는 3이며;
펩티드는 하기 화학식 II를 가지며:
aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-aa30-aa31-aa32-aa33-aa34-aa35-aa36-aa37-Z 화학식 II(서열 번호 1108)
상기 식에서,
Z는 -OH, -NHR3 또는 -N(R4)His이며, 여기서
R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
R4는 H, C2-C10 아실 또는 -C(=O)-아릴이며;
aa1은 His, N(R3)His, N(R4)His 또는 pGlu-His이며;
aa2는 Ser, D-Ser, Ala, Gly, Pro, MePro, Aib, Ac4c 또는 Ac5c이며;
aa3은 Gln 또는 Cit이며;
aa4는 Gly 또는 D-Ala이며;
aa5는 Thr 또는 Ser이며;
aa6은 Phe, Trp, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa7은 Thr 또는 Ser이며;
aa8은 Ser 또는 Asp이며;
aa9는 Asp 또는 Glu이며;
aa10은 Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser, Arg 또는 U이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U이며;
aa14는 존재하지 않거나 또는 Leu, Met, Nle, Glu, Lys 또는 U이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg 또는 U이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Cit, Aib, Ac4c, Ac5c, Lys 또는 U이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U이며;
aa19는 존재하지 않거나 또는 Ala, Val, Aib, Ac4c, Ac5c 또는 U이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c 또는 U이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib, Ac4c, Ac5c 또는 U이며;
aa22는 존재하지 않거나 또는 Phe, Trp, Nal2, Aib, Ac4c, Ac5c 또는 U이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib, Ac4c, Ac5c 또는 U이며;
aa24는 존재하지 않거나 또는 Ala, Gln, Glu, Cit 또는 U이며;
aa25는 존재하지 않거나 또는 Trp, Nal2 또는 U이며;
aa26은 존재하지 않거나 또는 Leu 또는 U이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U이며;
aa28은 존재하지 않거나 또는 Asn, Lys, Glu, Gln, Cit 또는 U이며;
aa29는 존재하지 않거나 또는 Thr, Gly, Aib, Ac4c, Ac5c 또는 U이며;
aa30은 존재하지 않거나 또는 Lys, Aib, Ac4c, Ac5c, Arg 또는 U이며;
aa31은 존재하지 않거나 또는 Arg, Aib, Ac4c, Ac5c 또는 U이며;
aa32는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa33은 존재하지 않거나 또는 Arg, Aib, Ac4c, Ac5c 또는 U이며;
aa34는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa35는 존재하지 않거나 또는 Asn, Aib, Ac4c, Ac5c 또는 U이며;
aa36은 존재하지 않거나 또는 Ala, Ile, Aib, Ac4c, Ac5C 또는 U이며;
aa37은 존재하지 않거나 또는 U이며;
U는 계면활성제 X에의 공유 결합에 사용된 작용기를 포함하는 천연 또는 비천연 아미노산이며;
aa1-aa37 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa37 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 링커 아미노산 U이다. - 제1항에 있어서, 계면활성제 X가 단당류, 예컨대 적절하게 작용화된 글루코스, 갈락토스 또는 만노스(예를 들어, 글루쿠론산, 갈락투론산 또는 만노우론산) 또는 이당류, 예컨대 적절하게 작용화된 멜리비오스, 말토스, 이소말토스, 겐티오비오스 또는 락토스(예를 들어, 멜리비오우론산, 말토우론산, 이소말토우론산, 겐티오비오우론산 또는 락토우론산)를 포함하는 것인 펩티드 생성물.
- 제1항 또는 제2항에 있어서, 계면활성제 X가 하기 구조를 갖는 것인 펩티드 생성물:
상기 식에서,
R1a는 비치환된 또는 치환된 C1-C30 알킬 기이며;
R1b, R1c 및 R1d는 H이며;
R2는 U에의 결합이며;
W1은 -(C=O)-NH-이며;
W2는 -O-이다. - 제1항 내지 제3항 중 어느 한 항에 있어서,
a) R1a의 하나 이상의 존재가 비치환된 또는 치환된 C8-C20 알킬 기이거나; 또는
b) 계면활성제 X가 1-알킬 글리코시드, 예컨대 1-에이코실 베타-D-글루쿠론산, 1-옥타데실 베타-D-글루쿠론산, 1-헥사데실 베타-D-글루쿠론산, 1-테트라데실 베타-D-글루쿠론산, 1-도데실 베타-D-글루쿠론산, 1-데실 베타-D-글루쿠론산, 1-옥틸 베타-D-글루쿠론산, 1-에이코실 베타-D-디글루쿠론산, 1-옥타데실 베타-D-디글루쿠론산, 1-헥사데실 베타-D-디글루쿠론산, 1-테트라데실 베타-D-디글루쿠론산, 1-도데실 베타-D-디글루쿠론산, 1-데실 베타-D-디글루쿠론산, 1-옥틸 베타-D-디글루쿠론산, 1-에이코실 베타-D-이소말토우론산, 1-옥타데실 베타-D-이소말토우론산, 1-헥사데실 베타-D-이소말토우론산, 1-테트라데실 베타-D-이소말토우론산, 1-도데실 베타-D-이소말토우론산, 1-데실 베타-D-이소말토우론산, 1-옥틸 베타-D-이소말토우론산, 1-에이코실 베타-D-겐티오비오우론산, 1-옥타데실 베타-D-겐티오비오우론산, 1-헥사데실 베타-D-겐티오비오우론산, 1-테트라데실 베타-D-겐티오비오우론산, 1-도데실 베타-D-겐티오비오우론산, 1-데실 베타-D-겐티오비오우론산, 1-옥틸 베타-D-겐티오비오우론산, 1-에이코실 베타-D-멜리비오우론산, 1-옥타데실 베타-D-멜리비오우론산, 1-헥사데실 베타-D-멜리비오우론산, 1-테트라데실 베타-D-멜리비오우론산, 1-도데실 베타-D-멜리비오우론산, 1-데실 베타-D-멜리비오우론산 또는 1-옥틸 베타-D-멜리비오우론산 또는 작용화된 1-에이코실 베타-D-글루코스, 1-옥타데실 베타-D-글루코스, 1-헥사데실 베타-D-글루코스, 1-테트라데실 베타-D-글루코스, 1-도데실 베타-D-글루코스, 1-데실 베타-D-글루코스, 1-옥틸 베타-D-글루코스, 1-에이코실 베타-D-말토시드, 1-옥타데실 베타-D-말토시드, 1-헥사데실 베타-D-말토시드, 1-테트라데실 베타-D-말토시드, 1-도데실 베타-D-말토시드, 1-데실 베타-D-말토시드, 1-옥틸 베타-D-말토시드, 1-에이코실 베타-D-멜리비오시드, 1-옥타데실 베타-D-멜리비오시드, 1-헥사데실 베타-D-멜리비오시드, 1-테트라데실 베타-D-멜리비오시드, 1-도데실 베타-D-멜리비오시드, 1-데실 베타-D-멜리비오시드 또는 1-옥틸 베타-D-멜리비오시드, 또는 6-카르복실 기 또는 6,6'-디카르복실 기를 갖는 상응하는 1-알킬 글리코시드, 또는 상응하는 1-알킬 알파-아노머인 펩티드 생성물. - 제1항 내지 제4항 중 어느 한 항에 있어서, 펩티드가 아미노산 잔기 aa1-aa27, aa1-aa28, aa1-aa29 또는 aa1-aa30을 포함하는 것인 펩티드 생성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 하기 구조 a) 또는 b)를 갖는 펩티드 생성물:
a) aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-Z 화학식 III-A(서열 번호 1109)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
aa1은 His, N(R3)His, N(Ac)His 또는 pGlu-His이며;
aa2는 Ser, Ala, Gly, MePro, Aib, Ac4c 또는 Ac5c이며;
aa3은 Gln 또는 Cit이며;
aa4는 Gly 또는 D-Ala이며;
aa5는 Thr 또는 Ser이며;
aa6은 Phe, Trp, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa7은 Thr 또는 Ser이며;
aa8은 Ser 또는 Asp이며;
aa9는 Asp 또는 Glu이며;
aa10은 Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U(X)이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U(X)이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser, Arg 또는 U(X)이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U(X)이며;
aa14는 존재하지 않거나 또는 Leu, Met, Nle, Glu, Lys 또는 U(X)이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U(X)이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg 또는 U(X)이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Lys, Cit, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa19는 존재하지 않거나 또는 Ala, Val, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa22는 존재하지 않거나 또는 Phe, Trp, Nal2, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa24는 존재하지 않거나 또는 Ala, Gln, Glu, Cit 또는 U(X)이며;
aa25는 존재하지 않거나 또는 Trp, Nal2 또는 U(X)이며;
aa26은 존재하지 않거나 또는 Leu 또는 U(X)이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U(X)이며;
aa28은 존재하지 않거나 또는 Asn, Lys, Glu, Gln 또는 U(X)이며;
aa29는 존재하지 않거나 또는 Thr, Gly, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa1-aa29 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa12 및 aa16-aa29 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 천연 또는 비천연 아미노산 U이다; 또는
b) His1-aa2-aa3-Gly4-Thr5-aa6-Thr7-Ser8-Asp9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-aa30-Z 화학식 III-B(서열 번호 1111)
상기 식에서,
Z는 -OH 또는 -NHR3이며, 여기서 R3은 H, 비치환된 또는 치환된 C1-C12 알킬 또는 10 Da 미만의 PEG 함유 기이며;
aa2는 Gly, MePro 또는 Aib이며;
aa3은 Gln 또는 Cit이며;
aa6은 Phe, 2FPhe, MePhe, 2FMePhe 또는 Nal2이며;
aa10은 Tyr, Nal2, Bip, Bip2EtMeO, Glu, Lys 또는 U(X)이며;
aa11은 존재하지 않거나 또는 Ser, Asn, Bip 또는 U(X)이며;
aa12는 존재하지 않거나 또는 Lys, Glu, Ser 또는 U(X)이며;
aa13은 존재하지 않거나 또는 Tyr, Gln, Cit 또는 U(X)이며;
aa14는 존재하지 않거나 또는 Leu, Nle, Glu, Lys 또는 U(X)이며;
aa15는 존재하지 않거나 또는 Asp, Glu 또는 U(X)이며;
aa16은 존재하지 않거나 또는 Ser, Gly, Glu, Ala, Aib, Lys, Arg 또는 U(X)이며;
aa17은 존재하지 않거나 또는 Arg, hArg, Gln, Glu, Lys, Cit, Aib 또는 U(X)이며;
aa18은 존재하지 않거나 또는 Arg, hArg, Ala, Aib, Ac4c, Ac5c 또는 U(X)이며;
aa19는 존재하지 않거나 또는 Ala, Aib 또는 U(X)이며;
aa20은 존재하지 않거나 또는 Gln, Lys, Arg, Cit, Glu, Aib 또는 U(X)이며;
aa21은 존재하지 않거나 또는 Asp, Glu, Leu, Aib 또는 U(X)이며;
aa22는 존재하지 않거나 또는 Phe 또는 U(X)이며;
aa23은 존재하지 않거나 또는 Val, Ile, Aib 또는 U(X)이며;
aa24는 존재하지 않거나 또는 Ala, Glu, Gln 또는 U(X)이며;
aa25는 존재하지 않거나 또는 Trp 또는 U(X)이며;
aa26은 존재하지 않거나 또는 Leu 또는 U(X)이며;
aa27은 존재하지 않거나 또는 Met, Val, Leu, Nle, Lys 또는 U(X)이며;
aa28은 존재하지 않거나 또는 Asn, Glu, Gln, Cit 또는 U(X)이며;
aa29는 존재하지 않거나 또는 Thr, Aib 또는 U(X)이며;
aa30은 존재하지 않거나 또는 Arg 또는 U(X)이며;
aa1-aa23 중 임의의 2개는 이들의 측쇄를 통하여 임의로 고리화되어 락탐을 형성할 수 있고;
단, aa10-aa12, aa16-aa24 및 aa28 중 하나 또는 하나 이상은 계면활성제 X에 공유 결합된 천연 또는 비천연 아미노산 U이다. - 제1항 내지 제6항 중 어느 한 항에 있어서,
aa2가 Gly, Aib 또는 Ac4c이거나; 또는
aa12가 리신이거나; 또는
aa14가 류신이거나; 또는
aa17이 글리신 또는 호모아르기닌(hArg)이거나; 또는
aa17, aa18, aa20, aa24 또는 aa28 또는 이들의 임의의 조합이 계면활성제 X에 결합된 리신이거나; 또는
aa16 및 aa20이 이들의 측쇄를 통하여 고리화되어 락탐을 형성하거나; 또는
펩티드가 하나 이상의 Aib 잔기, 예컨대 aa2에서의 Aib를 포함하거나; 또는
계면활성제 X가 비치환된 또는 치환된 도데실, 테트라데실, 헥사데실 또는 옥타데실 알킬 기를 포함하거나; 또는
상기의 임의의 조합 또는 전부인 펩티드 생성물. - 제1항 내지 제7항 중 어느 한 항에 있어서,
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 601);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 602);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 603);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu16 *-Gln17-Ala18-Ala19-Lys20 *-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥타데실 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 604);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥틸 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 630);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 631);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 632);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 633);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-옥타데실 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 634);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 805);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-테트라데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 819);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 820);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-옥타데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 821);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-도데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-도데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1114);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-테트라데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-테트라데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1115);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-헥사데실 알파-D-멜리비오우로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-헥사데실 베타-D-글루코우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1116);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1117);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1118);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-글루쿠로닐])17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Gln24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1119);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1120);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1121);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-글루쿠로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1122);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(13-카르복실-트리데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1123);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(15-카르복실-펜타데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1124);
His1-Aib2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-Ser11-Lys12-Tyr13-Leu14-Asp15-Glu* 16-Gln17-Ala18-Ala19-Lys* 20-Glu21-Phe22-Ile23-Lys(N-오메가[1-(17-카르복실-헵타데실옥시) 베타-D-멜리비오우로닐])24-Trp25-Leu26-Leu27-Gln28-Thr29-NH2(서열 번호 1125);
및 이들의 약학적으로 허용되는 염으로부터 선택되는 펩티드 생성물로서, Glu16 * 및 Lys20 *은 이들의 측쇄를 통하여 고리화되어 락탐을 형성하는 잔기를 나타내는 것인 펩티드 생성물. - 제1항 내지 제8항 중 어느 한 항에 있어서, 신장 질환이 만성 신장 질환인 펩티드 생성물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 간 질환이 지방간 질환, 예컨대 비알콜성 지방간 질환(NAFLD)인 펩티드 생성물.
- 제10항에 있어서, NAFLD가 비알콜성 지방간염(NASH)인 펩티드 생성물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 치료가 펩티드 생성물의 비경구(예를 들어, 피하, 정맥내 또는 근육내) 투여를 포함하는 것인 펩티드 생성물.
- 제1항 내지 제12항 중 어느 한 항에 있어서, 치료가 경구 흡입 또는 코 흡입 또는 취입에 의한 펩티드 생성물의 투여를 포함하는 것인 펩티드 생성물.
- 제1항 내지 제13항 중 어느 한 항에 있어서, 치료가 약 0.1 ㎎ 내지 약 1, 5 또는 10 ㎎, 또는 약 0.1-1 ㎎ 또는 1-10 ㎎의 투약량으로 약 1 주의 기간에 걸친 펩티드 생성물의 비경구(예를 들어, 피하[sc], 정맥내[iv] 또는 근육내[im]) 투여를 포함하는 것인 펩티드 생성물.
- 제14항에 있어서, 치료가 약 0.1-1 ㎎, 또는 약 0.1-0.5 ㎎ 또는 0.5-1 ㎎의 투약량으로 약 1 주의 기간에 걸친 펩티드 생성물의 비경구(예를 들어, sc, iv 또는 im) 투여를 포함하는 것인 펩티드 생성물.
- 제1항 내지 제15항 중 어느 한 항에 있어서, 치료가 1 주당 1회 펩티드 생성물의 비경구(예를 들어, sc, iv 또는 im) 투여를 포함하는 것인 펩티드 생성물.
- 제1항 내지 제16항 중 어느 한 항에 있어서, 치료가 1종 이상의 추가적인 치료제의 투여를 더 포함하는 것인 펩티드 생성물.
- 제17항에 있어서, 1종 이상의 추가적인 치료제가 당뇨병 치료제, 비만증 치료제, 소염제, 항섬유화제, 항산화제, 혈압강하제 및 이들의 조합으로부터 선택되는 것인 펩티드 생성물.
- 제17항 또는 제18항에 있어서, 간 질환이 NAFLD(예를 들어, NASH)이며, 1종 이상의 추가적인 치료제가 퍼옥시좀 증식체 활성화 수용체(PPAR) 효능제(예를 들어, PPAR-δ 효능제, 예컨대 엘라피브라노 또는/및 PPAR-γ 효능제, 예컨대 피오글리타존), HMG-CoA 리덕타제 억제제(예를 들어, 스타틴, 예컨대 로수바스타틴), 파르네소이드 X 수용체(FXR) 효능제(예를 들어, 오베티콜산) 또는 항산화제(예를 들어, 비타민 E) 또는 이들의 임의의 조합이거나 또는 이들을 포함하는 것인 펩티드 생성물.
- 제1항 내지 제8항 중 어느 한 항의 펩티드 생성물 또는 이의 약학적으로 허용되는 염, 또는 이들을 포함하는 약학 조성물; 및
다낭성 난소 증후군, 신장 질환 또는 간 질환을 치료하기 위한 펩티드 생성물 또는 약학 조성물의 투여 또는 사용에 대한 설명서
를 포함하는 키트. - 제20항에 있어서, 간 질환이 지방간 질환, 예컨대 NAFLD(예를 들어, NASH)인 키트.
- 제20항 또는 제21항에 있어서, 펩티드 생성물 또는 약학 조성물이 피하, 정맥내, 근육내 투여와 같은 비경구 투여를 위하여, 또는 경구 흡입 또는 코 흡입 또는 취입에 의한 투여를 위하여 제제화되는 것인 키트.
- 제20항 내지 제22항 중 어느 한 항에 있어서, 펩티드 생성물 또는 약학 조성물을 투여하기 위한 디바이스, 예컨대 인젝션 펜 또는 흡입기를 더 포함하는 키트.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862613396P | 2018-01-03 | 2018-01-03 | |
| US62/613,396 | 2018-01-03 | ||
| PCT/US2019/012194 WO2019136158A1 (en) | 2018-01-03 | 2019-01-03 | Improved peptide pharmaceuticals for treatment of nash and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200106173A true KR20200106173A (ko) | 2020-09-11 |
Family
ID=65409472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207022417A KR20200106173A (ko) | 2018-01-03 | 2019-01-03 | Nash 및 다른 질병의 치료를 위한 개선된 펩티드 약제 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11541028B2 (ko) |
| EP (1) | EP3735295A1 (ko) |
| JP (2) | JP2021509892A (ko) |
| KR (1) | KR20200106173A (ko) |
| CN (1) | CN111818971A (ko) |
| AU (1) | AU2019205905A1 (ko) |
| BR (1) | BR112020013644A2 (ko) |
| CA (1) | CA3086918A1 (ko) |
| IL (2) | IL311775A (ko) |
| MX (1) | MX2020006999A (ko) |
| WO (1) | WO2019136158A1 (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158964A2 (en) * | 2011-05-18 | 2012-11-22 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals for osteoporosis |
| JP6525456B2 (ja) * | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
| KR20230084337A (ko) * | 2014-05-28 | 2023-06-12 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| GB2576705A (en) * | 2018-08-17 | 2020-03-04 | E Miller Norman | Improvements in or relating to organic material |
| EP4106796A4 (en) * | 2020-02-21 | 2024-04-17 | Spitfire Pharma LLC | GLP-1R AND GCGR AGONISTS, FORMULATIONS AND METHODS OF USE |
| CN111514276B (zh) * | 2020-06-29 | 2021-07-27 | 黑龙江中医药大学 | 短肽Asp-His-Tyr在制备治疗多囊卵巢综合征的药物中的应用 |
| WO2022178366A1 (en) * | 2021-02-21 | 2022-08-25 | Spitfire Pharma Llc | Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use |
| CN113171446B (zh) * | 2021-05-06 | 2022-03-29 | 合肥天汇孵化科技有限公司 | 利拉鲁肽组合物及其用途 |
| CN114767665B (zh) * | 2021-06-11 | 2023-10-10 | 同济大学 | 5-十四烷氧基-2-呋喃甲酸在制备用于治疗银屑病样皮炎的药物中的用途 |
| EP4154913A1 (en) | 2021-09-28 | 2023-03-29 | Københavns Universitet | Conjugates of glucagon and ampk activators |
| WO2024017964A1 (en) * | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
| WO2024026012A1 (en) * | 2022-07-29 | 2024-02-01 | The Regents Of The University Of California | Compositions and methods for treating metabolic disorders |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| SG159381A1 (en) | 2001-10-10 | 2010-03-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| JP4334480B2 (ja) | 2003-03-19 | 2009-09-30 | ザ ジェネラル ホスピタル コーポレイション | α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン |
| KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP2457580A1 (en) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| WO2006096426A2 (en) | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| EP1883419A4 (en) | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| US7390788B2 (en) | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
| EP1767545B1 (en) | 2005-09-22 | 2009-11-11 | Biocompatibles UK Limited | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| CA2720654A1 (en) | 2008-04-22 | 2009-10-29 | Merck Frosst Canada Ltd. | Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| US10471127B2 (en) * | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| WO2012158964A2 (en) | 2011-05-18 | 2012-11-22 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals for osteoporosis |
| US10005817B2 (en) | 2012-11-20 | 2018-06-26 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
| JP6525456B2 (ja) | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
| TW201609798A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Ｅｘｅｎｄｉｎ－４胜肽類似物 |
| KR20230084337A (ko) * | 2014-05-28 | 2023-06-12 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| TWI772252B (zh) * | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| JP6581656B2 (ja) * | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト |
| CN106046145B (zh) * | 2016-04-22 | 2022-11-04 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
-
2019
- 2019-01-03 IL IL311775A patent/IL311775A/en unknown
- 2019-01-03 BR BR112020013644-1A patent/BR112020013644A2/pt unknown
- 2019-01-03 EP EP19704897.8A patent/EP3735295A1/en active Pending
- 2019-01-03 CA CA3086918A patent/CA3086918A1/en active Pending
- 2019-01-03 WO PCT/US2019/012194 patent/WO2019136158A1/en unknown
- 2019-01-03 IL IL275777A patent/IL275777B1/en unknown
- 2019-01-03 CN CN201980016883.6A patent/CN111818971A/zh active Pending
- 2019-01-03 KR KR1020207022417A patent/KR20200106173A/ko not_active Application Discontinuation
- 2019-01-03 AU AU2019205905A patent/AU2019205905A1/en active Pending
- 2019-01-03 JP JP2020535129A patent/JP2021509892A/ja active Pending
- 2019-01-03 US US16/958,597 patent/US11541028B2/en active Active
- 2019-01-03 MX MX2020006999A patent/MX2020006999A/es unknown
-
2022
- 2022-12-20 US US18/068,788 patent/US20230218564A1/en active Pending
-
2023
- 2023-05-01 JP JP2023075840A patent/JP2023153115A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3735295A1 (en) | 2020-11-11 |
| US20230218564A1 (en) | 2023-07-13 |
| CA3086918A1 (en) | 2019-07-11 |
| US20200352900A1 (en) | 2020-11-12 |
| MX2020006999A (es) | 2020-12-10 |
| IL311775A (en) | 2024-05-01 |
| JP2021509892A (ja) | 2021-04-08 |
| IL275777B1 (en) | 2024-05-01 |
| BR112020013644A2 (pt) | 2020-12-01 |
| JP2023153115A (ja) | 2023-10-17 |
| AU2019205905A1 (en) | 2020-07-30 |
| CN111818971A (zh) | 2020-10-23 |
| US11541028B2 (en) | 2023-01-03 |
| IL275777A (en) | 2020-08-31 |
| WO2019136158A1 (en) | 2019-07-11 |
| RU2020125550A (ru) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230218564A1 (en) | Peptide pharmaceuticals for treatment of nash and other disorders | |
| JP6684396B2 (ja) | インスリン抵抗性のための改善されたペプチドの調合薬 | |
| KR102126484B1 (ko) | 개선된 펩티드 제약 | |
| US20210290732A1 (en) | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | |
| WO2004104018A2 (en) | Compositions for delivering peptide yy and pyy agonists | |
| CN113264994A (zh) | 针对胰岛素抵抗的改良肽药物 | |
| US20240148879A1 (en) | Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use | |
| KR20230129425A (ko) | Glp-1r 및 gcgr의 균형 잡힌 작용제를 사용하여 혈당및/또는 체중을 낮추기 위한 치료 요법 및 방법 | |
| RU2790209C2 (ru) | Улучшенные пептидные лекарственные средства для лечения nash и других расстройств | |
| US20230104501A1 (en) | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | |
| WO2024059753A2 (en) | Therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp-1r and gcgr agonist | |
| WO2024098071A1 (en) | Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |